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Abstract 
 
Lactic acid bacteria (LAB) are used in the production of fermented food products but bacteriophage 
(phage) killing of susceptible cultures is a persistent problem for the use of LAB in industrial 
fermentations. Through the time of evolution a number of different phage resistance mechanisms 
have evolved to protect the bacteria by attacking different points in the life cycle of infecting phages. 
One group of phage resistance mechanisms is called abortive infection (Abi), which functions after 
phage DNA has been transferred to the infected cell but before cell lysis. Through the molecular 
actions of a given Abi system, phage proliferation is halted and the infected cell dies. Due to the 
commercial interest in protecting LAB against phage attacks, the Abi systems of especially 
Lactococcus lactis have been studied intensively during the last decades and to date twenty-three 
natural Abi systems have been isolated from this species. However, except for a few cases, the 
detailed molecular modes of action (MOA) of these systems remain largely unknown.  
 
We discovered the new phage resistance mechanism AbiV on the chromosome of L. lactis subsp. 
cremoris MG1363 using insertional mutagenesis in which the silent abiV gene was turned on by a 
promoter in a plasmid integrated on the chromosome. AbiV provides protection against phages 
from the 936 and c2 species with an efficiency of plaquing (EOP) of ca 10-4 but it is not active 
against the P335 species. The AbiV system consists of a single gene with low G+C content that 
encodes a protein of 201 amino acids with no similarity to other known proteins. Native AbiV 
forms a dimer which is non-toxic and most likely exists in the cytosol of the cell. 
 
AbiV insensitive phage mutants were isolated and analyzed to elucidate factors involved in 
sensitivity of the wild type phages to AbiV. Whole genome sequencing was carried out for the 
phage mutant p2.1 (936 species) while selected regions of the genomes were sequenced in the 936-
like phage mutants sk1.1, jj50.1, P008.1, bIL170.1 and the c2-like phage mutants c2.1 and bIL67.1. 
Sequence analysis revealed mutations in the early transcribed gene sav which was concluded to be 
responsible for the AbiV sensitive phenotype. The translated SaV protein consists of 128 amino 
acids and no putative function could be assigned based on database sequence similarity searches. 
The protein forms a dimer, which exhibits a strong and fast working toxic effect in both Escherichia 
coli and L. lactis when overexpressed. However, this effect is relieved when a mutated version of 
the protein is cloned and expressed. The majority of the mutations discovered in the phage mutants 
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effectively prevent translation of the SaV protein (nonsense mutations, deletion of start codon). 
Interestingly, most mutations were located in a region of the protein which is conserved among a 
wide array of phage species and a phylogenetic analysis of this region suggests that it has evolved 
from a common ancestor. We suggest that the conserved region is involved in sensitivity to AbiV 
and that it might also be responsible for the antimicrobial activity of the native SaV protein. 
 
Using several independent methods, AbiV and SaV were demonstrated to interact directly most 
probably as two homodimers (AbiV2SaV2). The effects of this interaction on the lytic cycle of 
phage p2 (936-species) were investigated and we found that while RNA synthesis was only slightly 
affected, protein synthesis was severely inhibited shortly after phage infection. More details were 
revealed using mRNA dot blot and western blotting. Phage gene transcription was shown to be 
more inhibited at later stages in the phage lytic cycle, while translation of both early and late phage 
proteins was completely inhibited shortly after infection. It was therefore concluded that the AbiV 
system functions by inhibition of the translation apparatus of the cell. The phenotypic effects of the 
AbiV system on phage development were different between phages from the 936 species and c2 
species. In the former, DNA replication occurred and concatemeric DNA was accumulated, 
whereas in the latter, no DNA replication was observed. Furthermore, to be efficient against c2 
phages a higher expression of AbiV was needed compared to what was required to provide 
protection against 936 phages. Assuming that the AbiV system inhibits the cellular translation 
apparatus, we propose a model to explain that the different phenotypic observations can be caused 
by the same molecular MOA. This includes SaV activation of the AbiV protein which might 
undergo conformational changes thereby exposing a putative RNA binding site. 
 
Finally, the industrial applications of the AbiV system were investigated by the isolation of 
bacterial mutants spontaneously expressing AbiV to gain phage resistance. It was further 
demonstrated that abiV can be transferred between different bacteria using chromosomal 
conjugation. To the best of our knowledge it is the first time that conjugal transfer of a 
chromosomally encoded phage resistance mechanism has been demonstrated. 
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Dansk resumé 
 
Mælkesyrebakterier bruges til produktion af fermenterede fødevarer men bakteriofag (fag) angreb 
af sensitive kulturer er et stort og vedvarende problem for den industrielle brug af 
mælkesyrebakterier til fermentering. I løbet af evolutionen er der blevet udviklet en række 
forskellige typer fag-resistens mekanismer der beskytter bakteriecellen ved at angribe inficerende 
fager forskellige steder i deres livscyklus. En gruppe af fag-resistens mekanismer hedder abortiv 
infektion (Abi), og de virker ved at hæmme faktorer i fagens lytiske cyklus efter at DNA er blevet 
overført til den inficerede celle men før celle lysis. Som følge af de molekylære mekanismer for et 
givent Abi system bliver udviklingen af nye fag partikler standset og den inficerede celle dør. På 
grund af den kommercielle interesse i at beskytte mælkesyrebakterier mod fag-angreb, er Abi 
systemer fra specielt Lactococcus lactis blevet undersøgt grundigt hvilket har resulteret i isolering 
af 23 naturlige Abi systemer fra denne art. Imidlertid er de specifikke molekylære mekanismer der 
fører til Abi fænotypen stort set ukendte når man ser bort fra enkelte velundersøgte Abi systemer. 
 
Vi identificerede den nye fag resistens mekanisme AbiV på kromosomet af L. lactis subsp. cremoris 
MG1363 ved hjælp af mutagenese med et insertion element lokaliseret på et plasmid, hvilket førte 
til at abiV der normalt ikke udtrykkes i denne bakterie blev udtrykt fra en promoter i det 
kromosomalt integrerede plasmid. AbiV beskytter mod infektion af fager fra arterne 936 og c2 med 
en plaquing effektivitet (EOP) på ca. 10-4, men virker ikke mod P335 fager. AbiV systemet består af 
et enkelt gen med lavt G+C indhold som koder for et protein med 201 aminosyrer der ikke har 
signifikant identitet til andre kendte proteiner. Det native AbiV protein danner en dimer som ikke er 
giftig for bakteriecellen og som sandsynligvis eksisterer i cellens cytosol. 
 
Fag mutanter som ikke er sensitive til AbiV blev isoleret og analyseret for at belyse hvilke faktorer 
der er involveret i vild-type fagernes sensitivitet til AbiV. Vi sekventerede det komplette genom fra 
fag mutanten p2.1 (fra arten 936) foruden udvalgte regioner på genomet af 936-fag mutanterne 
sk1.1, jj50.1, P008.1, bIL170.1 samt c2-fag mutanterne c2.1 og bIL67.1. Sekvens analyser viste at 
mutationerne forekom i det tidligt transskriberede fag gen sav og vi konkluderede derfor at dette 
gen er ansvarligt for fagens sensitivitet til AbiV. Det udtrykte SaV protein består af 128 aminosyrer 
og det var ikke muligt på baggrund af database søgninger at knytte en formodet funktion til 
proteinet. Det native protein danner en dimer som har en stærk og hurtigtvirkende toksisk effekt 
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både når det bliver overudtrykt i Escherichia coli og L. lactis. Denne toksiske effekt ses dog ikke 
når en muteret udgave af proteinet bliver klonet og udtrykt. De fleste mutationer der blev opdaget i 
de sekventerede fag-mutanter forhindrer translationen af det oprindelige SaV protein (pga. nonsens 
mutationer og deletion af start-kodon). Det er interessant at bemærke at de fleste mutationer ligger i 
en del af proteinet som er meget konserveret i en lang række af fag-arter og en fylogenetisk 
undersøgelse af denne region antyder desuden en evolutionær sammenhæng mellem de forskellige 
fag-proteiner. Vi foreslår at den konserverede del af SaV er involveret i fagens sensitivitet til AbiV 
og at den muligvis også er ansvarlig for den antimikrobielle funktion i SaV proteinet. 
 
Adskillige metoder blev brugt til at vise at AbiV og SaV interagerer direkte samt at dette 
sandsynligvis sker mellem to homodimerer (AbiV2SaV2). Effekten af denne interaktion på den 
lytiske cyklus i fagen p2 (fra arten 936) blev undersøgt og vi fandt ud af at mens RNA biosyntesen 
kun blev påvirket minimalt blev protein biosyntesen hæmmet betragteligt kort efter faginfektionens 
start. Et mere detaljeret billede fremkom ved at bruge mRNA dotblot samt western blotting. Her 
blev det vist at fagens gen transskription var kraftigere nedsat jo senere i den lytiske cyklus genet 
blev transskriberet mens translationen af både tidlige og sene fagproteiner var fuldstændig standset 
kort tid efter infektionens start. Det blev derfor konkluderet at AbiV systemet virker ved at hæmme 
translations-apparatet i den inficerede celle. AbiV systemets fænotypiske effekter på den lytiske 
cyklus var forskellig fra 936 fager til c2 fager. Således observerede vi DNA replikation i 936 fager 
der resulterede i akkumulering af konkateneret fag DNA hvorimod DNA replikation ikke blev 
observeret i c2 fager. Derudover var et højere niveau af AbiV nødvendigt for at beskytte bakterien 
mod infektion af c2 fager i forhold til infektion af 936 fager. Vi antager at AbiV systemet virker ved 
en effektiv hæmning af cellens translations apparat og vi fremsætter desuden en model der skal 
forklare at de forskellige fænotypiske observationer kan forårsages af den samme underliggende 
molekylære mekanisme. Modellen inkluderer at SaV proteinet aktiverer AbiV proteinet som derved 
muligvis ændrer konformation således at et formodet RNA bindende område bliver eksponeret.  
 
Endelig blev de industrielle anvendelsesmuligheder af AbiV systemet undersøgt. Vi viste af 
bakterien kan mutere til spontant at udtrykke AbiV hvorved den opnår fagresistens. Endvidere blev 
det demonstreret at abiV genet kan flyttes mellem forskellige bakterier ved at benytte kromosomal 
konjugation. Det er, så vidt vides, første gang det er blevet vist at en kromosomal fag-resistens 
mekanisme kan overføres mellem bakterier ved hjælp af konjugation. 
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Aim and outline of thesis 
 
The aim of this PhD study was to identify factors involved in phage resistance in the lactococcal 
model bacterium L. lactis subsp. cremoris MG1363 and subsequently reveal the molecular 
mechanisms leading to the phage resistance phenotype. Upon identification of the phage resistance 
mechanism AbiV, the focus was to reveal which factors in an infecting phage that triggers the Abi 
phenotype as well as the kind of interaction between the Abi mechanism and the phage lytic cycle. 
Investigations were carried out mainly using 936 phages due to the abundance of information 
available on these phages. The industrial applicability of the AbiV system was also investigated as 
part of a 7-month patent proof-of-concept project. 
 
A general introduction to phage biology, lactococcal phages, and phage resistance mechanisms with 
emphasis on Abi mechanisms is presented in Chapter 1. The following chapters (2-5) contain the 
obtained results which are presented in 5 individual manuscripts. Chapter 2 contains the manuscript: 
“Identification of AbiV, a novel abortive phage infection mechanism on the chromosome of L. 
lactis subsp. cremoris MG1363” (Manuscript I), which describes the discovery and microbiological 
characterization of AbiV. This manuscript has been accepted for publication in Applied and 
Environmental Microbiology (AEM). Manuscript II (Chapter 3) which is named: “Identification 
and characterization of a phage gene sav involved in sensitivity to the lactococcal abortive infection 
mechanism AbiV”, describes the identification of SaV which is involved in AbiV sensitivity and 
exhibits a strong antimicrobial effect in L. lactis and E. coli. This manuscript was submitted to 
AEM prior to submission of the present thesis. Chapter 4 consists of the manuscript entitled: 
“Direct interaction between the lactococcal abortive infection protein AbiV and the phage protein 
SaV prevents translation of phage proteins” (Manuscript III). In this manuscript we provide 
evidence for the direct protein interaction between AbiV and SaV and we describe the molecular 
mode of action of the system which inhibits the cellular translational apparatus. This manuscript 
awaits ongoing work focused on resolving the three dimensional structure of AbiV before 
submission to a hitherto not specified journal. Chapter 5 contains 2 manuscripts. The first 
(Manuscript IV) is entitled: “Industrial applications of the novel lactococcal abortive infection 
mechanism AbiV” and it demonstrates spontaneous expression and conjugal transfer of AbiV. This 
manuscript will be submitted as a note to AEM shortly after submission of this thesis. The second 
manuscript (Manuscript V) is an international PCT patent application covering the phage resistance 
12
properties of AbiV and SaV. The application was filed to the Danish Patent and Trademark Office 
in July 2008. Chapter 6 contains a summary and general discussion of the obtained results along 
with suggestions for future work. References are listed individually for each manuscript and 
references outside the manuscripts are found at the end of the thesis. 
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INTRODUCTION 
 
LACTOCOCCUS LACTIS 
The Gram-positive bacterium Lactococcus belongs to the heterogeneous group of lactic acid 
bacteria (LAB) with a low genomic G-C content. Lactococci are non-sporulating, aerotolerant and 
acid-tolerant. They lack a respiratory chain and supply their energy by means of fermentation in 
which they convert carbohydrates into the main end product, lactic acid 146. L. lactis is used as a 
starter culture in industrial fermentations for cheese production and the world-wide use of this 
bacterium produces annually an estimated 107 tonnes of cheese, which makes lactococcal milk 
fermentation the largest volume of bacterial culture controlled by man 26,57. A typical mixed starter 
culture consists of 2-3 well defined strains and the activity and specific properties of these strains 
are important for the consistency of the end product quality. A major problem for industrial milk 
fermentations is the aseptic nature of the fermentation process, which makes the starter cultures 
vulnerable to attack by ubiquitous phages. Since the discovery of phages in milk fermentations in 
1935 155, dairy scientist have put a great effort into preventing phage mediated fermentation failures. 
Still, 70 years later, phages remain a significant problem for the dairy industry and it is estimated 
that ca 0.1% to 10% of all milk fermentations are negatively affected by phage attacks 109. This has 
serious economic consequences for the dairy industry which is dependent on specific quality 
requirements of their products and therefore significant resources have been spent on research that 
can protect the vulnerable production strains against phage attack. 
 
LACTOCOCCAL PHAGES 
All isolated phages of L. lactis have double stranded DNA genomes and they belong to the order of 
tailed phages called Caudovirales 79, which is divided into the families Myoviridae (long contractile 
tails), Siphoviridae (long non-contractile tails), and Podoviridae (short non-contractile tails). Each 
family is further divided into morphotypes depending on the head shape (isometric or prolate) and 
individual phages species are classified using DNA homology 114. About half of all characterized 
phages and the majority of lactococcal phages are isometric headed and belong to the group of 
Siphoviridae 1,17. Though lactococcal phages have been divided into ten different species 38,56, the 
vast majority of phages isolated from dairy plants belong to the three species 936, c2, and P335 107. 
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Phages of the 936 and c2 species are strictly virulent whereas the P335 group contains both virulent 
and temperate species. The three species share very limited interspecies DNA homology and the 
P335 phages furthermore shows large intraspecies variation. The 936 and c2 species on the other 
hand has high intraspecies homology at >90% of their genomes 24. 
 
PHAGE SK1 AS A REPRESENTATIVE OF 936-SPECIES 
The results in this thesis are mainly based on studies on phages p2 and 
sk1 from the 936 species (Fig. 1). The genome of phage sk1 is 
characterized 22,23 and publicly available (GenBank acc.nr. 
NC_001835). Temporal transcription data exists 6,21, and the functions 
of several proteins have been determined. On the other hand, phage 
p2 was isolated more recently and less information is available, 
although comparative whole genome sequence analyses have revealed 
that sk1 and p2 are very close relatives (S. Moineau, unpublished 
data). In this thesis, data obtained using phage p2 is therefore 
compared to phage sk1 data which has a 28.5 kbp genome of the cos 
type like all other 936 phages 17,23. The genome is divided into the 
three regions (early, middle, and late) according to the timing of 
transcription during the lytic cycle 21 (Fig. 2).  
 
The early region encompasses 30 small orfs of which several have overlapping stop/start codons. 
Sequence data of the overlapping genes suggested that several genes were coupled by programmed 
translational frameshift 22,132. The functions of the early orfs, which are not encoding structural 
phage proteins, are unknown and a putative function based on DNA similarity has only been 
proposed for ORFs 43 and 44 (DNA polymerase, large and small subunit) and ORF35 (single 
strand DNA annealing protein). The early transcripts are observed from 2-5 minutes after infection 
Fig. 2. The genomic map of phage sk1 showing orfs in the early, middle, and late regions. Arrows symbolize 
promoters. Orf26 in the early region is the sav homologue of sk1; adapted from Brøndsted & Hammer (2005) 17 
Fig. 1. Electron micrograph 
of phage sk1; adapted from 
Dupont et al (2004) 48 
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and are repressed in the later phase of the lytic cycle 21. Transcription of the early region probably 
occurs from several lactococcal consensus promoters, which are recognized by the host RNAP 87. 
Three of the promoters were mapped by primer extension and promoter activity was further 
demonstrated for two of them by promoter fusion experiments 22.  
 
The middle region contains 4 ORFs, with a high degree of DNA similarity to the middle region of 
the 936 phage bIL66 8, where one of the ORFs previously was suggested to be a RuvC-like 
endonuclease 9,17,30. The middle region is divergently oriented compared to the early region and 
transcripts appear 7-10 minutes after infection (Fig. 2). Transcription occurs from the promoter PM, 
which requires activation by an early expressed phage encoded protein. Deletion and mutagenesis 
analyses determined that the region from -36 to -55 upstream of the transcriptional start site was 
necessary for PM promoter activity 22. The middle region is also expected to contain an activator of 
late gene transcription since late transcripts are not observed before 15 minutes after infection 21. 
The authors also identified a terminator structure in the relatively large (ca. 1 kbp) non-coding 
region containing the cos site (Fig. 2). However, this terminator structure is not succeeded by the 
oligo(T) sequence (T-stretch) which is crucial for intrinsic transcription termination 63. It is 
therefore likely that this terminator structure is inefficient and that this accounts for an observed 
read-through from the PM promoter 21. 
  
Transcription of the late region begins ca 15 minutes after infection, presumably after phage-
mediated induction, though neither the late promoter nor the activator protein have been identified. 
The region encodes structural proteins as well as proteins needed for virion assembly and cell lysis 
(Fig. 2). The protein functions have been deduced from sequence similarity to other phage proteins 
for most of the late ORFs 19,22,48. Only ORFs 19 and 20 were determined experimentally to encode 
the holin and lysin enzymes, respectively 22. The gene order of the structural genes in the late region 
was highly similar to the order of the structural genes in phage λ, except for a few inversions 22. 
However, phages are known to cluster genes of related functions together and the conservation 
might therefore reflect a functional more than an evolutionary relationship between the phages 87.  
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PHAGE BIOLOGY 
Initial infection 
A phage infection starts with the adsorption of the phage to a cell. For several phages (presumably 
also lactococcal phages), the adsorption process happens in two steps: First, phage anti-receptors 
bind reversibly to carbohydrate structures allowing the phage to “walk” on the cell surface to obtain 
the correct position for binding irreversibly to a secondary receptor 67,69. Following binding, the 
phage DNA is transferred to the cell cytoplasm by energy driven processes that require membrane 
potential 87. The DNA transfer is not very well understood but it involves enzymatic degradation of 
PG and penetration of the cell membrane. The process differs among phage species and it is adapted 
to the general strategy of the infecting phage. Thus coliphage T7 transfers it DNA in a two-step 
process that involves “dragging” of the DNA into the cell using the host RNAP. The transfer is 
slow allowing expression of early proteins to protect sensitive DNA regions that are transferred 
later 110,111. Other phages transfer DNA very quickly as for example in T4 where DNA enters the 
cell with a speed of 3-10 kbp per second 113. Often a few proteins carried in the phage capsid are 
also transferred to the cell to mediate a fast take-over of the cellular machinery 87. Mechanisms of 
DNA transfer in lactococcal phages are unknown.  
Once the DNA has entered the cell, further development depends on the type of phage. All phages 
can be divided into two functional classes depending on their ability to integrate the phage genome 
into the bacterial chromosome. Phages with this ability are classified as temperate while phages 
lacking this ability are classified as virulent 64.  
 
The lysogenic cycle 
When the DNA of a temperate phage enters the bacterial cell it has the choice of entering the lytic 
or the lysogenic cycle, where the most frequent choice is to enter the lytic cycle. In the cases where 
the phage enters the lysogenic cycle a repressor protein (CI in phage λ) prevents transcription from 
the promoter from which the lytic genes are transcribed. Instead the lysogenic module is expressed 
and the phage integrates into the host chromosome. For the lactococcal phage TP901-1 the 
lytic/lysogenic choice is determined by regulation of a genetic switch containing the two oppositely 
oriented promoters PL and PR 17 (Fig 3). Genes for the lytic cycle are transcribed from PL 96, 
whereas genes needed for establishing and maintaining lysogeny are transcribed from PR. The 
switch is regulated by the protein CI (transcribed from PR) which represses both promoters and the 
20
  
protein MOR (transcribed from PL) which counteracts the effect of CI. The relative amount of the 
two proteins determines the choice between lytic and lysogenic cycle 97,98. If the phage enters the 
lysogenic cycle, an integrase mediates site specific integration at the attB site of the host 
chromosome 16. The phage then exists as a passive prophage until an induction event, typically 
induced by the SOS response, and in which the host encoded RecA protein is needed, causes the 
phage to excise from the host chromosome and enter the lytic cycle 15,97.  
 
The lytic cycle 
The lytic cycle is a tightly regulated and efficient molecular machine that within very short time can 
produce and release complete infective phage particles from a single phage DNA molecule. The 
main processes are: replication of phage DNA, production of the structural proteins that will make 
up the virion, assembly of these proteins, packaging of phage DNA in the head, and finally the lysis 
of the host cell that releases the progeny phages to the environment. This process can in many 
phages be accomplished within 30 minutes 87.  
Fig. 3. The genomic map of the temperate phage TP901-1 showing orfs in the early, middle, and late regions. 
Arrows symbolize promoters. The region left of the PR promoter is the lysogeny module; adapted from Brøndsted 
& Hammer (2005) 17 
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The lytic cycle of coliphage T4 
Insights into the molecular biology of the well characterized lytic cycle of coliphage T4 has 
revealed a complex and tightly regulated web of interactions that allows the phage to efficiently 
complete its lytic cycle while adapting to different situations imposed by the host or the 
environment 82,113 (Fig. 4).  
As a general rule, phage T4, like many phages has clustered related genes together in early, middle, 
and late transcribed genes. The early genes are mainly used to shut-down cellular functions and 
redirect the cell to produce phage particles, the middle region controls timing of DNA replication as 
well as transcription of the late region, which is primarily encoding structural proteins 87. 
Regulation is mainly at the transcriptional level, using modification of the host RNAP and sigma-
factors to direct the timing of the transcription 113. Thus, one of the first synthesized proteins in the 
T4 lytic cycle modifies the host RNAP to exclusively transcribe T4 DNA (which is distinguished 
from host DNA by the methylation of cytosine) thereby efficiently shutting off transcription of host 
genes 46. For both early and middle transcription, T4 uses the host σ70 factor, which however gets 
modified by an early phage protein 75 to recognize middle instead of early promoters. Late 
Fig. 4. The lytic cycle of coliphage T4. Different steps of the cycle are presented according to the timing of the 
lytic cycle (below picture). The complex regulatory mechanisms are not presented. Heads, tails, and tailfibers are 
prefabricated before assembly; adapted from Mosig & Eiserling (2005) 113 
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transcription uses the phage encoded σ55 transcribed from the middle region 83 but many other 
factors are involved in the transition from middle to late transcription 85. Late transcription is further 
mechanically coupled to DNA replication and packaging 10, presumably as a way to match the 
amount of replicated DNA to the available phage heads. 
  
The virion is assembled from prefabricated tails and heads filled with DNA, both of which have 
been synthesized at a membrane associated complex (Fig 4). Contrary to the early part of the lytic 
cycle where gene transcription is the regulating factor of phage development, the control of virion 
assembly lies in the ordered sequential assembly of proteins which are synthesized almost 
simultaneously 91. Throughout the lytic cycle lysin and holin are produced and holin molecules 
gather on the inner cell membrane. Upon a signal, the holin produces a hole in the membrane that 
allows lysin to specifically adhere to and break down the PG layer after which the cell lyses quickly 
due to osmotic pressure 53. 
The size of the phage T4 genome is 170 kbp and it consists of about 300 genes of which about 160 
have a known function. Some of the genes have been shown to be non-essential for phage 
proliferation under normal laboratory conditions but to be important for the adaptation of the phage 
to changing environmental conditions. This apparent “gene redundancy” has therefore been 
suggested to be an important parameter in the success of T4 as a molecular parasite 113.  
 
The lytic cycle of lactococcal phages 
The structure and assembly of the tail of phage TP901-1 and the closely related phage Tuc2009 are 
studied in details and they represent some of the best studied phage tails 80,102,123,133,151,152. For most 
other lactococcal phages, the functions of the majority of the structural genes have been determined 
using sequence similarity and the molecular mechanisms of their lytic cycle are virtually unknown. 
Almost none of the early proteins of lactococcal phages show sequence similarity to proteins with 
known functions and therefore knowledge on gene regulation in the early lytic cycle is completely 
absent. The genomes of lactococcal phages are much smaller than the T4 genome (typically ca. 15-
40 kbp). It can therefore be expected that they have less redundant genes since a larger fraction of 
the genome must be occupied by structural and other essential genes. On the other hand, 
redundancy has been demonstrated in the lysogenic module and near the attP site in temperate 
lactococcal phages. In the early region of the virulent phage sk1 some of the 30 non-structural genes 
are also redundant and many of these genes are expected to be involved in regulation of the lytic 
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cycle. The regulation of the lytic cycle in lactococcal phages might turn out to be a complex 
interaction network as observed in phage T4. 
 
NATURAL PHAGE RESISTANCE MECHANISMS 
Lactococci contain a variety of natural anti-phage barriers to protect the bacterial populations 
against phage attacks. They are usually encoded on conjugal plasmids like most other factors 
required for optimized growth in milk. Due to the economical interest in L. lactis, research in phage 
resistance has mainly been focused on this species from which a number of phage resistance 
mechanisms have been isolated. Phage resistance mechanisms can be categorized into four different 
types according to where in the lytic cycle phage development is arrested. The four different types 
are: 1) inhibition of phage adsorption, 2) inhibition of phage DNA transfer to the cell, 3) 
restriction/modification (R/M) systems, and 4) abortive infection (Abi) mechanisms. The different 
phage resistance mechanisms have been reviewed extensively 2,26,29,34,54,70,81,107,135.  
 
Adsorption inhibition 
Inhibition of adsorption is thought to be the most frequent type of mutation in the isolation of 
bacteriophage insensitive mutants (BIMs) due to spontaneous mutations leading to changes in the 
phage receptor molecule on the bacterial cell wall 70. Host-encoded adsorption inhibition 
mechanisms have also been isolated and this usually involves the production of cell surface antigens, 
or alteration or physical masking of the cell wall structures used for phage adsorption 2,54. However, 
the general lack of knowledge of phage receptors on the lactococcal cell wall and the molecular 
mechanisms of the phage adsorption complicates the research in the adsorption inhibition phage 
resistance mechanisms 2. 
 
DNA transfer inhibition  
As for phage adsorption, the DNA transfer mechanisms into the cell are very poorly understood for 
lactococcal phages and thus the phage injection blocking resistance mechanisms also remain 
scarcely characterized 54. The gene pip (phage infection protein) was shown to be important for 
irreversible attachment of c2-like phages as well as for DNA injection 112. Pip is a membrane 
spanning protein but the cellular function is unknown since pip- strains show no reduction in growth 
potential 58. Garvey et al. demonstrated a plasmid encoded DNA injection phage resistance 
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mechanism on the plasmid pNP40 (which also contains the abortive infection mechanisms AbiE 
and AbiF) 59,60. Another injection blocking mechanism was demonstrated in the lysogeny module of 
the phage Tuc2009 and other temperate phages 103. The gene sie2009 encodes a protein which is 
associated with the cell membrane and cells expressing this gene were observed to adsorb 936 
phages that were unable to transfer DNA into the cell.  
 
Restriction/Modification (R/M) systems 
Once the phage DNA has entered the cell, restriction/modification (R/M) systems exist, that protect 
the cell against invading DNA. R/M systems constitute the vast majority of isolated bacterial phage 
resistance systems 129, probably due the practical application of restriction enzymes as a tool in 
molecular biology. The R/M systems are widespread in lactic acid bacteria where they are usually 
located on plasmids 81. They function by degrading foreign incoming DNA, which is distinguished 
from cellular DNA by methylation of cytosine or adenine at the recognition site on the cellular 
DNA. R/M systems are divided into general types depending on subunit composition and mode of 
action (Table 1). R/M systems are not 100% efficient which is a problem since DNA of a phage that 
escapes a R/M system will be methylated thereby offering complete protection against the given 
system 54,81. Other phage strategies to circumvent R/M systems include: elimination of restriction 
sites on the phage genome, acquisition of methylase genes, and expression of endonuclease 
inhibitors 54. Therefore, single R/M systems alone are not very powerful and are often used in 
combination with other R/M systems or abortive infection (Abi) systems 81.  
 
TABLE 1. Different types of R/M systems 
 Type I Type II Type III 
    
Structural genes 
 
hsdR, hsdM, and hsdS R and M mod and res 
Characteristics All three proteins form a 
multifunctional multisubunit 
complex. HsdS and HsdM are 
responsible for recognition and 
methylation, respectively. 
R is a restriction enzyme 
while M is a modification 
enzyme. R and M do not 
function as a multisubunit 
Mod recognizes and 
modifies DNA while Res 
in complex with Mod is 
responsible for cleavage 
DNA cleavage Cleavage occurs far from 
recognition site 
Cleavage within a 
symmetrical recognition 
site 
Cleavage occurs at a fixed 
distance from recognition 
site 
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Abortive infection (Abi) systems 
Whereas the R/M systems protect the bacterium against any invading foreign DNA, abortive 
infection mechanisms only protects the bacterial population against attacks from specific phages. 
Abi systems constitute the last barrier for the bacterial population against phage proliferation and 
they always cause the death of the individual cell. However, since the cell does not release progeny 
phages (or only very few), the invading phage particles are titrated and the bacterial population 
survives. This general feature of Abi mechanisms has led to the suggestion that Abi systems are 
altruistic phage resistance mechanisms. However, the general lack of knowledge on the mode of 
action in Abi systems prevents scientists to determine if Abi systems are designed to kill the cell or 
if cell death is just a secondary effect in a process designed to arrest phage development 2,134. Abi 
systems exists in many bacterial species 5,27,90,136,137,148,68 but the majority of the described Abi 
systems have been isolated in L. lactis 2. They share several phenotypic characteristics: Efficiency 
of plaquing (EOP) is reduced to values ranging from 10-1 to <10-9, the efficiency of which centres 
of infection form (ECOI) is reduced, burst size is reduced, and latency time might be prolonged, 
leading to a reduction in plaque size 70. Furthermore, Abis are characterized by an unusually low 
G+C content (24-31 %) compared to the average 37 % of lactococcal genes 54. This has been 
suggested to be caused by horizontal gene transfer from other bacterial species 117, or by codon bias 
in the Abi genes resulting in the use of rare tRNA species 26. The majority of lactococcal Abi 
systems are encoded by a single gene but a few consist of two 11,32,36,59,117 or three genes 150. Abi 
proteins generally lack secretion signal sequences and membrane spanning domains, and they 
contain hydrophilic charged residues, which indicate that they are present in the cytosol of the cell 2. 
Only a few Abi systems are found on the chromosome of the host 28,65,124,126. Thus the majority of 
the Abi mechanisms are located on plasmids, which are often conjugative 135, thereby facilitating 
the sharing of anti-phage barriers among bacterial populations 26.  
 
The regulation of Abi systems is not very well understood 2. The genes encoding AbiA and AbiB 
are expressed from constitutive promoters 28,73, while regulation of a toxic Abi protein has been 
demonstrated for AbiD1, AbiK, AbiN, and AbiO 26,3,52. It can be speculated that the latter systems 
are designed to kill the bacterium upon expression induced by the phage infection whereas the 
constitutively expressed proteins either function by inhibiting phage development directly or they 
need activation by phage encoded factors to become toxic for the host cell. In all cases, the Abi 
systems interact with phage factors involved in the infection to ultimately halt phage proliferation. 
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Though Abi systems share common phenotypic characteristics, they likely share very few 
similarities in their molecular mode of action (MOA). For most Abi systems, the MOA has only 
been investigated at a general level and the few studies where more detailed information of the 
molecular MOA has been obtained, data indicates that the term Abi mechanism covers a wide range 
of molecular un-related interactions which have been grouped together by scientists in a “black 
box” called abortive infection 26. The apparent diversity in molecular MOA is not surprising given 
that the lytic cycle of phages is a complex web of temporally regulated interactions between 
components of both host and phage, as described above 113. Some Abi mechanisms, have even been 
shown to differ in their MOA depending on which phage is infecting 3,14,26,65, which supports the 
apparent complex molecular nature of the interactions between Abi systems and infecting phages. 
 
Mode of action of lactococcal Abi systems 
Traditionally, Abi system mode of actions have been characterized as early or late depending if the 
system halts phage proliferation before or after DNA replication 54,59. According to this definition 
AbiA 71, AbiF 59, and AbiR 150 are early Abi mechanisms while AbiK 14 and AbiV Manuscript I+III are 
“partly early” mechanisms since they inhibit DNA replication of P335 and c2 phages, respectively 
while allowing DNA replication of 936 phages. Most other Abi systems have been classified as late 
11,50,54. It can be difficult to determine the exact MOA of Abi systems since the primary effect on the 
Abi target is followed by a range of deleterious physiological effects in the cell, which can be hard 
to separate from the primary effects 26. Therefore, the use of Abi-insensitive phage mutants can be a 
valuable tool in elucidating the molecular MOA of individual Abi systems. With a few exceptions 
these phage mutants can be obtained and by using genomic analyses, the mutated phage gene(s) 
rendering the phage insensitive to Abi systems can subsequently be determined. Using this 
approach, genes involved in the Abi sensitivity of lactococcal P335-like phages have been identified 
either by specific point mutations in the genome of phage escape mutants or by exchange of genetic 
material with a prophage 11-13,40,89,108. In the case of virulent 936 phages, Abi sensitivity genes were 
identified by point mutations in the escape phage mutants 7,8,11,40,54 or by recombination between 
two virulent phages 45. Among these genes there is a prevalence of early expressed phage genes, 
which remain virtually uncharacterized, thereby complicating the process of revealing the MOA of 
a given Abi system. 
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Individual Abi systems 
Several Abi systems have been characterized to some detail regarding the molecular mode of action 
(see Table 2 for a summary of the different Abi characteristics). For example, AbiC was shown to 
contain putative transmembrane helices and to cause a ca 50% reduction in major capsid protein 
production 49. AbiQ as demonstrated for many Abi systems allowed DNA replication of 936 and c2 
phages, however only the concatemeric form of DNA was observed. In addition, synthesis of the 
major capsid protein was observed and the authors speculated that defective assembly possibly due 
to insufficient packaging of the concatemeric phage DNA might be involved in the MOA of AbiQ 
51. The effect of AbiR that works by impeding phage DNA replication is dependent on the 
methylase LlaKR2I which is part of a R/M system located on the same plasmid as AbiR. This 
methylase protects the host against a toxic effect of the Abi system 150,156 and AbiR functions 
whether methylated or non-methylated phage DNA is used for infection. This made the authors 
suggest that the MOA could involve inhibition of DNA replication initiation if the ori was not 
methylated 156.  
 
Some Abi systems have been shown to interfere with transcription of phage genes. For example a 
northern analysis of phage RNA in AbiU containing cells suggested that transcription was delayed 
for 936 phages and c2 phages 32. Interestingly, transcription delay was also shown for 936 phages in 
cells harbouring AbiG 117 and it was noted that AbiG and AbiU both are two-component systems 
that even appear to be related on the basis of sequence similarity 32. The last Abi system that has 
been shown to interact with transcription is AbiB which is one of the few known chromosomally 
encoded Abi systems 28. This Abi system is only effective against 936 phages and it is expressed 
constitutively from a promoter in a nearby ISS1 element though overexpression is toxic for L. lactis 
and E. coli 26. DNA replication and RNA transcription was demonstrated to occur normally until 
10-15 minutes after infection. At this time a dramatic decay of phage transcripts was observed in 
AbiB containing cells 122. Though the MOA was not determined at the molecular level, the effect, 
which arrested phage proliferation, was suggested to be caused by RNase activity. By blocking 
phage protein synthesis at different time points during infection, the authors further demonstrated 
that the decay was induced by an early phage protein which was suggested to either activate or 
induce the production of the RNase 122.  
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AbiA was the first Abi system to be isolated by Klaenhammers group 73,74. It is active against the 
three main lactococcal phage species 936, c2, and P335 and it prevents DNA replication. It is 
encoded on the conjugative plasmid pTR2030 from which it is expressed constitutively 73. AbiA 
efficiency against all three main phage species is increased with higher gene expression 39. 
Interestingly, as the first Abi system to cross a bacterial species barrier, AbiA was demonstrated to 
be active against phages of Streptococcus thermophilus, which is a close relative to L. lactis. AbiA 
is temperature sensitive in both S. thermophilus and L. lactis with no phage resistance effect at 37ºC 
142. The system causes almost complete inhibition of phage capsid production, probably as a 
secondary effect of the early inhibition of DNA replication. The central part of AbiA contains a 
leucine repeat which was demonstrated by site directed mutagenesis to be required for the phage 
resistance function of the protein. This leucine repeat was speculated to be involved in either 
homodimer formation or heterodimer formation with a phage encoded target protein 41. Different 
AbiA targets were determined by genetic analyses of AbiA insensitive phage mutants. One 
mutation was found to cause a arginine to leucine change in the ORF245 on the Φ31 genome 40. 
This gene shows sequence similarity to DNA polymerase accessory proteins and might therefore be 
involved in the DNA replication of Φ31. In an independently isolated phage Φ31 mutant, mutations 
were found in an intergenic region containing two inverted repeats upstream of ORF245 and 
complementation experiments coupled this region to the action of AbiA 40. The authors suggested 
that the region might function as a false target for AbiA. Interestingly, the genetic regions providing 
the AbiA targets found in Φ31 are not present in phage c2 and it was therefore suggested that AbiA 
might work with different MOAs against P335 and c2 phages 40.  
 
AbiA shares 23 % protein sequence similarity with AbiK which is also efficient against all the three 
main lactococcal phages and works by preventing DNA replication in at least P335 phages 14,52. 
AbiK is also sensitive to higher temperatures and the efficiency of the system was demonstrated to 
depend on copy number. No phage proteins were produced in AbiK containing cells which was 
probably a secondary effect of the inhibited DNA replication. The many similarities to AbiA led the 
authors to suggest that AbiA and AbiK belong to the same protein family 52. Furthermore, it was 
shown that AbiK insensitive phage mutants carry mutations in proteins that are related to single 
strand annealing proteins 13 and thus are functionally related to the AbiA target 2. Interestingly, 
phage mutants of the 936 species are also mutated in genes encoding single strand annealing 
proteins even though the MOA of AbiK was suggested to be different in this phage species due to 
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observed DNA replication 13,26. More recently, AbiK was demonstrated to be part of an operon 
containing a phage related transcriptional repressor suggesting regulation of the abiK transcription 
55. A reverse transcriptase region was also discovered in AbiK which was demonstrated by site-
directed mutagenesis to be essential for the Abi phenotype. A model was proposed to explain the 
MOA of AbiK. This included the synthesis of a single-stranded cDNA molecule that could titer the 
mRNA from which phage single strand binding proteins are encoded, thereby inhibiting DNA 
replication. This however, cannot explain the AbiK phenotype of an infection with 936 phages in 
which DNA replication and early transcription is not affected by AbiK. The authors suggested 
protein synthesis inhibition to be the MOA of AbiK against these phages 55. 
 
Another Abi system interfering with DNA replication is AbiP. This protein is encoded in a two-
gene operon and is only effective against 936 phages 45. AbiP is a membrane-anchored protein 
which is able to bind ssRNA or DNA in a sequence dependent manner. It shares 22 % amino acid 
sequence similarity with AbiC 45. In cells harbouring AbiP, DNA replication is halted 10 minutes 
after infection which probably causes the observed lower levels of middle and late transcription. 
During a normal infection with 936 phages, early transcription is switched off ca 15 minutes after 
infection. This was not observed in AbiP containing cells, where the level of early transcription 
continued to rise throughout the experiment. An early transcribed phage gene involved in sensitivity 
to AbiP was determined and in the same study it was demonstrated that virulent phages may acquire 
resistance to Abi mechanisms by homologous recombination during co-infection with a phage 
which has a high degree of nucleotide sequence similarity 44.  
 
AbiT also consists of a two gene operon which is constitutively expressed and it affects phages 
from the 936 and P335 species 11. As for several other Abi systems, increased expression causes 
increased efficiency (EOP) against the tested phage species. The level of DNA replication was 
lowered in cells harbouring AbiT and only concatemeric DNA existed, indicating that the MOA is 
arresting phage development after DNA replication and that secondary effects cause the lower level 
of DNA replication. Gene expression was measured using Northern Blotting for an early and a late 
gene observing no difference in cells with or without AbiT. It was therefore suggested that AbiT 
affects the phage cycle at a late stage. Electron microscopy revealed the assembly of phage capsids 
but the phage morphogenesis was inhibited before correct assembly and lysis. Site directed 
mutagenesis was used to demonstrate that a putative membrane spanning domain of AbiT was 
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essential for the Abi phenotype. An AbiT insensitive phage mutant was analyzed and it was found 
that a late phage protein is essential for the Abi phenotype probably by activating AbiT which then 
causes rapid and premature cell death. It was speculated that the membrane spanning domain is 
involved in making pores in the membrane to cause the premature lysis as observed in the Rex Abi 
systems of E. coli 137.  
 
Another Abi system also functioning by premature killing of the host cell is AbiZ 50. This Abi 
protein which was recently discovered on the pTR2030 plasmid that also harbours AbiA and a R/M 
system is effective against P335 phages but not phages from the 936 or c2 species. Two putative 
transmembrane helices were found in the protein which as for AbiT were suggested to be involved 
in the phage resistance phenotype. AbiZ causes premature lysis (15 minutes early) of the infected 
cells. Nisin induced expression of holin and lysin caused partial lysis of cells without AbiZ whereas 
the presence of AbiZ caused lysis to occur 30 minutes earlier while also increasing the membrane 
permeability. This made the authors suggest that AbiZ may interact with holin to cause the 
premature lysis 50. However, through sequence analysis of AbiZ insensitive phage mutants, it was 
discovered that an early or middle phage encoded factor is involved in the AbiZ phenotype since 
mutant phages had exchanged the complete middle and late region of the genome and no mutations 
were found in either holin or lysin 50.  
 
Probably the best understood lactococcal Abi system with regards to molecular MOA is AbiD1 
3,7,8,26. This is a plasmid encoded Abi system that is effective against phages from the 936 and c2 
species. High expression of the gene is toxic to L. lactis and it is therefore tightly regulated at the 
transcriptional 3 and translational 26 level. The protein contains two putative HTH motifs and is 
highly charged with a pI of 10.4 which indicates that the protein is involved in DNA binding in the 
cytosol. The phage middle region of the genomes of 936 phages was demonstrated to be essential 
for AbiD1 function since complementation with a mutated middle region abolished the Abi 
phenotype. The middle region consists of 4 genes which are transcribed from the phage activated 
middle promoter. Independently obtained point mutations in the orf1 gene of this region strongly 
indicated this gene product being essential for the AbiD1 function 8. The abiD1 gene is transcribed 
from a strong promoter and the tight transcriptional regulation is imposed by a very efficient 
transcription termination ca 50 bp downstream of the promoter 3. It is therefore possible that ORF1 
functions as an anti-termination protein that allows fast and high expression of AbiD1 upon phage 
35
  
infection. In support of this, AbiD1 efficiency was shown to be positively correlated to the 
expression level of ORF1 but did not depend on expression of a mutated ORF1 7. The ORF1 was 
suggested to exhibit a dual function where the N-terminal part is important for interaction with 
AbiD1 whereas the C-terminal part interacts with the downstream ORF3. This gene has a high 
degree of amino acid sequence similarity to the E. coli RuvC endonuclease and it is likely that the 
protein is involved in resolving branched DNA generated during DNA replication. The ORF3 
endonuclease, which is essential for phage proliferation, was also demonstrated to alleviate the 
effect of AbiD1 when expressed in trans suggesting that AbiD1 functions by decreasing the amount 
of ORF3 8, thereby interfering with phage DNA packaging. Interestingly, expression in trans of 
ORF3 from phage bIL66 (936-phage) allows bIL67 (c2-phage) to proliferate in cells containing 
AbiD1 thereby demonstrating ORF3 being the target for AbiD1 in these two different phages. 
However, the induction process must differ since bIL67 does not contain an orf1 homologue 26. The 
authors constructed a model to explain the molecular MOA of AbiD1 (Fig. 5).   
Fig. 5. Model for AbiD1 mode of action. (a) Following infection of AbiD1- cells, phage bIL66 produces an 
essential RuvC-like endonuclease, which resolves branched DNA structures generated during phage DNA 
replication. (b) In AbiD1+ cells, abiD1 translation is repressed under normal conditions. (c) Following infection of 
AbiD1+ cells, Orf1 induces abiD1 translation, resulting in inhibition of the RuvC-like endonuclease activity and 
arrest of phage multiplication. (d) bIL66 AbiD1-resistant mutants all produce a mutated Orf1, which is unable to 
induce abiD1 translation. Phage multiplication proceeds normally; adapted from Chopin et al. (2005) 26 
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E. COLI PHAGE EXCLUSION MECHANISMS 
A few Abi systems (also referred to as phage exclusion proteins) have been well described in E. coli 
and reviewed by Snyder 137.  
 
The Rex system 
The Rex exclusion system is encoded by phage λ presumably to protect the prophage against 
invading virulent phages as observed for the lactococcal Sie systems 103. The system consists of the 
two gene products RexA and RexB which are cytoplasmic and transmembrane proteins, 
respectively. It was shown that the lytic cycle of phage T4 rII mutants would proceed normally until 
the onset of DNA replication at which time the membrane potential of the cell drops and the cell 
dies causing the arrest of phage development. Although the specific molecular mechanism is 
unknown, a protein-DNA complex, possibly a replication or recombination complex was suggested 
to trigger the sudden decrease of membrane potential, which was mediated by RexB forming an ion 
channel allowing passage of monovalent cations 137. The similarities between the RexA/RexB 
system and the lactococcal Abi system AbiT are interesting. Thus both systems are two component 
systems containing a membrane spanning protein and a cytosolic protein, and both systems work 
relatively late by sudden cell death 11,137. 
 
The Lit and PrrC systems 
Two other phage exclusion systems have been described in E. coli both of which have comparable 
patterns of MOA. Both systems consist of a constitutively expressed inactive protein which is 
activated upon phage infection by a small phage encoded peptide. Once activated, the protein 
interferes with evolutionary conserved and essential components of the cell translation machinery 
by cleaving in one case an elongation factor and in the other case the tRNALys 137. In the former case, 
the Lit protein is activated by a short peptide determinant located in the major head protein (MHP) 
which is expressed late in the lytic cycle of phage T4. The presence of Lit simultaneously induces 
transcription termination of the MHP thereby arresting phage assembly and hindering folding of the 
native MHP protein which will leave the small inducing peptide region exposed for activation of Lit 
proteins. The resulting Lit cleavage of the EF-Tu elongation factor arrests translation and thus 
phage development.  
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The second system aborts infection of polynucleotide kinase or RNA ligase deficient mutants of T4 
by the activity of the prrC gene which encodes a ribonuclease that specifically cleaves the host 
lysine tRNA 137. The PrrC is activated by the small (26 amino acids) phage encoded peptide Stp 
which is redundant for normal proliferation of T4. The apparent paradox as to why the phage would 
encode a non-essential protein which only known function is to inhibit phage proliferation was 
solved and gives an insight into the complex molecular interactions in the ongoing arms race 
between phage and host. The prrC gene is located inside a Type Ic R/M restriction cassette between 
the hsdS and hsdR genes and the PrrC protein interacts physically with the HsdS and HsdR proteins. 
In this configuration and in the absence of phage infection the activity of PrrC is not observed, but 
cloning and expression of a solitary prrC revealed an active enzyme. It was therefore suggested that 
the physical interaction between the R/M proteins and PrrC masks the deleterious effects of the 
endonuclease. The real target of the phage encoded Stp might therefore not be the PrrC but the R/M 
system. Since Type I R/M systems need to form a complex to be active, the Stp might function by 
dissociating the R/M complex thereby releasing the PrrC protein that subsequently halts translation 
and phage proliferation by cleaving the lysine tRNA. Thus, the PrrC Abi system possibly functions 
as a second line of defence to arrest phage development if the R/M system is bypassed by an 
infecting phage 137.  
 
It is interesting to note that the MOA of AbiD1 resembles the general pattern of the Lit and PrrC 
systems. The majority of investigations carried out on the MOA of lactococcal Abi systems have 
only been performed for one of the three main phage species. This is unfortunate since the MOA of 
several lactococcal Abi systems differs according to which phage is infecting 8,14,26,40, Manuscript III. In 
general, more research focused on the MOA of lactococcal Abi systems is needed to reveal the 
underlying molecular mechanisms of these interesting phage resistance barriers. 
 
OTHER PHAGE RESISTANCE MECHANISMS 
Engineered phage resistance 
Although natural phage resistance mechanisms constitute the majority of known anti-phage barriers, 
the persistence of industrial phage problems combined with increased availability of phage and 
bacterial genome data and development of molecular tools, has made it feasible to attempt to 
engineer phage resistance mechanisms for protection of industrial production strains 29,81,107. One 
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approach is to produce antisense mRNA by transcription of essential phage genes on the non-coding 
DNA strand. In theory, the antisense mRNA will hybridize to the mRNA thereby blocking 
transcription and therefore also phage development 104. However, in general this method has been 
demonstrated to have only very limited effect on phage inhibition 84.  
The system designated PER for phage encoded resistance utilizes the cloning of a bacteriophage 
origin of replication (ori) on a plasmid. Upon phage infection, the alternative ori will function by 
competitive inhibition, titrating the phage replication factors and thereby inhibit phage proliferation 
72. As expected the effect was shown to be dependent on the copy number of the plasmid. The 
system has been applied as a defence against different lactococcal phages 104,105,119 but generally, 
PER systems suffer from acting very specifically against phages with a specific ori. 
Another engineered phage resistance system takes advantage of phage promoters which are 
activated at a late stage of the lytic cycle by a phage encoded activator molecule. These promoters 
are not recognized by the host RNAP and if a toxic gene is cloned after such promoters it will work 
as a phage induced suicide mechanism. This was exploited and patented by Klaenhammers group 43. 
The system was improved with respect to promoter strength and copy number as well as an 
enhancer of restriction activity 42 and also combined with a PER system specific for Φ31 in addition 
to AbiA. By stacking the phage resistance mechanisms the occurrence of insensitive phage mutants 
was completely eliminated.  
A problem with these engineered phage resistance mechanisms is that generally they are less 
efficient against the target phages and they only function against a narrow range of phages as 
compared to the natural phage resistance mechanisms which have evolved through the never ending 
arms race between phages and bacteria 81. They might however be used as supplements to natural 
anti-phage barriers to increase the overall efficiency by the combined effects of stacking different 
phage resistance mechanisms. A different problem using engineered phage resistance in industrial 
bacterial strains is the characterization of these strains as genetically modified organisms (GMO). 
The industrial use of GMOs is prevented by legal limitations in many countries 54,107 but also 
consumer skepticism is becoming an increasing problem for the use of GMO microorganisms 
33,54,153.  
Despite the focused research in lactococcal phage biology and the emergence of still more 
sophisticated molecular tools, problems with phages in industrial fermentations remain a significant 
economical issue for the dairy industry. Combined with the legislative limitations as well as 
consumer skepticism against GMO, this explains the constant need for discovering and/or 
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improving naturally existing phage resistance mechanisms without using the molecular tools 
regarded as genetic manipulation.  
 
CRISPR – a novel type of phage resistance system 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are found in most Bacteria 
and Archae 4. CRISPRs are found in 50% of the known lactic acid bacteria genomes and though 
they have not been observed in L. lactis a brief description of this novel type of phage resistance 
mechanisms is included in this section.  
A CRISPR is a locus consisting of short (ca 20 bp) conserved repeats which are interspaced by 
other short sequences (ca 20 bp) with a fixed length known as spacers. These spacers consist 
primarily of DNA originating from phages or plasmids. CRISPR associated genes (cas) are located 
adjacent to the CRISPR sequence. By analyzing the CRISPR locis of a phage resistant mutant of S. 
thermophilus charged with a specific phage, it was revealed that this mutant had added repeats and 
spacers, the latter matching DNA sequence from the phage against which the mutant had acquired 
resistance 4. By cloning the newly acquired spacers in the wt strain and confirming that the strain 
had become resistant to the specific phage, the authors demonstrated that the phage resistance 
phenotype was indeed caused by the acquired extra spacer sequences. Knock-out experiments 
revealed that also the cas genes were involved in the resistance phenotype and acquisition of new 
spacer sequences. For the CRISPR phage resistance system to function, 100% sequence identity 
between spacer and phage is required. Since such a high level of sequence identity is required for 
the efficacy of the CRISPR system, it is not surprising that phage mutants that overcome the system 
have mutated primarily by single nucleotide mutations but also deletions in the genes that matches 
the spacer sequences in order to escape the CRISPR system 37. 
One of the most interesting aspects of the CRISPR phage resistance system is that the resistance is 
acquired by the bacterium and that it is heritable in the bacterial cell line 4. It was shown that 
continuous charging with different phages lead to iterative addition of spacers thereby extending the 
range of phages against which the system provides protection 37. This strongly suggest that 
prokaryotes have evolved a kind of a DNA based trainable immunity system in which the spacer 
sequences determine the range of immunity and the cas proteins mediate the resistance 4. 
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ABSTRACT 
 
Insertional mutagenesis with pGhost9::ISS1 resulted in independent insertions within a 350 bp 
region of the chromosome of Lactococcus lactis subsp. cremoris MG1363 that conferred phage 
resistance to the integrants. Orientation and location of the insertions suggested that the phage 
resistance phenotype was caused by a chromosomal gene turned on by a promoter from the inserted 
construct. RT-PCR analysis confirmed higher levels of transcription of a downstream orf in the 
phage-resistant integrants compared to the phage-sensitive L. lactis MG1363. This gene was also 
found to confer phage resistance to L. lactis MG1363 when cloned into an expression vector. A 
subsequent frameshift mutation in the orf completely abolished the phage resistance phenotype 
confirming that the ORF was necessary for phage resistance. This ORF provided resistance against 
virulent lactococcal phages of the 936 and c2 species with efficiency of plaquing (EOP) of 10-4 but 
did not protect against members of the P335 species. High expression of the ORF did not affect 
cellular growth rate. Assays for phage adsorption, DNA ejection, restriction/modification activity, 
plaque size, phage DNA replication, and cell survival showed that the ORF encoded an abortive 
infection (Abi) mechanism. Sequence analysis revealed a deduced protein of 201 amino acids, 
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 which, in its native state, probably forms a dimer within the cytosol. Similarity searches showed no 
homology to other phage resistance mechanisms and thus, this novel Abi mechanism was named 
AbiV. The mode of action of AbiV is unknown but its activity prevented the cleavage of the 
replicated phage DNA of 936-like phages.  
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 INTRODUCTION 
 
The use of Lactococcus lactis starter cultures for the production of fermented dairy products is 
a worldwide practice. However, bacteriophage infection of the added starter cultures may lead to 
fermentation delays or even halt the process. Despite considerable progress made over the past 
decades that has led to improve phage control measures, this natural phenomenon still remains a 
significant risk to the dairy industry 2,14,53. Three groups of lactococcal phages cause the vast 
majority of milk fermentation failures, namely members of the 936 and c2 species, which display 
great intra-species homogeneity but are genetically distinct from each other 12,29,48 and phages from 
the P335 species which exhibit a much greater genomic mosaicism 12,42. To survive this phage 
diversity L. lactis strains possess a wide variety of resistance mechanisms. Lactococcal phage 
defense systems are classified into four general groups depending on the step of the phage lytic 
cycle they inhibit 37. The first two groups either prevent phage adsorption or block DNA ejection 53. 
The last two groups are intracellular antiphage hurdles, namely restriction/modification systems and 
abortive infection (Abi) mechanisms, the latter are reviewed in 14,70 and are arguably the most 
efficient.  
To date, twenty-two lactococcal Abi mechanisms have been isolated, characterized, and 
designated AbiA through AbiZ 14,24. Remarkably, most of them appear to have a distinct mode of 
action, although they do share some common features. These include reduction in burst size, 
reduction in efficiency of plaquing 18,25, reduction in efficiency to form centers of infection (ECOI) 
as well as death of the infected cells 70. The Abi phenotype is usually mediated by a single gene 
though in a few cases (AbiE, G, L, T, and U), the system consists of two genes 9,18,19,30,60. Some 
degree of sequence similarity exists between different Abi proteins 14, but in general, they show 
little similarity to other genes or proteins in databases. This feature is in agreement with their 
antiviral activity towards specific phages or phage groups as well as their particular mechanistic 
models. Indeed, the characterized Abi mechanisms from wild-type L. lactis strains have been shown 
to disable members of one, two or more lactococcal phage groups, although there is a tendency 
towards a broader efficacy against 936 phages 14 which represent the group causing the most dairy 
fermentation failures. The general effects on the phage lytic cycle have been revealed for most Abi 
mechanisms, although in most cases much further characterization is still required. For example, 
AbiA, F, K, P, and T were shown to interfere with DNA replication 9,22,26,30,34 while AbiB, G, and U 
affected RNA transcription 15,18,61. AbiC was shown to cause limited major capsid protein 
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 production 57 whereas AbiE, I, and Q affected phage packaging 25. AbiD1 was found to interfere 
with a phage RuvC-like endonuclease 6,7 and the presence of AbiZ caused premature lysis of the 
infected cells 24.  
Most Abi systems are encoded on plasmids of which some are conjugative, thereby enabling 
the lateral transfer of the resistance mechanism to phage sensitive L. lactis strains and the 
subsequent industrial use of the phage-resistant derivatives. Usually, Abi mechanisms provide a 
much stronger phage resistance phenotype when they are plasmid-encoded (due to higher gene copy 
number) as compared to chromosomally-encoded systems which may explain why so few Abi 
genes are encoded on bacterial genomes 15,62,64. 
Natural Abi mechanisms have been used extensively for protection of industrial starter 
cultures 16,27. Not surprisingly, this added selective pressure has led to the emergence of phage 
mutants capable of overcoming these resistance barriers 16,27. Therefore, it is highly desirable to 
isolate novel phage resistance mechanisms that can be used alone or in combination with other 
mechanisms to provide increased phage protection to the starter cultures 53.  
We report here a novel lactococcal Abi system, named AbiV, which is chromosomally-
encoded and effective against virulent phages of the 936 and c2 species. This novel system was 
discovered through insertional mutagenesis of the laboratory workhorse strain L. lactis MG1363. 
Although insertional mutagenesis is usually used in loss-of-function studies to characterize the 
effect of a genetic knock-out 23,47,50, our data indicated that the expression of AbiV was turned on by 
the insertion of pGhost9::ISS1. The microbiological and molecular characterizations of AbiV are 
also presented.  
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 MATERIALS AND METHODS 
 
Bacterial strains, phages, and plasmids. Bacterial strains used in this study are listed in Table 1, 
whereas bacteriophages and plasmids are listed in Table 2. Bacteriophages sk1 and jj50 were kindly 
provided by F.K. Vogensen (University of Copenhagen). L. lactis strain MB112 was used as host 
for the selection of phage resistant integrants. This strain is a derivative of L. lactis subsp. cremoris 
MG1363, with a mutation in the upp gene. This mutation renders L. lactis MB112 resistant to 
fluorouracil, which provided an additional marker to confirm that the phage resistant integrants 
were derived from the parental strain 49. Escherichia coli was grown at 37ºC in LB medium 68. L. 
lactis was grown in M17 71 supplemented with 0.5 % glucose (GM17). When fluorouracil resistance 
was tested, L. lactis strains were grown in SA medium supplemented with 0.5 % glucose 36. 
Lactococci were grown at 30ºC, except strains containing the thermo-sensitive vector 
pGhost9::ISS1, which were grown at 28ºC or 37ºC to allow replication or integration, respectively 
of the vector. When L. lactis grew at temperatures above 30ºC, NaCl (1%) was added to the 
medium 39. In phage infection experiments, 10 mM CaCl2 was added to plates or medium. When 
appropriate, antibiotics were added as follows: for E. coli, 100 µg ml-1 of ampicillin, 10 µg ml-1 of 
chloramphenicol, and 150 µg ml-1 of erythromycin; for L. lactis, 3 µg ml-1 of chloramphenicol, 3 µg 
ml-1 of erythromycin, and 0.3 µg ml-1 fluorouracil. 
 
Insertional mutagenesis with pGhost9::ISS1 and isolation of phage-resistant mutants. Phage-
resistant derivatives of L. lactis MB112, were obtained by insertional mutagenesis using the vector 
pGhost9::ISS1, essentially as described by Maguin et al. 47. Subsequent cloning of the flanking 
chromosomal DNA was also performed according to Maguin et al. 47. To ensure the isolation of 
phage-resistant integrants from distinct events, the mutagenesis was performed on three 
independent cultures of L. lactis MB112 containing pGhost9::ISS1. These cultures were grown 
overnight at 28ºC in GM17 containing erythromycin. The cultures were then diluted 100-fold in 
GM17 and grown for 2.5 h at 28ºC to attain exponential growth. The cells were incubated at 37˚C 
for 2.5 h to allow plasmid integration. The cultures were diluted again but 10,000-fold in 50 ml 
GM17 supplemented with erythromycin and incubated overnight at 37ºC to allow phenotypic 
expression. These overnight cultures were inoculated (1 %) in fresh GM17 medium with 
erythomycin and incubated at 37ºC. When they reached exponential growth, aliquots were mixed 
with the virulent lactococcal phage sk1 (MOI > 1). Following 10 min incubation at 37ºC, the 
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 infected cells were plated on GM17 plates containing erythromycin, NaCl (1%), and CaCl2 (10 
mM) and incubated two days at 37ºC. The frequency of phage-resistant mutants was calculated and 
one hundred of them were selected at random from the three independent cultures. The phage 
resistant phenotype of these mutants was verified by cross-streaking with virulent phage sk1 at 
37ºC. Finally, curing the phage-resistant mutants of the pGhost9::ISS1 plasmid, thereby leaving a 
single copy of ISS1 at the integration site, was performed as described by Maguin et al. 47. 
 
RNA isolation, purification and RT-PCR analysis. Overnight cultures were diluted 100-fold and 
grown to OD600 of 0.5 at 37ºC. Aliquots (2 ml) were harvested by quick centrifugation (20,000 g, 30 
sec) and the pellet was resuspended in a solution of 0.5 M sucrose with 60 mg ml-1 lysozyme. 
Following incubation (37ºC, 15 min), the cells were pelleted and resuspended in 1 ml TRIzol 
Reagent (Invitrogen). Total RNA was isolated according to the manufacturer’s instructions. Prior to 
reverse transcription (RT)-PCR, RNA samples were treated with the DNase based TURBO DNA-
free kit (AB).  
RT-PCR was carried out using the RevertAid First Strand cDNA Synthesis kit (Fermentas) as 
recommended by the manufacturer. As a control, the RT-PCR procedure was carried out without 
reverse transcriptase to ensure that the RNA samples were free of contaminating DNA.  
 
Phage assays. Propagation of phages 26, titers of phage lysates 40, efficiency of plaquing (EOP) 69 
and cross streaking assays 67 were performed as described previously. Adsorption assays were 
conducted as described elsewhere 69, except that a 5 min incubation period was used instead of 15 
min. Cell survival 5 was assayed using a multiplicity of infection (MOI) of 5. One-step growth 
curve experiments and center of infection (COI) assays 57 were performed using MOIs of 0.2 and 
0.5, respectively. ECOI (efficiency of COI) and burst size was calculated as previously reported 57.  
 
Phage DNA replication. Replication of phage DNA was followed in a time course experiment 33. 
Briefly, total DNA of L. lactis cells was isolated at 10 min intervals from cultures infected with 
reference phage p2 (MOI of 2), which is closely related to phage sk1. Total DNA was digested with 
EcoRV and heated (65ºC, 10 min) prior to gel electrophoresis allowing identification of resolved 
cos sites that were used to distinguish concatemeric and mature phage DNA. 
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 TABLE 1. Bacterial strains used in this study 
Bacterial strain Relevant characteristicsa Source 
L. lactis   
  IL1403 subsp. lactis, host for 936-like phages 8 
  MB112 subsp. cremoris MG1363, Δupp, host for 936- and c2-like phages 49 
  MG1363 subsp. cremoris, host for 936-like and c2-like phages 31 
  SMQ-86 subsp. cremoris, host for P335-like phages, ErmR 26 
  JH-20 MB112 (pJH2), CamR, Abi+ This study 
  JH-22 IL1403 (pJH2), CamR, Abi+ This study 
  JH-23 SMQ-86 (pJH2), CamR, Abi+ This study 
  JH-24 MB112 (pJH3), CamR, Abi- This study 
  JH-32 MB112 (pGhost9::ISS1 inserted into Lin at 1962); ErmR, Abi+ This study 
  JH-46 MB112 (pGhost9::ISS1 insertion into Lin at 1962); ErmR, Abi+ This study 
  JH-47 MB112 (pGhost9::ISS1  insertion into Lin at 2296); ErmR, Abi+ This study 
  JH-48 MB112 (pGhost9::ISS1  insertion into Lin at 2240); ErmR, Abi+ This study 
  JH-49 JH-32 cured of pGhost9, ISS1+, Abi- This study 
  JH-50 JH-46 cured of pGhost9, ISS1+, Abi- This study 
  JH-51 JH-47 cured of pGhost9, ISS1+, Abi- This study 
  JH-52 JH-48 cured of pGhost9, ISS1+, Abi- This study 
  JH-53 MB112 (pJH6), CamR, Abi- This study 
  JH-54 MB112 (pLC5), CamR, Abi- This study 
  JH-79 MG1363 (pJH2), CamR, Abi+ This study 
E. coli   
  EC1000 RepA+ MC1000, KmR 43 
  JH-56 EC1000 (pJH7), ErmR This study 
  JH-57 EC1000 (pJH8), ErmR This study 
  JH-58 EC1000 (pJH9), ErmR This study 
  JH-59 EC1000 (pJH10), ErmR This study 
  JH-62 M15 (pJH11), KmR, AmpR This study 
  M15 pREP4, KmR, used for cloning of pQE-70 His-tag vector Qiagen 
  MC1061 Laboratory strain, cloning host 52 
  TOP10F' Chemically competent cells from the TOPO TA cloning kit Invitrogen 
aLin refers to GenBank sequence accession number AF324839. Abi+, phage resistance phenotype; Abi-, 
phage sensitive phenotype; AmpR, ampicillin resistance; CamR, chloramphenicol resistance; ErmR, 
Erythromycin resistance; KmR, Kanamycin resistance. 
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 TABLE 2. Phages and plasmids used in this study 
Phage/plasmid Relevant characteristica Sourcea 
Phages   
  bIL170 Small isometric headed, 936 species 17 
  jj50 Small isometric headed, 936 species 38,48 
  p2 Small isometric headed, 936 species 58 
  P008 Small isometric headed, 936 species 44,48 
  sk1 Small isometric headed, 936 species 13 
  712 Small isometric headed, 936 species 48 
  c2 Prolate headed, c2 species 69 
  bIL67 Prolate headed, c2 species 69 
  eb1, ml3 Prolate headed, c2 species 58 
  ul36 Small isometric headed, P335 species 41,55 
  ul36.k1t1 Small isometric headed, P335 species 42 
  ø31, ø50 Small isometric headed, P335 species 1 
  P335 Small isometric headed, P335 species 11 
  Q30, Q33 Small isometric headed, P335 species 54 
Plasmids   
  pCI372 Cloning vector for E. coli and L. lactis, CamR 32 
  pCR II-TOPO Cloning vector, AmpR Invitrogen 
  pGhost9::ISS1 Temperature sensitive vector used for mutagenesis, ErmR 47 
  pJH2 1021-2320 fragment cloned in PstI site of pLC5; CamR This study 
  pJH3 pJH2 cut in ClaI site, filled with Klenow, abiV frameshift mutation; CamR This study 
  pJH6 1021-2320 fragment cloned in PstI and XbaI sites of pCI372 This study 
  pJH7 HindIII rescue of pGhost9::ISS1 with flanking chromosomal DNA of JH-32 This study 
  pJH8 HindIII rescue of pGhost9::ISS1 with flanking chromosomal DNA of JH-46 This study 
  pJH9 HindIII rescue of pGhost9::ISS1 with flanking chromosomal DNA of JH-47 This study 
  pJH10 HindIII rescue of pGhost9::ISS1 with flanking chromosomal DNA of JH-48 This study 
  pJH11 1273-1875 fragment cloned in pQE-70, C-terminal His-tag, AmpR This study 
  pLC5 E. coli - L. lactis shuttle expression vector, promoter in front of PstI, CamR This study 
  pQE-70 Cloning vector for C-terminal His-tagging of proteins, AmpR Qiagen 
a Fragment refers to GenBank accession number AF324839; AmpR, ampicillin resistance;  
CamR, chloramphenicol resistance; ErmR, erythromycin resistance; KmR, kanamycin resistance. 
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  Phage adsorption and DNA injection assays using SYBR-Gold staining. Visualization of phage 
DNA by labeling with the fluorescent dye SYBR-Gold was performed as described by Noble and 
Fuhrman 59 with the following modifications. The original SYBR-Gold solution was first diluted 
1000-fold. The phage lysate was treated with 1 μg ml-1 DNAse and RNAse for 30 min at 37oC and 
then stained with the diluted SYBR-Gold to give a final concentration of 2.5% (vol/vol). The 
mixture was incubated for a minimum of 12 h at 4ºC in the dark. One µl of the labeled phage lysate 
was mixed with 1 µl exponentially growing cell culture and visualized under a Zeiss axioplan 
microscope. 
 
Rescue cloning and sequencing of the flanking chromosomal DNA. Chromosomal DNA was 
analyzed for six phage-resistant integrants. The HindIII-digested DNA was purified, diluted to favor 
self-ligation and ligated as described by Maguin et al. 47. The ligation mixture was electroporated in 
E. coli EC1000 43 and plated on LB agar with erythromycin. Plasmid DNA containing the rescued 
pGhost9::ISS1 and the flanking chromosomal DNA was isolated from E. coli cells (JH-56 to JH-
59). Chromosomal DNA flanking the ISS1 element was sequenced using the primer (5’-
GAAGAAATGGAACGCTC-‘3), annealing to the ISS1 sequence. The above procedure was 
successful for four of the six candidates. 
 
DNA isolation and manipulation. Plasmid DNA was isolated from L. lactis using the QIAprep 
Spin Miniprep Kit (Qiagen) according to the manufacturer’s recommendation with the exception 
that lysozyme (15 mg ml-1) was added to buffer P1 and the lysis solution with the resuspended cells 
was incubated at 37ºC for 30 min before proceeding with the protocol. Restriction enzymes, T4 
DNA ligase, and Klenow fragment (Fermentas) were used according to the manufacturer’s 
instructions. Electroporation of L. lactis was performed as described previously 35,56. The DNA 
fragment corresponding to nucleotides 1021 to 2320 in the GenBank sequence AF324839 (Fig. 1) 
was first cloned into the E. coli pCR II-TOPO vector (Invitrogen) using TOP10F' cells prior to 
cloning into the E. coli-L. lactis shuttle vectors pCI372 and pLC5. For protein purification, the 
DNA fragment corresponding to nucleotides 1273 to 1875 in the GenBank sequence AF324839 was 
cloned into the His-tag vector pQE-70 (Qiagen) as recommended by the manufacturer to create 
pJH11 in the strain JH-62. 
Protein purification and gel-filtration. A C-terminally his-tagged protein was purified according 
to the manufacturer’s instructions (Qiagen). Gel-filtration was carried out on a HiPrepTM 16/60 
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 SephacrylTM S-300 High-Resolution column from GE Healthcare, using 150 µg AbiV and a 
flowrate of 0.2 ml min-1. The column was connected to a Shimadzu HPLC system. The solvent 
delivery module used was LC-10ADvp and the detector used was SPD-M10Avp (280 nm). The 
composition of the mobile phase was 50 mM Tris-HCl, 200 mM NaCl pH 7.6. A Bio-RAD protein 
standard (cat. No. 151-1901) was used to determine the molecular weight of the purified protein. 
Each run lasted 800 minutes. The molecular weight was estimated by taking the mean of four 
different trials. 
 
Construction of the expression vector pLC5. The low-copy vector pGKV259 73 was digested 
with PstI (located downstream from the P59 promoter) followed by gel purification. Two 
complementary oligonucleotides  
(5’- TGGATCCAAAGGAGGTCCTGCA-3’ and 5’- GGACCTCCTTTGGATCCATGCA-3’)  
were annealed together 68 to create a double-stranded linker with PstI-compatible sticky ends. This 
linker also contained a unique BamHI site and a ribosome-binding site (RBS: 5’-AGGAGG-3’). 
The linker was inserted into the PstI site of pGKV259 and the ligation mixture was transformed into 
E. coli MC1061. Transformants were selected on LB plates containing 20 µg ml-1 of 
chloramphenicol. Positive clones with the linker inserted in the right direction were identified by 
colony PCR and clones were confirmed by sequencing. Upon introduction of the linker into 
pGKV259, the PstI site on the 5’-side of the linker was disrupted whereas the one on the 3’-side 
was conserved. Thus, a unique PstI site was created 8-bp downstream from the RBS. Cloning of a 
DNA fragment possessing an ATG start codon into the PstI site of pLC5 enables efficient 
transcription from the P59 promoter, and translation from the introduced RBS.  
 
DNA and protein analyses. Sequence similarity searches in databases were performed using 
BLAST 3 at the NCBI website: http://www.ncbi.nlm.nih.gov/blast/Blast.cgi. Search for helix-turn-
helix motifs were done using the website: http://npsa-pbil.ibcp.fr/. Molecular weight and pI of the 
investigated proteins were estimated using the Protein Calculator at the website: 
http://www.scripps.edu/~cdputnam/protcalc.html. Searches for transmembrane domains and signal 
peptide motifs were performed using the predictor websites 
http://www.cbs.dtu.dk/services/TMHMM-2.0/ and http://www.cbs.dtu.dk/services/SignalP/.  
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 RESULTS 
 
Isolation of phage-resistant mutants of L. lactis subsp. cremoris MG1363 using insertional 
mutagenesis. The laboratory strain L. lactis subsp. cremoris MB112 (MG1363∆upp) 49 is sensitive 
to several virulent phages from the 936 and c2 species. To identify genes involved in the sensitivity 
of L. lactis MG1363 to 936 phages, mutant cells resistant towards phage sk1 were isolated after 
insertional mutagenesis of the host. The insertional mutagenesis was performed on three cultures 
resulting in the isolation of three independent insertion libraries. Selection for resistance to virulent 
lactococcal phage sk1 was performed for all three libraries (MOI > 1). The frequency of phage 
resistant colonies was 6.2 ± 2.6 x 10-6 which is 100-fold higher as compared to the frequency of 
spontaneous phage resistant mutants obtained from wild-type cultures (5.9 ± 3.0 x 10-8). 
 
Identification of a chromosomal gene involved in phage resistance. A total of 6 confirmed 
phage-resistant mutants (two randomly selected from each of the three independent cultures) were 
chosen for plasmid rescue experiments. In four cases it was possible to isolate the inserted plasmid 
along with a piece of flanking chromosomal DNA (pJH7 to pJH10). Sequence analysis revealed 
insertions within the same 350 bp region on the chromosome of the four phage-resistant mutants. 
The insertions were located within the intergenic region between two genes (designated orf1 and 
trans) or within the 3’ end of the trans gene (Fig. 1A). The inserts were located at nucleotide 1962 
(for phage resistant mutants JH-32 and JH-46), 2240 (JH-48), and 2296 (JH-47). The nucleotide 
positions are based on the sequence available under the GenBank accession number AF324839. JH-
32 and JH-46 originated from the same mutation library and may be daughter cells. Since insertions 
in the three different phage-resistant mutants were observed both within the trans gene and in the 
intergenic region between trans and orf1, the phage resistance phenotype could not be caused by a 
knocked out trans gene. Furthermore, the lin gene downstream of orf1 is transcribed in the opposite 
direction. Taken altogether, these results pointed toward orf1 as a key player in the phage resistance 
phenotype.  
At least two hypotheses could explain the involvement of orf1 in the phage resistance 
phenotype. Orf1 could be part of an operon transcribed from a promoter upstream of trans and thus 
terminated by the pGhost9::ISS1 insertions, thereby inactivating the transcription of the gene. A 
second possibility could be that the pGhost9::ISS1 insertion provided a promoter upstream of orf1. 
In this latter scenario, the transcription of orf1 would be initiated from a promoter within the ISS1 
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 sequence or from the Emr gene in the pGhost9::ISS1 construct, leading to the activation of a phage 
resistance phenotype. When the insertion mutants were cured of the vector pGhost9::ISS1, leaving a 
single copy of ISS1 at the integration site, the cured L. lactis strains (JH-49 to JH-52, Table 1) lost 
the phage resistance phenotype, suggesting that a promoter activity originated from the vector, 
possibly from the Emr gene (Fig. 1A). 
To test the hypothesis that orf1 was transcribed from a promoter within the inserted 
pGhost9::ISS1, a RT-PCR assay was made on L. lactis strains with and without the insertion. RNA 
from exponentially growing cells was used as template for random reverse transcription of total 
RNA and primers annealing to an internal region of orf1 were used to amplify the cDNA by PCR. 
A PCR product of the expected size was observed in the mutant with the insertion (Fig. 2, Lane 3) 
but not in the wild-type strain (Fig. 2, Lane 2), indicating that the transcription of orf1 was turned 
on in the mutant. A negative control experiment was conducted without reverse transcriptase 
confirming that the samples were free of contaminating DNA (Fig. 2B). A positive control 
Fig. 1. Localization of orf1 (abiV) on the chromosome of L. lactis MG1363. Numbers refer to nucleotide positions in the 
GenBank sequence AF324839. (A) L. lactis strains with the transposon containing vector pGhost9::ISS1 or cured of 
pGhost9 thus containing a solitary ISS1 inserted on the chromosome. Numbers and arrows indicate the position and 
direction of the inserts. (B) L. lactis strains with the cloned DNA fragment (bp 1021-2320) including orf1. Arrows 
indicate promoter P59 and the × in JH-24 represents the position of the frameshift mutation introduced into this strain. 
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 experiment was included using primers for the glycolytic genes gapB and pfk (data not shown). The 
positive result of this experiment excluded artifacts due to loss of RNA in the sample. 
 
 
A silent phage resistance mechanism encoded by orf1 exists on the chromosome of L. lactis 
subsp. cremoris MG1363. To test the hypothesis that orf1 is encoding a phage resistance 
mechanism, a DNA fragment (positions 1021 to 2320 in the GenBank sequence AF324839) 
comprising only one ORF (orf1) and the upstream region including the most distant insertional 
mutation site at position 2296 was cloned in the promoter-less shuttle vector pCI372 (pJH6) and in 
the expression vector pLC5 (pJH2) (Fig. 1B). These constructs were transformed in L. lactis 
MB112 and the resulting strains (JH-53 and JH-20, respectively) were tested for phage resistance. 
L. lactis JH-53 (pJH6, with no promoter upstream of orf1) was sensitive to phage sk1 whereas L. 
lactis JH-20 (pJH2, with a strong promoter upstream of orf1) was resistant to phage sk1 (Fig. 1B). 
In fact, the highest level of expression was observed when orf1 was expressed from the pLC5 
vector, which was probably due to the strong P59 promoter (Fig. 2, lane 1 and 3). Furthermore, 
Fig. 2. RT-PCR (20 PCR cycles) on RNA isolated from exponentially growing L. lactis cultures. Lane 1, JH-20 (pJH2); 
Lane 2, JH-54 (pLC5); Lane 3, JH-32 (insertion mutant); Lane C, control PCR with L. lactis MB112 chromosomal DNA; 
Lane L, ladder (GeneRulerTM, 100-10,000 bp (Fermentas)). (A) The experiment was performed with reverse transcriptase. 
(B) The experiment was performed without reverse transcriptase. 
55
 expression of orf1 (pJH2) in another host (Lactococcus lactis subsp. lactis IL1403) also conferred a 
phage resistance phenotype. The above results indicated that the expression of orf1 was responsible 
for the phage resistance phenotype.  
To verify that a protein encoded by orf1 was responsible for the resistance to phage sk1, a 
frameshift mutation was introduced into orf1, by digesting at a unique ClaI site (codon 36 in orf1), 
filling the ends with Klenow fragment followed by ligation, confirmation by sequencing, and 
transformation of the resulting plasmid pJH3 into L. lactis MB112. The frameshift mutation 
abolished the phage resistance phenotype in the resulting strain JH-24 (Fig. 1B). We concluded that 
the protein encoded by orf1 was responsible for the phage resistance phenotype. 
 
Sequence and analysis of orf1. The 1300 nucleotide DNA fragment cloned into pJH2 was 
sequenced and found to be 100 % identical to the region encompassing nucleotides 1021 to 2320 in 
the GenBank accession number AF324839 as well as positions 697547 to 698846 in the complete 
genome sequence of L. lactis MG1363 (AM406671). The G+C content of orf1 was 31.7 %. No 
suitable promoter could be found upstream of orf1 (bp 1 to 430) using Winseq software (F. G. 
Hansen, unpublished). This is in agreement with the experimental results that orf1 is silent in wild-
type L. lactis MG1363. The translation start codon of orf1 was preceded by a suitable ribosome-
binding site (5’-TGAACGGAGAG-3’, underlined sequence matches consensus sequence). DNA 
sequence analysis did not identify any transcription terminator structures between orf1 and the 
upstream trans gene leaving the possibility that orf1 could be part of an operon initiated upstream of 
trans. However, the negative RT-PCR data for orf1 transcription in the wild type strain (Fig. 2, 
Lane 2) suggests that orf1, and perhaps trans as well, is not expressed under the conditions tested. 
This was further confirmed by Northern analysis of the insertion mutant L. lactis JH-32 and wild-
type L. lactis MG1363 in which transcription of orf1 was observed only in JH-32 (data not shown). 
 
The phage resistance mechanism encoded by orf1 is effective against virulent lactococcal 
phages of the 936 and c2 species. Representatives from the three main lactococcal phage species, 
namely 936, c2, and P335, were tested for their sensitivity to orf1 (Table 3). Efficiency of plaquing 
(EOP) values of approximately 10-4 were obtained for the four tested c2-like phages and for five of 
the six tested members of the 936 species (Table 3). Phage 712 (936 species) was insensitive to orf1 
(EOP of 1, Table 3). The seven phages of the P335 species were also unaffected by the presence of 
orf1 (Table 3). Because the efficacy of orf1 on virulent P335 phages was tested with another L. 
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 lactis host (SMQ-86), we needed to rule out the possibility that the insensitivity of P335 phages was 
due to a mutation in pJH2 present in L. lactis SMQ-86 (L. lactis JH-23). Thus, the plasmid pJH2 
was isolated from L. lactis JH-23 and re-introduced into L. lactis MB-112. Phage p2 was unable to 
effectively replicate on this recombinant host (EOP of 10-4), indicating that pJH2 was indeed 
functional and confirming that the P335 phages are insensitive to orf1. 
 
TABLE 3. Efficiency of plaquing (EOP) 
 Phage L. lactis strain EOPc 
936 speciesa sk1 JH-20 (pJH2) 2.7 ± 1.4 x 10-4 
 p2 JH-20 (pJH2) 4.8 ± 1.8 x 10-4 
 jj50 JH-20 (pJH2) 8.3 ± 0.5 x 10-5 
 712 JH-20 (pJH2) 1.1 ± 0.2 
 P008 JH-22 (pJH2) 3.8 ± 1.5 x 10-4 
 bIL170 JH-22 (pJH2) 3.1 ± 1.2 x 10-4 
    
c2 speciesa c2 JH-20 (pJH2) 5.2 ± 0.4 x 10-5 
 bIL67 JH-20 (pJH2) 2.0 ± 1.2 x 10-4 
 ml3 JH-20 (pJH2) 3.4 ± 0.3 x 10-4 
 eb1 JH-20 (pJH2) 2.2 ± 0.7 x 10-4 
    
P335 speciesb ul36 JH-23 (pJH2) 1.0 
 ul36.k1t1 JH-23 (pJH2) 1.6 
 ø31 JH-23 (pJH2) 1.0 
 ø50 JH-23 (pJH2) 1.0 
 Q33 JH-23 (pJH2) 0.7 
 Q30 JH-23 (pJH2) 0.8 
 P335 JH-23 (pJH2) 0.4 
a EOP of 936- and c2-like phages is 1.0 on L. lactis MG1363 (MB112) and 
MB112 + pLC5 (JH-54). EOP of phages P008 and bIL170 is 1.0 on L. lactis 
IL1403.  
b EOP of P335 species is 1.0 on L. lactis SMQ-86. 
c EOP was calculated as an average of three independent assays. 
 
The efficiency of plaquing of 936 and c2-like phages was also tested at 30ºC and 37ºC and 
found to be similar, indicating that the system is stable within this temperature range. EOP values of 
1.6 ± 0.2 x 10-5 and 2.7 ± 0.3 x 10-4 were obtained for phages sk1 and p2, respectively when orf1 
was expressed from the chromosome in the insertion mutants. These values are in the same range as 
when orf1 is expressed from a strong promoter in the low-copy expression vector pLC5. However, 
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 when the insertion mutants were tested against phage c2, EOP values of 4.6 ± 0.9 x 10-1 were 
obtained, indicating that orf1 needs higher expression to be efficient against c2. Finally, pJH2 was 
transformed into L. lactis MG1363 (JH-79) and tested for efficiency of plaquing against phages p2, 
712, and c2. EOP values similar to the ones obtained on MB112 excluded the possibility that the 
upp deletion in MB112 is influencing the phage resistant phenotype.  
The efficiency of orf1 as a phage resistance mechanism was further characterized using phage 
p2 and L. lactis strains JH-20 (pJH2) and MB112 (Table 4). The ECOI of phage p2 on L. lactis JH-
20 was 0.5 ± 0.2 % indicating that only 5 out of 1000 infected cells released at least one virulent 
phage. One-step growth curve experiments were then performed in presence or absence of pJH2 
(orf1). The burst size was reduced by 72 % (from 38.8 ± 5.7 in MB112 to 11.1 ± 5.2 in JH-20) 
(Table 4). 
 
TABLE 4. Effect of AbiV on phage p2 
Assay a MB112 (wt) JH-20 (AbiV) 
EOP b 1.0  4.8 ± 1.8 x 10-4 
ECOI (%)c 100 0.5 ± 0.2 
Burst size (pfu/cell)d 38.8 ± 5.7 11.1 ± 5.2 
Latency time (min)d 20-30 20-30 
Cell survivale (%) 6.1 ± 1.3 x 10-5 3.1 ± 0.3 x 10-6 
DNA replicationf + + (concatemeric) 
Plaque size (mm) 1.5 to 1.7 pinpoint to 0.7 
a All assays were conducted at 30 ºC. 
b n=3, EOP of phage p2 is 1.0 on L. lactis MG1363 (MB112). 
c MOI = 0.5, n=3, ECOI of phage p2 is 1.0 on L. lactis MB112. 
d MOI = 0.2, n=3. e MOI = 5, n=3. f MOI = 2, n=1. 
 
 
The phage resistance system encoded by orf1 is an abortive infection (Abi) mechanism. A 
series of experiments were conducted to determine the type of phage resistance mechanism encoded 
by orf1. Adsorption assays showed that the level of adsorption of phage sk1 to phage resistant cells 
was 95.9 ± 10.6 %, which is similar to adsorption level to the wild type host. Furthermore, 
fluorescently labeled (SYBR-Gold) phage DNA was visualized after sk1 infection of the phage-
resistant strain L. lactis JH-20 and the phage-sensitive strain MB112. Immediately following phage 
infection, a fluorescent halo of adsorbed phages was seen surrounding the host cells (data not 
shown). Less than 15 min after the beginning of phage infection, the fluorescent signal on the cell 
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 surface was reduced while a bright fluorescent signal was observed in the center of the cell, 
indicating that the phage DNA had been ejected into the host cell (data not shown). Identical results 
were obtained for phage resistant and phage sensitive strains. The above results indicated that the 
phage resistance mechanism was not an adsorption or ejection blocking mechanism.  
Smaller phage plaques can be observed at a frequency of 10-4 on L. lactis JH-20, which 
contains orf1. These plaques were propagated on L. lactis JH-20 cells as well as on the phage-
sensitive host L. lactis MG1363 and found to be insensitive to the antiphage mechanism, which 
demonstrates that it is not a restriction/modification system. A cell survival assay showed virtually 
no survival of cells from the sensitive or the phage resistant strain upon phage infection (Table 4). 
Moreover, the size of the few plaques of phage p2 arising at a frequency of 10-4 were smaller on the 
phage resistant strain as compared to the wild-type sensitive L. lactis strain (Table 4). The above 
results are well-documented characteristics of abortive phage infection mechanisms. The low G+C 
content of orf1 (31.7 %) is also typical of Abi mechanisms. Taken altogether, the phage resistance 
mechanism encoded by orf1 is an abortive infection mechanism. Accordingly, the gene was named 
abiV and the Abi mechanism was named AbiV. 
 
Analysis of the AbiV protein. AbiV consists of 201 amino acids and has a calculated molecular 
weight of 22,692 Da. A His-tagged AbiV protein was overexpressed in E. coli and purified. The 
native molecular weight of the purified AbiV protein was estimated to 49 ± 0.3 kDa by gel filtration 
(data not shown), suggesting that AbiV forms a dimer in its native form. The pI was calculated to be 
5.37. The protein does not contain any putative transmembrane or signal peptide motifs and it is 
therefore likely cytosolic. Although 69 % of AbiV consists of α-helixes, no helix-turn-helix motif 
was found in AbiV. Similarity searches using several bioinformatics tools did not reveal any 
similarity to other lactococcal proteins or any other phage resistance mechanism, nor was AbiV 
found in other sequenced lactococcal strains. Likewise, no conserved domains were found in the 
protein. 
 
Expression of AbiV does not affect cellular growth rate or final biomass. A cell growth 
experiment was conducted to test whether the expression of AbiV from a strong plasmid-encoded 
promoter could influence the cell growth rate or final biomass. L. lactis JH-20 (Abi+) and MB112 
(Abi-) grew exponentially in GM17 at 30ºC with growth rates of 1.04 ± 0.08 h-1 and 1.00 ± 0.03 h-1, 
respectively. Final biomasses were 2.49 ± 0.10 x 109 cells ml-1 and 2.45 ± 0.02 x109 cells ml-1, 
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 respectively. From these experiments, it was concluded that the expression of AbiV did not affect 
cellular growth. Moreover, it showed that the newly constructed expression vector pLC5 did not 
interfere with cell growth. 
 
AbiV affects phage DNA maturation. The DNA replication of the cos-type virulent lactococcal 
phage p2 was followed at time intervals during infection of a resistant (JH-20) and a sensitive (JH-
54) L. lactis strain. Phage DNA was analyzed by digesting the total DNA isolated from infected 
cells with EcoRV and then comparing the resulting fragments with the EcoRV restriction map of 
phage p2 (Fig. 3). Ten minutes after infection, replication of phage DNA was observed in both 
strains. In sensitive cells, the concentration of phage DNA decreased around 40 min after infection 
coinciding with lysis of the host culture. In comparison, phage DNA persisted in the resistant cells 
throughout the experiment, which was terminated after 2h. 
Analysis of the EcoRV-digested phage DNA pattern revealed, among others, two bands of 
1.3- and 4-kb as well as a 5.3-kb fragment in the phage sensitive culture. The 5.3-kb DNA fragment 
spans the cos site on the phage p2 genome with the 1.3- and 4-kb fragments representing the mature 
encapsidated phage DNA. Therefore, both replicative and encapsidated DNA was observed in the 
phage sensitive strain due to continuous DNA replication throughout the phage life cycle and 
simultaneous encapsidation of mature DNA. In the resistant cells, only the 5.3-kb fragment was 
observed. The absence of the 1.3- and 4-kb bands as well as the presence of phage DNA throughout 
the experiment indicated that phage DNA accumulated in its concatemeric (non-mature) form in the 
resistant L. lactis cells. Similar results were obtained with the closely related phage sk1 (data not 
shown). The above results showed that AbiV prevented the cleavage of the replicated phage DNA 
and thus that it acts at a later stage of the phage infection process. 
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Fig. 3. Replication of phage p2 DNA during infection of the phage sensitive strain L. lactis JH-54 (A) and the phage 
resistant strain L. lactis JH-20 (B). Samples were taken at: -10, 0, 10, 20, 30, 40, 50, 60, 90, and 120 minutes and total 
DNA was restricted with EcoRV. Band 5.3 kb (consisting of bands 1.3 kb and 4 kb in mature resolved DNA) is spanning 
the cos site which marks the extremities of the phage genome. Numbers refer to the size of phage p2 DNA fragments after 
EcoRV digestion and heat treatment (C). Ladder is GeneRulerTM, 100-10,000 bp (Fermentas). 
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 DISCUSSION 
 
Insertional mutagenesis was used to confer phage resistance to L. lactis subsp. cremoris 
MG1363. Four phage-resistant mutants obtained from three independent insertional mutagenesis 
experiments were selected for further analysis and in each case the insertion was located within the 
same 350 bp region of the bacterial chromosome. Insertional mutagenesis with the pGhost9::ISS1 
system 46,47 was previously used to knock-out factors involved in phage adsorption 23 and in DNA 
ejection 45. Such loss-of-function effects of insertional mutagenesis is the usual outcome of these 
experiments 23,65,72. However, using a similar strategy, Luccini et al. also isolated a phage-resistant 
mutant of Streptococcus thermophilus in which promoter activity from the insertion turned on a 
downstream R/M mechanism 45. A similar finding was obtained in this study as the integration of 
pGhost9::ISS1 conferred phage resistance to the cell by activating an abortive infection mechanism.  
All the ISS1 inserts were oriented in the same direction as orf1 which made us speculate that 
orf1 could be transcribed from a promoter within ISS1 or from the Emr gene in pGhost9::ISS1 47. 
Promoter activity has previously been reported outward of insertion sequences 28 both in forward 23 
and backward direction 15 and insertion sequences with a high degree of similarity to ISS1 have also 
been known to be in the vicinity of abortive infection mechanisms 4,15. Searches for promoter 
sequences in the forward direction of ISS1 were unsuccessful. This observation was supported by 
the reversion to a phage sensitive phenotype when the mutants were cured of the plasmid while 
keeping a single copy of ISS1 at the integration site (Fig. 1A). However, the activation hypothesis 
was supported by subsequent transcription analyses using RT-PCR on mRNA from L. lactis strains 
with and without the insertion. A higher level of transcription of orf1 was observed in the presence 
of an upstream pGhost9::ISS1 insertion. These results indicated that orf1 was indeed turned on by a 
promoter in pGhost9::ISS1, which was most likely the promoter of the Emr gene. The cloning of 
orf1 and its upstream region into the promoter-less vector pCI372 failed to confer resistance while a 
similar cloning into the expression vector pLC5 gave a phage resistance phenotype. An active orf1 
was later proved to encode the abortive infection protein AbiV thereby confirming the use of 
integration by pGhost9::ISS1 to transcribe silent genes on bacterial chromosomes.  
The ISS1 insertion sequence is reported to integrate randomly on the chromosome of L. lactis 
47. In the present study, ISS1 integrated in a 350 bp region in three independently obtained mutants 
conferring phage resistance. In a similar study with L. lactis subsp. cremoris Wg2 and L. lactis 
subsp. lactis IL1403, Dupont et al. 23 obtained phage resistant mutants that were due to a defect in 
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 phage adsorption with frequencies around 5 x 10-6, the same frequency obtained in the present 
study. We did not obtain any mutants with reduced phage adsorption, which indicates either that the 
phage receptors on L. lactis MG1363 are more difficult to mutate, perhaps being essential to cell 
growth, or that ISS1 integrates in a non-random manner in this strain. 
abiV is located on a 59-kb DNA region of the L. lactis MG1363 chromosome (nt 657,000 to 
706,000) which was previously referred as an “integration hot spot” 74 because it contains DNA 
sequences involved in DNA mobility. For example, it contains genes and sequences usually found 
on plasmids as well as almost 20 % of the 71 insertion sequences found in the 2,529,478-bp genome 
of MG1363. Interestingly, two of these insertion sequences, namely IS946 and IS1297 share 98 % 
and 85 % nucleotide similarity with ISS1, respectively. These two IS elements exist only in one 
copy in the genome of L. lactis MG1363. The high frequency of IS elements in this region suggests 
that it contains features favoring the integration of insertion sequences in general and in particular 
of the ISS1-type. Thus, the ISS1 integration may not be completely random in L. lactis MG1363. 
The location of abiV in the integration hot spot region among remnants of plasmid DNA and 
insertion sequences also makes it tempting to speculate that abiV originated from a plasmid. This 
would correspond to the observation that most of the previously described lactococcal Abi systems 
are encoded on plasmids 2,14,27,70. 
abiV conferred phage resistance when cloned in an expression vector but lost this function 
upon introduction of a frameshift mutation in the gene. Cells expressing AbiV exhibited typical 
abortive infection characteristics upon phage infection such as normal phage adsorption and DNA 
ejection, no R/M activity, and cell death. Very few infected cells released progeny phages and the 
burst size was also reduced. Since database searches revealed no similarity to any other phage 
resistance mechanism, it was concluded that AbiV is a novel Abi mechanism. 
AbiV inhibits proliferation of small isometric phages from the 936 species and of prolate 
phages from the c2 species but it has no effect on small isometric phages from the P335 species. 
This range of efficacy against the three main phage groups has been observed with other lactococcal 
Abi mechanisms 4,14,25,51,63,64 but the lack of similarity with other Abi proteins suggests a different 
mode of action. Combinations of diverse phage resistance mechanisms are often observed on 
plasmids isolated from wild-type strains of L. lactis that are highly resistant to phages 2,20,24,30. Since 
AbiV is a novel Abi mechanism, it may be suitable to use it in combination with other phage 
resistance mechanisms to confer efficient phage resistance to industrial strains of L. lactis. 
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 Lactococcal Abi mechanisms are often further characterized by identifying the general step of 
the phage lytic cycle that is inhibited 14. In infected AbiV-containing cells, we observed that phage 
DNA is replicated but maturation is halted resulting in the accumulation of concatemeric phage 
DNA. Replication of phage DNA indicated that transcription and translation of early phage genes 
was taking place in the presence of AbiV.  
It was also observed that the efficiency of AbiV (measured as EOP) against 936 phages was 
not improved by expressing abiV from the strong lactococcal promoter P59 73 in a low-copy number 
plasmid 66 as compared to expression from an internal promoter in pGhost9::ISS1 and in a single 
copy from the chromosome. This suggests that AbiV is only needed in small amounts or that 
competitive inhibition of a substrate is not part of its mode of action. However, the expression level 
was important for the efficiency against c2 phages. Toxicity of Abi proteins has been demonstrated 
for AbiD1, AbiK, AbiN, and AbiO 14 and in at least two cases, it was associated with regulation of 
the Abi gene expression 4,26. The absence of effects on cellular growth rate during high expression 
of abiV demonstrates that AbiV is not toxic to the cell. Absence of sequence similarity between Abi 
proteins 10,14 makes it desirable to obtain structural data on Abi proteins to investigate possible 
correlations between structure and function. The native multimer state of a protein might be a basic 
parameter to compare Abi proteins. However, except from motifs in AbiA which are putative 
multimerization sites 21, AbiV is the only Abi mechanism for which the native state (dimer) has 
been determined. 
In conclusion, AbiV is a novel abortive infection mechanism, which was discovered on the 
chromosome of L. lactis subsp. cremoris MG1363. This discovery was made possible due to 
transcription from a promoter within pGhost9::ISS1, which was integrated in the upstream region. 
AbiV is effective against 936 and c2 phages but the mode of action of this 23rd lactococcal Abi 
system still needs to be further investigated as it may involve an early-transcribed phage gene or 
gene product.  
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ABSTRACT 
 
Lactococcus lactis phage mutants that are insensitive to the recently characterized abortive infection 
mechanism AbiV were isolated and analyzed in an effort to elucidate factors involved in the 
sensitivity to AbiV. Whole genome sequencing of the phage mutant p2.1 suggested that an early 
transcribed orf was responsible for AbiV sensitivity. Sequencing of the homologous region in the 
genome of other AbiV insensitive mutants derived from 6 other lactococcal wild-type phages 
revealed point mutations in the same homologous orf. The orf was named sav (for sensitivity to 
AbiV) and the encoded polypeptide was named SaV. Purification of a His-tagged SaV polypeptide 
by gel-filtration suggested that it formed a dimer in its native form. Moreover, overexpression of 
SaV in Lactococcus lactis and Escherichia coli led to a rapid toxic effect. A conserved region in 
SaV which is evolutionary related among different phage groups is likely responsible for the AbiV-
sensitivity phenotype and the toxicity. 
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INTRODUCTION 
 
Milk fermentation failure due to bacteriophage (phage) attack of bacterial starter cultures 
remain a significant risk in the dairy industry 1,14. Several cheese making processes, which rely on 
mesophilic cultures containing L. lactis strains to drive the fermentation, are particularly at risk for 
phage attacks 6,47. Despite the diversity of the lactococcal phage population 22, members of only 
three genetically distinct phage groups (936, c2 and P335) are responsible for the majority of 
unsuccessful fermentations 45. To defend against these phages, lactococci possess a wide variety of 
anti-phage barriers and more than 50 phage resistance systems have already been characterized in L. 
lactis 49. These anti-phage hurdles are grouped into four general mechanisms of action, among 
which abortive infection (Abi) systems 14,65 are considered to be the most efficient. To date, 23 Abi 
mechanisms have been characterized in L. lactis 14,33. The Abi phenotype is often conferred by a 
single gene but in few cases multiple genes are needed 7,19,53,71. Overall, Abi systems constitute a 
heterogeneous group of proteins that share limited amino acid identity 36, but act after phage DNA 
entry and before the release of progeny phages. The consequence of the Abi activity is not only the 
inhibition of the phage infection but also the death of the infected cell, presumably due to phage 
induced deleterious effects on critical cellular functions 66.  
The extensive industrial use of lactococci containing phage resistance systems has led to the 
emergence of phage mutants, which are insensitive to the applied anti-phage barriers. This 
evolutionary process generates a need to constantly find new and/or improve existing phage 
resistance systems in order to keep phage population under control in these man-made ecological 
niches 17,45. To improve the efficiency of an Abi system it is crucial to know the molecular 
mechanism by which the system interacts with its target phages. For most of the characterized 
lactococcal Abi systems, only general effects on the phage life cycle have been revealed. For 
example, AbiA, F, K, P, and T were shown to interfere with DNA replication 7,25,29,32,34 while AbiB, 
G, and U affected RNA transcription 16,19,54. AbiC caused limited major capsid protein production 26 
whereas AbiE, I, and Q affected phage packaging 28. Recently, it was demonstrated that the 
presence of AbiZ caused premature lysis of the infected cells 27. Based on the genetic diversity of 
the lactococcal Abi systems their modes of action are likely to be diverse. Moreover, it has been 
inferred that their activity may be modulated depending on the targeted lactococcal phage species 
5,10,14.  
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In order to reveal the individual mechanistic model responsible for the resistance phenotype it 
is necessary to determine the molecular basis of the mode of action of an Abi system against 
various phages. From a practical standpoint, the analysis of Abi-insensitive phage mutants offers a 
great opportunity to identify the targeted phage component(s). Using this approach, genes involved 
in the Abi sensitivity of lactococcal P335-like phages have been identified either by specific point 
mutations in the genome of phage escape mutants or by exchange of genetic material with a 
prophage 7-9,23,24,40,46. In the case of virulent 936 phages, Abi sensitivity genes were identified by 
point mutations in the escape phage mutants 4,5,7,24,30 or by recombination between two virulent 
phages 25.  
Recently, we described the isolation and characterization of the lactococcal abortive infection 
system AbiV 33. Here, we report the identification of a specific gene in the genome of phages of the 
936-species and c2-species which is involved in the sensitivity to AbiV. Moreover, the phage gene 
product has a strong anti-microbial effect when expressed in L. lactis and E. coli. This gene appears 
to have an evolutionary relationship with a wide variety of phages. 
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MATERIALS AND METHODS 
 
Bacterial strains, phages, plasmids and growth conditions. Bacterial strains, phages and 
plasmids used in this study are listed in Table 1. E. coli was grown at 37ºC in LB medium 61. L. 
lactis was grown in M17 68 supplemented with 0.5 % glucose (GM17). L. lactis strains were grown 
at 30ºC except for strains with pGhost9::ISS1 insertions that were grown at 37ºC to maintain the 
insertion. In phage infection experiments, 10 mM CaCl2 were added to plates or medium. When 
appropriate, antibiotics were added as follows: for E. coli, 100 µg ml-1 of ampicillin, 10 µg ml-1 of 
chloramphenicol, 25 µg ml-1 of kanamycin and 10 µg ml-1 of tetracycline; for L. lactis, 5 µg ml-1 of 
chloramphenicol, 3 µg ml-1 of erythromycin, and 5 µg ml-1 of tetracycline. Phage mutants 
insensitive to AbiV were isolated from single plaques obtained on a host expressing AbiV followed 
by propagation in liquid medium on the same host. The latter procedure was repeated three times 
for all isolated phage mutants to ensure a pure isolate.  
 
Phage assays. Propagation of phages was performed as described by Emond et al. 29. Titers of 
phage lysates 39, efficiency of plaquing (EOP) 62 and cross streaking assays 60 were performed as 
described previously. One-step growth curve experiments and center of infection (COI) assays 48 
were performed using MOIs of 0.2 and 0.5, respectively. ECOI (efficiency of COI) and burst size 
was calculated as reported elsewhere 48. 
 
DNA isolation and manipulations. Phage DNA was isolated from phage lysates (titers of 
minimum 109 pfu ml-1) using the Lambda Maxi Kit (Qiagen) with the following modification to the 
manufacturer’s recommendation: Proteinase K (20 mg ml-1) was added to the cells resuspended in 
buffer L3 and incubated (65ºC, 30 min) before addition of buffer L4. Plasmid DNA was isolated 
from E. coli cells using the QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s 
recommendation and from L. lactis cells with the exception that lysozyme (15 mg ml-1) was added 
to buffer P1 and the lysis solution with the resuspended cells was incubated at 37ºC for 30 min 
before proceeding with the protocol. Restriction enzymes and T4 DNA ligase (Roche) were used 
according to the manufacturer’s instructions. Electroporation of L. lactis was performed as 
described previously 35,46.  
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Sequencing. Phage genome sequencing was performed with an ABI prism 3700 apparatus from the 
genomic platform at the research center of the Centre Hospitalier de l’Université Laval. 
Oligonucleotides previously used for sequencing other phage genomes 43 were used to sequence the 
major part of the phage p2.1 genome. Other oligonucleotides were designed to complete the 
genome sequencing of the phage mutants. Sequence data was assembled using the Staden Pregap4 
version 1.5 and Vector NTI version 10.3.0 (Invitrogen). 
 
DNA and protein analyses. Sequence similarity searches were performed using BLAST 2 and PSI-
BLAST 3 (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). Searches for protein composition of helix, 
strand, and sheet as well as helix-turn-helix motifs were done using the website: http://npsa-
pbil.ibcp.fr/. RNA secondary structure and calculation of free energy was performed using the 
website: http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi. Molecular 
weights of the investigated proteins were estimated using Protein Calculator 
(http://www.scripps.edu/~cdputnam/protcalc.html). Sequence alignment was performed using 
Multalin 18 (http://npsa-pbil.ibcp.fr/) and ClustalX software 69. Phylogenetic tree was constructed 
using the TREEVIEW software 59. 
 
Protein purification and gel filtration. The sav gene of phage p2 (nucleotides 1005 to 1388 in the 
GenBank sequence acc.nr. FJ010786) was cloned into the His-tag vector pQE-70 (Qiagen) to create 
plasmid pJH12 in E. coli JH-65. The cloning was performed according to the recommendations in 
The QIAexpressionist manual using the promoter and ribosome binding site (RBS) of the vector. 
All cloned DNA fragments were verified by sequencing. The C-terminally His-tagged SaV was 
purified and subsequently run on a gel-filtration column using the same conditions recently 
described 33. 
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TABLE 1. List of bacteria, phages and plasmids used in the study 
Bacterial strain, 
phage or plasmid 
Relevant characteristicsa 
 
Source 
 
L. lactis   
IL1403 L. lactis subsp. lactis IL1403, Host for phages P008, bIL170 and bIL67 7 
MB112 L. lactis subsp. cremoris MG1363, Δupp, host for phages p2, sk1, jj50, and c2 50 
NZ9000 L. lactis subsp. cremoris MG1363, pepN::nisRK 40 
JH-20 MB112 (pJH2); CamR, Abi+ 35 
JH-22 IL1403 (pJH2); CamR, Abi+ 35 
JH-32 MB112 (pGhost9::ISS1 insert upstream of abiV on chromosome); ErmR, Abi+ 35 
JH-74 NZ9000 (pJH14); CamR This study 
JH-76 NZ9000 (pNZ8010); CamR This study 
JH-86 MB112 (pJH13, pAJ80); CamR, TetR This study 
JH-87 MB112 (pMAP84, pAJ80),; CamR, TetR This study 
E. coli   
MC1000 Laboratory strain, cloning host 64 
DH5α Laboratory strain, cloning host 69 
AJ177 DH5α (pAJ80); CamR 
DTU strain 
collection  
M15 (pREP4), KmR, used for cloning of pQE-70 His-tag vector Qiagen 
JH-60 AJ177 (pJH13); CamR, TetR This study 
JH-65 M15 (pJH12); AmpR, KmR This study 
JH-77 M15 (pQE-70); AmpR, KmR This study 
JH-84 DH5α (pJH15); TetR This study 
JH-88 AJ177 (pJH15); TetR This study 
JH-89 MC1000 (pJH14); CamR This study 
   
Phages   
p2 Small isometric headed, 936 species 56 
sk1 Small isometric headed, 936 species 14 
jj50 Small isometric headed, 936 species 48 
P008 Small isometric headed, 936 species 48 
bIL170 Small isometric headed, 936 species 20 
c2 Prolate headed, c2 species 45 
bIL67 Prolate headed, c2 species 72 
p2.1 Small isometric headed, 936 species, deletion in orf26 This study 
sk1.1 Small isometric headed, 936 species, nonsense mutation in orf26 This study 
jj50.1 Small isometric headed, 936 species, nonsense mutation in orf25 (homologue to p2 orf26) This study 
P008.1 Small isometric headed, 936 species, nonsense mutation in orf33 (homologue to p2 orf26) This study 
bIL170.1 Small isometric headed, 936 species, nonsense mutation in e24 (homologue to p2 orf26) This study 
c2.1 Prolate headed, c2 species, mutation in e11 (homologue to p2 orf26) This study 
bIL67.1 Prolate headed, c2 species, mutation in orf8 (homologue to p2 orf26) This study 
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TABLE 1. List of bacteria, phages and plasmids used in the study 
Bacterial strain, 
phage or plasmid 
Relevant characteristicsa 
 
Source 
 
 
Plasmids 
  
pAB223 vector containing genetic switch of phage TP901-1 12 
pAJ80 CI repressor from phage TP901-1 cloned in pCI372 46 
pJH2 abiv cloned in shuttle expression vector pLC5; CamR 35 
pJH12 1005 to 1388 fragment cloned in pQE-70; AmpR This study 
pJH13 872 to 1446 fragment cloned in pMAP84; TetR This study 
pJH14 872 to 1446 fragment cloned in pNZ8010; CamR This study 
pJH15 corresponding to 872 to 1446 fragment but from p2.1 cloned in pNZ8010; CamR This study 
pMAP84 PL promoter of phage TP901-1 cloned in pPTPL (Fig. 1); TetR This study 
pNZ8010 PnisAgusA cat; CamR 23 
pPTPL low-copy E. coli – L. lactis shuttle and promoter cloning vector; TetR 62 
pQE-70 Cloning vector for C-terminal His-tagging of proteins; AmpR Qiagen 
aFragment refers to GenBank accession number FJ010786; Abi+, phage resistance phenotype; AmpR, ampicillin resistance; 
CamR, chloramphenicol resistance; ErmR, Erythromycin resistance; KmR, Kanamycin resistance, TetR, Tetracycline 
resistance. 
 
Cloning strategies. To express sav in trans in L. lactis, we first tried the synthetic promoter 
strategy 67. A forward primer was used 
 (5’-CCGCTCGAGNNNNNNTATTCTTNACANNNNNNNNNNNNNNNNNTATNATNNNNNC 
ATTTACATGGATTGGGGGTAACATCTAATGAATTATGGTACAAATAA-3’),  
which encompasses a randomized promoter region of p2 orf30 (GenBank FJ010786) fused to a part 
of sav (underlined) including the start-codon (bold face) and the ribosome-binding site. Using a 
reverse primer, a DNA fragment corresponding to nucleotides 980 to 1403 (GenBank acc.nr. 
FJ010786) was amplified by PCR and attempted cloned into the promoter-less shuttle-vector 
pPTPL 55. The cloning of a 1.4-kb DNA fragment from phage p2 containing the five genes (orf30, 
orf29, orf28, orf27, and sav) into pPTPL was also attempted. Both cloning experiments were 
unsuccessful. 
A 0.6-kb fragment from phage p2, corresponding to sav and the upstream gene orf27 
(nucleotide 872 to 1446 in Genbank FJ010786), was amplified by PCR and successfully cloned into 
the newly constructed expression vector pMAP84 (pJH13) using the E. coli strain AJ177, in which 
expression is repressed (see below). The same 0.6-kb fragment was also successfully cloned in the 
nisin inducible vector pNZ8010 21 (pJH14). Finally, the mutated orf27-sav region of phage mutant 
p2.1 was also PCR amplified and successfully cloned into pMAP84 (pJH15).  
 
Construction of the expression vector, pMAP84. The low-copy promoter-less shuttle-vector 
pPTPL 55 was used to construct the novel expression vector pMAP84. A DNA fragment 
encompassing nucleotides 3142 to 3458 in the lactococcal phage TP901-1 (GenBank acc.nr. 
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NC_002747) was amplified by PCR using vector pAB223 as template 11. This DNA fragment 
containing the PL promoter region from the genetic switch in TP901-1 42 was inserted in the 
multiple cloning site of pPTPL using the restriction sites XhoI and XbaI so that the PL promoter 
points towards the LacZ reporter gene in the vector (Fig. 1). 
 
Induction experiments. L. lactis cultures containing either pJH14 or pNZ8010 were grown 
exponentially to OD600 = 0.1 at which point each culture was split in two sub-cultures. At T=0 nisin 
(0.25 ng ml-1) was added to one of the sub-cultures and samples for OD600 and surviving cells 
(CFU/ml) were taken after 5, 35 and 135 minutes (Fig. 5A+B). A similar experiment was 
performed with E. coli JH-65, which contained sav cloned into the IPTG inducible vector pQE-70 
and E. coli JH-55 as a control, which had only pQE-70 vector. At OD600 = 0.2 (T = -2), IPTG was 
added (0.5mM) and samples were taken after 2 minutes (T=0) as well as after 30, 90, and 180 
minutes for OD600 measurements and cell counts (Fig. 5C+D). 
 
Nucleotide accession numbers. A sequence was submitted to the GenBank database under the 
accession number FJ010786. 
Fig. 1. Construction of the pMAP84 vector by cloning the promoter region of the TP901-1 genetic switch in 
the multiple cloning site of pPTPL 
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RESULTS 
 
Isolation of phage mutants insensitive to AbiV. Phage p2 is a small-isometric-headed phage of 
the 936-like group that propagates on L. lactis subsp. cremoris MG1363. This phage was recently 
shown to be sensitive to AbiV 33. When propagated on AbiV+ L. lactis cells (JH-20), phage p2 
forms small plaques with an efficiency of plaquing (EOP) of 10-4. One of these small plaques was 
picked up at random and chosen for further characterization. The phage mutant (named p2.1) was 
purified three times on L. lactis JH-20 and its insensitivity to AbiV was confirmed by EOP assays. 
The above isolation procedure was similarly applied to obtain insensitive mutants of the following 
AbiV-sensitive wild-type phages: sk1 and jj50 (936 species, host L. lactis MG1363), P008 and 
bIL170 (936, host L. lactis IL1403), c2 (host L. lactis MG1363) and bIL67 (c2 species, host L. 
lactis IL1403). The AbiV-insensitive phage mutants were named: sk1.1, jj50.1, P008.1, bIL170.1, 
c2.1 and bIL67.1, respectively. 
 
Microbiological analyses of phage mutant p2.1. This phage mutant was characterized for EOP, 
ECOI, burst size, latency, and plaque size on AbiV+ and AbiV- cells. Values for EOP, ECOI, burst 
size, and latency time were similar with both hosts (Table 2). Moreover, they were also similar to 
those obtained with the wild-type phage p2 on the sensitive host L. lactis MB112 33. Nonetheless, 
the plaque size of phage p2.1 was slightly smaller (0.7-1 mm) on AbiV+ cells as compared to AbiV- 
cells (1 mm). By comparison, the plaque size of the wild-type phage p2 on AbiV- cells is 1.5 mm. 
These data indicated that the mutation in phage mutant p2.1 conferred a complete in-sensitive 
phenotype to AbiV and that the fitness cost was small.  
 
TABLE 2. Effect of AbiV on lactococcal phage p2.1 
Assay L. lactis MB112 (AbiV-) L. lactis JH-20 (AbiV+) 
   
EOPa 1.0 1.1 
ECOI (%)b 100.0 94.0 ± 25.3 
Burst size (pfu/cell)c 38.8 ± 5.7 41.1 ± 4.6 
Latency time (min)c 20-30 20-30 
Plaque size (mm) 1 0.7 - 1 
 
aEOP of phages p2 is 1.0 on L. lactis subsp. cremoris MG1363 (MB112). 
bMOI = 0.5, n=3, ECOI of phages p2 is 1.0 on L. lactis subsp. cremoris 
MG1363 (MB112). 
cMOI = 0.2, n=3 
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An early transcribed gene is involved in the sensitivity to AbiV. Genomic DNA was isolated 
from the phage mutant p2.1, digested with EcoRV and the restriction profile compared to a 
restriction map of the wild-type phage p2. No difference was observed, indicating that no large 
deletion or genomic re-arrangement was responsible for the AbiV insensitive phenotype (data not 
shown). The entire genome was then sequenced and compared to the wild-type phage p2. A 
comparative genome analyses revealed a total of three point mutations as well as a deletion of 56 
nucleotides in the p2.1 genome (Fig. 2). All the point mutations and the deletion were located 
within a 255 bp region of the genome, which was previously shown to be early transcribed 12,13. 
Two point mutations were located in the orf26 leading to amino acid changes (A45T and A60D), 
and one point mutation was located upstream of orf27 (Fig. 2). The deletion covered the 3’-end of 
orf27, as well as the ribosome binding site (RBS) and start codon of orf26. The deletion occurred 
between two GGTA sequences and led to a translational in-frame fusion of orf27 and the 
downstream orf26 in the phage mutant p2.1 (see below).  
A BLAST analysis of orf26 revealed similarity to the following lactococcal phage genes: 
orf25 in jj50 (GenBank acc.nr. NC_008371), orf26 in sk1 (GenBank acc.nr. NC_001835), orf33 in 
P008 (GenBank acc.nr. NC_008363), e24 in bIL170 (GenBank acc.nr. NC_001909), as well as e11 
in phage c2 (GenBank acc.nr. NC_001706), and orf8 in bIL67 (GenBank acc.nr. L33769). All these 
phages containing the orf26 homologue are sensitive to AbiV 33. Interestingly, an orf26 homologue 
is absent in the genome of the phage 712 (936-species) which is insensitive to AbiV. Similarly, 
lactococcal phages of the P335 species, which are also insensitive to AbiV, do not contain an orf26 
homologue 33.  
Since mutations were only found in orf27 and orf26 of p2.1 genome, this region was 
sequenced in the other isolated phage mutants (jj50.1, sk1.1, P008.1, bIL170.1, c2.1, bIL67.1) and 
compared to the wild-type sequences. Comparative analyses revealed only point mutations in the 
orf26 homologue of all the phage mutants (Table 3) and no mutations in the orf27 homologue (data 
not shown). It was therefore concluded that orf26 of phage p2 is involved in sensitivity to AbiV and 
the gene was renamed sav (mnemonic for sensitivity to AbiV).  
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Fig. 2. Localization of mutations in the genome of phage mutant p2.1. Mutations are marked with an asterisk and 
include three point mutations and a 55 nt deletion which encompasses the ribosome binding site (RBS) and sav 
start codon. RBS and start codon are underlined in wild type sequence and orf27 stop as well as sav start codons 
are in bold face. Deduced SaV amino acid sequence is written below nucleotide sequence while the deduced 
sequence for ORF27 is written above. 
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Mutations in SaV. The point mutations in the sav homologues of all the phage mutants were 
analyzed for effects on the translated SaV (Table 3). Following changes in the amino acid sequence 
were observed: G-65-stop (jj50.1), M-1-I (sk1.1), W-33-stop (P008.1), E-58-stop (bIL170.1), T-48-
P (c2.1), and Y-10-stop (bIL67.1). Most phage mutants had a nonsense mutation in sav and two 
mutants (p2.1 and sk1.1) had a deleted start codon. The mutation in phage c2.1 caused a single 
amino acid change (T-48-P), most likely leading to a conformational change in the protein. 
Interestingly, this point mutation is located in a region of the protein, which has a high degree of 
conservation despite the otherwise large differences between the homologues of the c2- and 936-
like phages (Fig. 3). Moreover, the majority of the mutations in the different phage mutants are 
located in this region indicating that it serves an important function for the sensitivity to AbiV. 
Taken altogether, the nature of the point mutations suggests that the gene product SaV is involved 
in AbiV sensitivity. 
 
TABLE 3. sav homologues in phage mutants insensitive to AbiV 
Phage orf Amino acids Mutation (nt) Effect (aa) 
p2.1 26 128 --- 55nt deletion 
   GCT→ACT A-45-T 
   GCT→GAT A-60-D 
sk1.1 26 128 ATG→ATA M-1-I 
jj50.1 25 128 GGA→TGA G-65-stop 
P008.1 33 119 TGG→TAG W-33-stop 
bIL170.1 e24 130 GAA→TAA E-58-stop 
c2.1 e11 122 ACT→CCT T-48-P 
bIL67.1 8 116 TAC→TAA Y-10-stop 
 
 
Analyses of the sav gene. The sav gene in wild-type phage p2 consists of 384 bp and its gene 
product contains 128 amino acids (15.3 kDa). The sav gene marks the end of a putative 5-gene 
operon consisting of orf30 to orf26 (sav) (GenBank acc.nr. FJ010786). The region shares 97 % 
nucleotide identity with a region (nucleotides 17543 to 18862) found in the genome of lactococcal 
phage sk1 (GenBank acc.nr. NC_001835) for which DNA sequence 13 and transcription analyses 12 
are available. Preceding orf30 is a lactococcal consensus promoter and there are overlaps between 
orf28, orf27, and sav. Indeed, the start codon of sav overlaps with the stop codon of the upstream 
gene orf27 (Fig. 2) and the start/stop codons of orf27/orf28 also overlap, which suggests 
translational coupling of the gene products. The start codon of all the other sav homologues was 
overlapping the stop codon of a small upstream gene except for the orf26 homologue in phage c2, 
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which was separated (6 bp) from the upstream gene. The start codon of sav was preceded by a 
putative ribosome-binding site (GGATTGGGGGT, underlined sequence matches Lactococcus 
consensus). However, the RBS of orf27 (ACTTAGGAGGA) and orf28 (ACTAAGGAGAA), 
appeared closer to the consensus sequence and may therefore be stronger than the RBS of sav, 
supporting a possible translational coupling. This was further supported by estimated secondary 
structures of mRNA covering RBS of the three genes. These structures had calculated dG values of 
-6 kcal/mol, -9 kcal/mol, and -19 kcal/mol for orf28, orf27, and sav, respectively indicating that sav 
needs resolution of upstream RNA by ribosomes terminating translation of upstream orf27. 
 In lactococcal phage mutant p2.1, a 56-nucleotide deletion (Fig. 2) covered the 3’-end of orf27 
(117 bp, 39 aa, 4.2 kDa) as well as the RBS and the 5’-end of sav. This deletion created an in-frame 
fusion between orf27 and sav, generating a fused protein of 17.6 kDa. 
 
 
 
Fig. 3. Alignment of amino acid sequences of SaV from phage mutants insensitive to AbiV.  
Mutations are underlined and in bold face: line-through means deletion, X means stop-codon. 
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Analyses and overexpression of the SaV protein. A His-tagged SaV protein (15.3 kDa) of phage 
p2 was produced by IPTG induction of exponentially growing E. coli cells and subsequently 
harvested and purified. The molecular weight of the purified native SaV protein was estimated at 33 
± 0.7 kDa by gel-filtration (data not shown), suggesting that SaV forms a dimer in its native form. 
The protein consists of ca 84 % α-helixes and 16 % coils but no putative DNA-binding helix-turn-
helix motifs were identified by bioinformatics analyses. No similarity to proteins of known 
functions as well as no conserved domains was found in SaV. However PSI-BLAST (5 iterations) 
revealed that the conserved region observed in the SaV homologues in 936-like and c2-like phages 
(Fig. 3) is also present in proteins from phages infecting other hosts such as Klebsiella pneumoniae, 
E. coli, Yersinia enterocolitica, Salmonella enterica, Listeria monocytogenes, Fusobacterium 
nucleatum, Streptococcus sp., and Synechococcus sp. (Fig. 4). 
 
Fig. 4. Alignment of conserved region in SaV homologues of different phages using ClustalX. Bar diagram 
presents degree of conservation (A). Bootstrapped phylogenetic tree of the conserved region in SaV (B). 
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SaV is toxic to L. lactis and E. coli cells. It was investigated whether AbiV efficiency could be 
decreased or increased by expressing sav in trans. We first tried the strategy of a synthetic promoter 
library (SPL) to modulate the expression of sav 67. A DNA fragment including only sav behind a 
randomized promoter region was successfully obtained and cloning was attempted in both L. lactis 
MB112 and E. coli DH5α using the low-copy promoter-less shuttle vector pPTPL 55. No 
transformants were obtained suggesting that sav might be toxic when expressed in these two 
bacteria. Cloning of a region encompassing orf30 to sav, which includes a lactococcal consensus 
promoter upstream of orf30, into pPTPL was also unsuccessful in E. coli MC1000.  
To confirm the possible toxicity of sav, we first constructed a new vector with regulated gene 
expression, which was named pMAP84 (Fig. 1). In this vector, transcription from the PL promoter 
can be repressed by the lactococcal phage TP901-1 repressor protein CI expressed from a separate 
vector 42. A PCR fragment encompassing sav, orf27 and the upstream region with RBS was ligated 
in pMAP84 (to form pJH13) and the resulting plasmid was transformed in E. coli DH5α and E. coli 
AJ177 (expressing the CI repressor). No transformants were obtained in DH5α whereas cloning 
was successful in AJ177 (JH-60). To test if pJH13 could exist within the cell without repression by 
CI (pAJ80), total plasmid (pJH13 and pAJ80) was extracted from E. coli JH-60 and used to 
transform E. coli MC1000 and L. lactis MB112, followed by tetracycline selection (only selection 
for pJH13). Fifty E. coli and 100 L. lactis tetracycline-resistant transformants were tested for 
tetracycline and chloramphenicol resistance. All transformants were resistant to both antibiotics 
indicating that co-transformation of pJH13 and pAJ80 had occurred in all cases. We therefore 
concluded that pJH13 alone is toxic to the cells. 
A cell growth experiment was conducted using lactococcal cells expressing the CI repressor 
and either pJH13 or the cloning vector alone pMAP84. The cells containing both plasmids had a 50 
% reduced growth rate and a 15 % reduced final yield as compared to cells with only the empty 
vector. The same experiment was conducted with E. coli cells harbouring a repressed sav (JH-60) or 
expressing the mutated sav (JH-84). Similarly, cells of E. coli JH-60 (SaV+) had a 50 % reduced 
growth rate and a 15 % reduced final yield as compared to cells of E. coli JH-84 (data not shown). 
The above results strongly indicate that SaV is toxic in both E. coli and L. lactis, even when 
expressed at low levels.  
Further, we wanted to determine if the co-existence of AbiV and repressed SaV in the same 
cell was possible. The plasmids pJH13 and pAJ80 were transformed in cells expressing Abi. The 
transformation was done in hosts with low (L. lactis JH-32) and high (L. lactis JH-20) levels of 
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AbiV expression 33. PCR analysis of 40 colonies from each transformation showed an intact sav but 
a deleted abiV in all transformants. These observations were supported by sequencing and phage 
resistance tests, which showed that all the mutants had become sensitive to phage p2 (data not 
shown).  
Finally, a cloning experiment was made where a DNA fragment encompassing orf27-sav was 
PCR-amplified from phage mutant p2.1 using the same primerset as for the wild type cloning. This 
fragment was successfully cloned in the vector pMAP84 in the E. coli strains AJ177 (pAJ with CI 
repressor) and MC1000 (no repressor), yielding strains JH-88 and JH-84, respectively. The 
successful cloning of the unrepressed orf27-sav region from phage p2.1 (JH-84) therefore suggests 
that the toxicity of sav towards E. coli is due to the mutations that also renders the phage insensitive 
to AbiV.  
 
Induction of sav causes rapid cell death. A nisin inducible expression system was used to time the 
expression of sav in L. lactis. A PCR amplified fragment containing orf27-sav and RBS was ligated 
in pNZ8010 21 (pJH14) and cloned in E. coli MC1000 (JH-89). The construct was then transferred 
to L. lactis NZ9000 (JH-74) used for the nisin induction experiments 20. Due to the toxic properties 
of nisin, the nisin-induced control (Fig. 5A+B, c+) reached only 50 % of the cell density obtained in 
the non-induced cultures (Fig. 5A+B, sav- and c-). In the induced sav cultures, the OD600 rose from 
0.1 to 0.2 in the first 30 minutes after which no further increase of OD600 was observed and a 
number of cells rapidly died. Five minutes after the induction, the number of cells able to form 
colonies on normal GM17 plates was reduced 100-fold. It was further reduced 10-fold after 35 
minutes and ended at 0.5 % of the original cell count after 135 minutes. 
A similar experiment was performed with the IPTG inducible E. coli clone JH-65 
overexpressing C-terminal His-tag SaV (see above). The IPTG induced control (Fig. 5 C+D, c+) 
was only marginally inhibited during the experiment. However, the number of surviving SaV+ cells 
was severely reduced following the induction (Fig. 5D). After 30 minutes, the cell count was 
reduced 500-fold and ended at a 1000-fold reduction after 180 minutes. The above results strongly 
indicate that the expression of sav has a strong and fast-functioning anti-microbial effect. 
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Fig. 5. Growth (A/C) and surviving cells (B/D) after induction of sav with nisin or IPTG in L. lactis (A/B) and E. coli 
(C/D), respectively. Sav indicates vector pNZ8010 with cloned sav and c indicates empty vector, + and – indicate 
induction and no induction with nisin at T0 or IPTG at T2, respectively 
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DISCUSSION 
 
Lactococcal phage mutants that are insensitive to the abortive infection mechanism AbiV can 
be obtained at a frequency of 10-4. The analysis of these phage mutants was used in the present 
study to further investigate the mode of action of AbiV. The phage mutant p2.1 was randomly 
chosen for whole genome sequencing. Mutations and a deletion were found in a 255 nt region as the 
only difference with the wild-type genome. One gene was particularly affected by these genetic 
changes and was named sav. This is presumably the last of an early-transcribed five-gene cluster 
(GenBank acc.nr. FJ010786). This genomic region has 97 % nucleotide identity with a confirmed 5-
gene operon (orf30 to orf26) found in phage sk1 12.  This cluster is transcribed from a consensus 
promoter 72 upstream of orf30 13 which is likely recognized by host RNA polymerase and typically 
found in the early transcribed region of lactococcal phages 12.  
Sequence data from the sav region in other AbiV insensitive lactococcal phage mutants from 
both 936 and c2 species revealed a high frequency of nonsense mutations as well as significant 
amino acid changes in a region of the protein, which is highly conserved among SaV homologues 
of 936-like and c2-like phages (Fig. 3). The point mutation in phage c2.1 (T-48-P) most likely 
induces a conformational change in the conserved region of the polypeptide. Furthermore, two point 
mutations in phage p2.1 led to radical amino acid changes (A-45-T and A-60-D), which might also 
alter the property of the polypeptide due to the changes from neutral alanine (A) to polar (T and D) 
and charged (D) residues. Although the phage mutant p2.1 also contains a 56 nt deletion which 
prevents expression of native SaV, it creates an in-frame translational fusion of N-terminal ORF27 
(codon 1 to 25) with an almost complete SaV (residue 4 to 128). Such rearrangement appears to 
have an effect, albeit limited, on the phage lytic cycle and may not have affected the function of 
SaV. On the other hand, some of the mutations likely led to the production of a significantly altered 
SaV protein, which rendered the phage insensitive to AbiV while still allowing the assembly of 
functional phages.  
Analysis of the secondary structure of SaV revealed a high (84 % and 74 %) content of α-
helixes in phages p2 and c2, respectively. The distribution of α-helixes (interspersed with random 
coil) was remarkably similar in the two phages despite the lack of sequence similarity (Fig. 3). 
Furthermore, a coil in the middle of the conserved region is significantly prolonged by the two 
amino acid changes in phage p2.1. It is tempting to speculate that this conserved region might be a 
target site for the activity of AbiV. Interestingly, when PSI-BLAST was used to search for more 
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distant SaV homologues, similarity was found to putative proteins from phages infecting a very 
diverse range of bacterial hosts (gram-positive, gram-negative, and cyanobacteria). The similarity 
was primarily observed in the conserved region and an alignment of this region revealed a high 
degree of conservation in specific residues (Fig. 4A). A phylogenetic analysis suggested that this 
SaV-like region has evolved from a common ancestor. Nonetheless at this time, no putative 
function could be assigned to SaV though the conservation of the middle region of SaV suggests a 
common function in a wide range of phages. 
The start-codon of sav overlaps with the stop-codon of the upstream gene orf27 (Fig. 2). Such 
out-of-phase overlapping genes are often observed in phages, which are known to have compact 
genomes 52,63. Terminal overlap could cause translational coupling 57, a mechanism that ensures the 
tightly coupled translation of the two overlapping genes 63. Terminal overlap of sav with an 
upstream gene of about half the size was observed in all the investigated AbiV sensitive lactococcal 
phages, except for phage c2 where the two genes were separated by 6 bp. Similarly, 77 % of the 
homologous sav genes reported in Fig. 4 overlap with an upstream gene. It is therefore tempting to 
speculate that orf27 and sav are translationally coupled. This ensures an equimolar ratio of the two 
polypeptides and may not entail a direct functional relation of them. However, in case of a terminal 
overlap, it is generally observed that the two genes almost always encode structurally or 
functionally related polypeptides 63. Translational coupling has been demonstrated for phage 
structural genes 15,31,64 but also for polypeptides in the DNA polymerase holoenzymes of coliphage 
T4 70 and lactococcal phage sk1 13. 
To study the interaction of SaV with AbiV, we tried to complement SaV from the wild-type 
phage p2 by providing the gene in trans during infection with the AbiV-insensitive phage mutant 
p2.1 4,24. The sav cloning experiments together with subsequent SaV induction experiments showed 
that the expression of the protein causes cell death (Fig. 5). It has been demonstrated in a number of 
cases that gene products from early-transcribed phage genes can have antimicrobial activity when 
expressed in bacterial cells 51,44,55,55,56,58. These phage proteins produced early after the beginning of 
the infection have evolved to quickly inactivate or redirect critical processes of the bacterial cell 
machinery in order to shut down host metabolic activities and facilitate production of phage 
components 37,38,41,50. For example, early phage proteins have been demonstrated to inhibit 
transcription in E. coli by interaction with RNA polymerase 51, σ70 transcription factor 58 or to re-
direct DnaB helicase to favour phage DNA replication 44,55,56. The very quick toxic effects in both 
L. lactis and E. coli indicate that SaV might be such an early regulatory protein that targets a critical 
91
  
cellular mechanism common to the two distantly related bacterial species. At this time, the 
molecular mode of action of SaV is unknown. However, the expression of the mutated ORF27-SaV 
from phage p2.1 was not toxic in E. coli, which indicates that the mutations in the conserved region 
of SaV rendering the phage insensitive to AbiV is also involved in the antimicrobial activity of the 
protein. It is therefore likely that it is the translated SaV polypeptide, which is somehow involved in 
both the AbiV phenotype and toxicity towards the host cell.  
In conclusion, the early transcribed phage protein SaV was demonstrated to be involved in the 
sensitivity of 936- and c2-like phages to the recently described abortive infection mechanism AbiV. 
The middle region of SaV is conserved and evolutionary related among distantly related phages. 
Due to its fast-working toxic effect in both L. lactis and E. coli, we suggest that the function of SaV 
during the phage infection is to shut down or re-direct essential host functions. 
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ABSTRACT 
 
In this study, we characterized the interaction between the novel lactococcal phage abortive 
infection protein AbiV and the phage protein SaV which was recently shown to be involved in 
AbiV sensitivity. The two dimeric proteins interact directly by forming a complex consisting of 
AbiV2SaV2 and we propose that the otherwise non-toxic AbiV protein is activated by SaV by this 
interaction to inhibit the cellular translational machinery. 
The Abi mechanism severely inhibited total protein synthesis in cells infected with the 936 
phage p2 at an early stage of the lytic cycle while RNA synthesis was only slightly inhibited. A 
more detailed picture was obtained by analyzing early, middle, and late transcription as well as 
synthesis of specific early and late proteins during infection of AbiV+ cells with phage p2. These 
experiments revealed only slight inhibition of early transcription (including sav) while translation of 
the sav gene product (SaV) was non-detectable. We therefore concluded that the AbiV mechanism 
functions by inhibiting translation of phage proteins at an early stage. The early shut-down of 
translation probably caused the inhibition of middle and late transcripts which need activation by 
early phage encoded activator proteins. Phage DNA replication was observed for the isometric 
headed 936 phage sk1 but not for the prolate headed phage c2. We propose a hypothesis to explain 
the mode of action of the AbiV mechanism in both 936 phages and c2 phages. 
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INTRODUCTION 
 
Bacteriophages killing susceptible Lactococcus lactis strains during milk fermentation is a 
persisting problem for the dairy industry 1,47,49 that primarily suffers from phage attacks of the three 
lactococcal phage species 936, c2 and P335 12. As a defence against phage attacks, L. lactis has 
evolved numerous natural anti-phage barriers that protect the cell against phage adsorption, against 
injection of phage DNA, through restriction modification (R/M) systems or through abortive 
infection (Abi) mechanisms 23,37,47. Abi mechanisms inhibit the phage lytic cycle after DNA 
injection and before release of phage progeny 30 and the 23 Abi mechanisms isolated to date are 
designated AbiA 33 to AbiZ 21. They form a heterogeneous group of anti-phage mechanisms usually 
encoded by a single gene though some Abi systems are encoded by two 4,13,14,24,51 or more 61 genes. 
All the genes encoding lactococcal Abi systems have a low G+C content and they share only 
limited amino acid sequence similarity 11. They also vary significantly in their efficiency (measured 
as efficiency of plaquing – EOP) as well as efficacy against the three main lactococcal phage 
species 56. The effect of one Abi mechanisms on the phage lytic cycle can also vary according to the 
species of the infecting phage 7,11. 
The extensive industrial use of Abi systems favour emergence of Abi-insensitive phage 
mutants 47. From an industrial point of view there is therefore a permanent need for obtaining new 
anti-phage barriers either by discovering new natural phage resistance mechanisms or by 
engineering artificial phage resistance systems 55. Different engineering approaches have been 
applied such as production of anti-sense phage mRNA 46, phage encoded resistance (PER) 32, 
expression of the lytic repressor in temperate phages 32,44, super infection exclusion (sie) 45, and 
phage triggered suicide mechanisms 17,18. However, these artificial phage resistance mechanisms 
generally only have limited efficiency against a small range of phages 37. An alternative approach 
could therefore be to engineer existing Abi mechanisms to improve their efficiency or expand their 
range of efficacy to include more phage species. However, understanding the mode of action of a 
given Abi system against different phages is a prerequisite for such engineering approaches.  
For most Abi systems the overall effect on the phage lytic cycle has been revealed 11,20,56 and 
for many of them, the phage gene responsible for sensitivity to the Abi mechanism has been 
identified by investigating Abi-insensitive phage mutants 2-6,15,16,19,29,40,48. However, a deeper 
understanding of the molecular interactions between the Abi mechanism and the phage components 
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that confer the Abi phenotype will provide valuable information for designing engineered strategies 
to improve Abi systems.  
Recently, we characterized the novel abortive infection mechanism AbiV 28 and the phage 
protein SaV with anti-microbial properties that is involved in AbiV sensitivity 29.  
Here we investigate the mode of action of the AbiV anti-phage system. We demonstrate the 
effect of AbiV on DNA replication, transcription, and translation during the phage lytic cycle. 
Moreover, we demonstrate that AbiV interacts directly with SaV to arrest the phage lytic cycle. 
Finally, we propose a model for the mode of action for AbiV that might explain observed 
differences in the effect on the lytic cycle of 936-phages and c2-phages.   
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MATERIALS AND METHODS 
 
Bacterial strains, phages, plasmids and growth conditions. Bacterial strains, bacteriophages and 
plasmids used in this study are listed in Table 1. E. coli was grown at 37ºC in LB medium 54 or 
Turbo Broth (AthenaES) for protein expression. L. lactis was grown at 30ºC in M17 59 
supplemented with 0.5 % glucose (GM17). However, in experiments with incorporation of 
radioactive nucleosides L. lactis was grown in SA medium supplemented with 0.5 % glucose 35 and 
with reduced methionine concentration (5 µg ml-1) 38.  
During phage infection experiments, bacterial growth and lysis of phage infected cultures were 
determined by cell density (OD450 in GSA medium and OD600 in GM17 medium) using a BioScreen 
C apparatus (Oy Growth Curves Ab Ltd).  
In phage infection experiments, 10 mM CaCl2 was added to the medium. Propagation of 
phages and phage lysate titration was performed as described previously 22. When appropriate, 
antibiotics were added as follows: for E. coli, 100 µg ml-1 of ampicillin, 34 ug ml-1 of 
chloramphenicol and 25 µg ml-1 of kanamycin; for L. lactis, 5 µg ml-1 of chloramphenicol.  
 
 
 
TABLE 1. List of bacteria and phages used in the study 
Bacterial strain or phage Relevant characteristics Source 
Bacteria   
JH-20 L. lactis subsp. cremoris MB112 (pJH2); CamR, AbiV+ 28,34 
JH-54 L. lactis subsp. cremoris MB112 (pLC5); CamR, AbiV- 28 
JH-62 E. coli M15 (pJH11); AbiV His-tag. AmpR, KmR 28 
JH-65 E. coli M15 (pJH12); SaV His-tag.  AmpR, KmR 29 
Phages   
p2 Small isometric headed, 936 species 50 
sk1 Small isometric headed, 936 species 10 
c2 Prolate headed, c2 species 43 
CamR, chloramphenicol resistance  (5 µg ml-1); AmpR, ampicillin resistance (100 µg ml-1); 
KmR, Kanamycin resistance (25 µg ml-1); AbiV+, AbiV phage resistance phenotype;  
AbiV-, AbiV phage sensitive phenotype. 
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Purification of His-tagged proteins. AbiV and SaV were previously cloned into the pQE-70 
vector (Qiagen) to create C-terminal His-tags on both proteins in E. coli M15 strains (strains JH-62 
and JH-65, respectively). Proteins were purified using the following protocol: After over night 
induction at 25oC with 0.5mM IPTG cells were harvested by centrifugation for 10 min at 4000×g. 
The pellet was resuspended in 40 ml liter-1 of lysis buffer (Tris 50 mM, NaCl 300 mM, imidazole 
10 mM, pH 8) supplemented with 0,25 mg ml-1 lysozyme, 20 ug ml-1 DNase, 20 mM MgSO4 and 
antiproteases (Complete EDTA-free antiprotases, Roche) and frozen at –80oC. After thawing and 
sonication, lysates were cleared by centrifugation (30 min at 12,000×g. The proteins were purified 
on a Pharmacia AKTA FPLC by nickel affinity chromatography (His-Trap 5 ml column, GE 
Healthcare) using a step-gradient of imidazole followed by a preparative Superdex 200 gel filtration 
in 50 mM Tris, 50 mM NaCl, pH 8. Proteins used in the crosslinking experiment were purified 
according to the recommendations in the QIAexpressionist manual (Qiagen).  
Concentrations of the purified proteins were determined using Advanced Protein Assay 
Reagent (Fluka) and NanoDrop 1000 (Thermo Scientific). A280 values were corrected for 
differences in absorption coefficient due to amino acid composition using the ProtParam tool 
(http://www.expasy.org/tools/protparam.html).  
 
Size exclusion chromatography (SEC) with On-line Multiangle Laser Light Scattering, 
Absorbance, and Refractive Index (MALS/UV/RI) Detectors. SEC was carried out on an 
Alliance 2695 HPLC system (Waters) using a Superose S12 column eluted with 50 mM Tris and 50 
mM NaCl at pH 8.0 at a flow of 0.5 ml min-1. Detection was performed using a triple-angle light 
scattering detector (Mini-DAWNTM TREOS, Wyatt Technology), a quasi-elastic light scattering 
instrument (DynaproTM, Wyatt Technology), and a differential refractometer (Optilab_rEX, Wyatt 
Technology). Molecular weight and hydrodynamic radius determination was performed by the 
ASTRA V software (Wyatt Technology) using a dn/dc value of 0.185 ml g-1. Proteins were loaded 
at a final concentration of 0.22 mM and 0.33 mM for AbiV and SaV, respectively. 
 
Cross-linking of AbiV and SaV. A glutaraldehyde (GA) cross-linking experiment was performed 
as described previously 53. Purified AbiV and SaV were diluted both separately and mixed in 50 
mM Hepes, pH 6.2 to a final concentration of 17.6 µM and 32.9 µM, respectively for the two 
proteins. At time zero, glutaraldehyde was added to the protein samples to a final concentration of 
0.05 % and the samples were incubated at room temperature. Aliquots were removed at time T-5 
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(before GA addition), T1 and T30 and immediately mixed with SDS-PAGE sample loading buffer 
followed by heating (99ºC, 2 min) and storing on ice until analyzed on SDS-PAGE gels. The cross-
linked proteins were analyzed on two identical SDS-PAGE gels of which one was Coomassie 
stained for identification of all protein bands and the other was analyzed by western blotting for 
identification of protein complexes containing SaV. The molecular weight of the protein bands was 
estimated using the marker Precision Plus Protein Dual Color Standard (Biorad). 
 
Fluorescence quenching experiments. Fluorescence experiments were carried out on a Varian 
Eclipse spectrofluorimeter using a quartz cuvette in a right-angle configuration as previously 
described 60. Briefly, the light path was 1.0 and 0.4 cm for the excitation and emission, respectively. 
The interaction of AbiV with SaV was monitored by recording the quenching of the intrinsic SaV 
protein fluorescence upon addition of AbiV aliquots which does not have an intrinsic fluorescence 
or absorbance at 295 nm. The excitation wavelength was 295 nm, and emission spectra were 
recorded in the range of 320 to 400 nm. The excitation slit was 5 nm while the emission slit was 10 
nm for a protein concentration of 2 µM. A moving-average smoothing procedure was applied, with 
a window of 5 nm. Titrations were carried out at room temperature with 2 µM protein in 10 mM 
Tris Buffer, 50 mM NaCl, pH 8. No correction of the fluorescence at the maximum level (341 nm) 
was needed since the fluorescence and absorbance levels of the buffer and the quencher protein 
were negligible. The affinity was estimated by plotting the decrease of fluorescence intensity at the 
emission maximum as 100 - (Ii - Imin)/(I0 - Imin)  x 100 against the quencher concentration; I0 is the 
maximum of fluorescence intensity of the protein alone, Ii is the fluorescence intensity after the 
addition of quencher (i), and Imin is the fluorescence intensity at saturating concentration of 
quencher. The Kd values were estimated using Prism 3.02 (GraphPad Software Inc.) by nonlinear 
regression for a double binding site with the equation Y = [(Bmax1 • X)/(Kd1 • X)] + [(Bmax2 • X)/(Kd2 
• X)], where Bmax is the maximal binding and Kd is the concentration of ligand required to reach 
half-maximal binding. 
 
Western blotting. Primary SaV antibody was produced by customhybridoma.com, while primary 
antibodies against ORF11 and ORF16 were produced by C. Cambillau. 
Proteins were separated by SDS-PAGE electrophoresis 41 using 11 % gels for ORF11 and 
ORF16 and 9 % gels for SaV. The proteins were then electroblotted (200 mA for 1 h) onto a PVDF 
membrane (Hybond P) by using a 20% ethanol solution containing 25 mM Tris and 192 mM 
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glycine pH 8.3 as transfer buffer in a Trans-Blot SD apparatus (BioRad). The membranes were 
subsequently treated with blocking buffer (5 % non-fat dry milk (NFDM) in phosphate buffered 
saline supplemented with 0.1 % tween-20 (PBS-T)) for 1 h on an orbital shaker and then treated (1 
h, shaking) with primary antibody diluted in blocking buffer. For SaV, ORF11, and ORF16 primary 
antibodies, the following dilutions were used: 1:75,000; 1:100,000 and 1:25,000, respectively. After 
three washes with PBS-T the membrane was incubated (1 h, shaking) with secondary antibody 
(anti-rabbit IgG alkaline phosphatase linked whole antibody, Amersham) diluted 1:100,000 in 
blocking buffer. This was followed by three washes with PBS-T and 10 min equilibration in PBS 
before the membrane was treated with the ECF-substrate (Amersham) according to the 
manufacturers’ instructions. The protein bands were then visualized using a STORM 860 scanner in 
the blue excitation (450 nm) fluorescence acquisition mode. Quantification of the fluorescent signal 
was performed using the software ImageQuant TL v.2003.03 (Amersham). 
 
Oligonucleotides and 32P-labelling. Oligonucletides used for probing blotted mRNA were 
designed ensuring a high specificity for the target. These oligonucleotides were labelled with 
[32P]ATP (Easytides, Perkin Elmer) using polynucleotide kinase (Roche) and subsequent 
purification with NucAway spin columns (Ambion). Labelling efficiency was determined by 
quantification of 5 µl labelled probe using a Packard Instant Imager.  
 
RNA isolation and dot blotting. Cell pellets were resuspended and incubated (37ºC, 15 min) in 0.5 
M sucrose with 60 mg ml-1 lysozyme before being mixed with 1 ml TRIzol reagent (Invitrogen). 
Total RNA was then isolated according to the manufacturers’ instructions and the samples were 
treated with the DNase based TURBO DNA-free kit (Applied Biosystems) before storing at -80ºC. 
Immediately before use, the RNA samples were thawed and 0.5 µg RNA was added to 0.5 ml of a 
denaturing solution containing 10 mM NaOH and 1 mM EDTA. The RNA samples were blotted 
onto Zeta-probe nylon membranes (BioRad) by use of a Bio-Dot SF slot blot apparatus (BioRad). 
After a brief rinse in 2× SSC 54 plus 0.1% sodium dodecyl sulfate (SDS) for 1 min at room 
temperature, the membrane was air dried for 10 min and fixed by exposure to UV-light for 2 
minutes on each side. Membranes were prehybridized for minimum 2 h in UltraHyb-Oligo 
hybridization buffer (Ambion) before 32P-labeled riboprobe was added. After hybridization 
overnight at 42°C, the membranes were washed three times at 42ºC in 2× SSC + 0,5 % SDS for 
30 min before being air-dried. The amount of radioactivity retained by the riboprobes on the 
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membranes was measured by overnight exposure of Storage Phosphor Screens (Amersham) and 
subsequent detection in a STORM 860 scanner in storage phosphor acquisition mode. 
Quantification of the radioactive signal was performed using the software ImageQuant TL 
v.2003.03 (Amersham). 
 
Radioactive determination of total RNA and protein synthesis. For labelling of RNA, 2.3 ml of 
culture was mixed with 2 µl of [14C]uridine (50 µCi ml-1) and 6 µl of 10 mM uridine to a final 
uridine concentration of 55 µM. Labelling of proteins was done by adding 5 µl of [35S]methionine 
(15 mCi ml-1) to 1.7 ml of culture (the concentration of methionine in the SA medium was reduced 
to 5 µg ml-1). Samples (200µl for RNA and 150 µl for protein) were taken from the labelled cultures 
at 5 min intervals, transferred to a tube with 3 ml of cold 5% trichloroacetic acid (TCA) and put on 
ice for 1 to 1.5 h. Macromolecules were collected on a membrane filter (0.45-µm pore size; 
Schleicher & Schuell, Dassel/Reliehausen, Germany), washed twice with cold 5% TCA and once 
with boiling water, and left to air dry. The radioactivity on the filters was counted in a Packard 
Instant Imager 36.  
 
Phage DNA replication. Replication of phage DNA was followed in a time course experiment as 
described previously 28,31,36. Briefly, total DNA from L. lactis cells was isolated at regular intervals 
from cultures either infected with phage sk1 or phage c2 or from non-infected cultures. Total DNA 
was digested with EcoRV, heated (65ºC, 10 min), and analyzed by eletrophoresis on an agarose gel. 
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RESULTS 
 
AbiV and SaV interact by direct protein-protein interaction. To determine if AbiV and SaV 
were interacting directly to form complexes, we have used three different approaches: cross-linking 
assays, SEC-MALS/UV/RI and fluorescence quenching experiments.  First, we made an in vitro 
cross-linking experiment with purified AbiV and SaV. The proteins were assayed at room 
temperature separately and also mixed in the molecular ratio AbiV:SaV = 1:1. Samples were 
analyzed using coomassie staining (Fig. 1A) and SaV specific western blotting (Fig. 1B). On figure 
1A, the AbiV monomer (22.7 kDa, Fig. 1C) is visible along with faint high-MW band in lane 2 
before GA addition. The monomer band is fading in the lane 3 and 4 (T1 and T30, respectively) 
concomitantly with the appearance of a band around 50 kDa, which probably represents an AbiV 
dimer. The same pattern is observed for SaV (Fig. 1A, lanes 5-7). In the AbiV-SaV mixed condition 
(Fig. 1A, lanes 8-9) both monomers and the SaV dimer are observed along with a distinct band of 
about 40 kDa, which corresponds to an AbiV-SaV heterodimer (39.3 kDa, Fig. 1C). Lysozyme 
(monomer, ca. 14.5 kDa) was treated for 30 min with 0.05 % GA and the absence of cross-linking 
of this protein serves as a negative control (Fig. 1A, lane 10).  
MW (kDa) ×1 ×2 ×3 ×4 
AbiV 22.7 45.4 68.1 90.8 
SaV 16.6 33.2 49.8 66.4 
AbiV+SaV 39.3 78.6 117.9 157.2 
C 
Fig. 1. Cross-linking experiment with AbiV and SaV using Coomassie stained SDS-PAGE gel (A) and western blot 
with detection of SaV (B). The theoretical molecular weights (kDa) of different hypothetical multimeric combinations 
of AbiV and SaV are presented in (C). Molecular weight was determined using Precision Plus Protein Standard 
(Biorad). Lane designations are: L is ladder, -GA is before addition of glutaraldehyde, 1 and 30 represents minutes and 
Lys is lysozyme. Numbers above gel represent lane numbers. 
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Lane 4 on the Western Blot (Fig. 1B) shows SaV before cross-linking including distinct bands of ca 
15 and 30 kDa. These bands may represent monomers and dimers. An additional band of ca 50 kDa 
that would correspond to a SaV trimer is observed after addition of GA. In the AbiV-SaV mix, the 
SaV monomer and dimer are observed but also a very distinct band of ca 40 kDa (Fig. 1B, lane 7). 
This protein contains SaV and the molecular weight indicates that it is a hetero-dimer consisting of 
a SaV monomer and an AbiV monomer. Several other bands are observed including a band of ca 80 
kDa that possibly represents the cross-linking of a SaV dimer and an AbiV dimer. In addition to 
suggesting AbiV-SaV interaction, the above data supports our previous observations that both AbiV 
and SaV are native dimers 28,29.  
To determine more precisely the sizes of the AbiV and SaV homodimers, and the size of the 
complex AbiV/SaV, we used SEC-MALS/UV/RI. SEC is a simple way to estimate the size of a 
protein complex based on a calibration curve obtained with a protein standard. However, the elution 
position is not only related to the molecular mass but is also influenced by the protein shape and the 
affinity of the protein with the matrix used in the column. Therefore, to obtain a better estimate of 
the molecular mass of the protein, it is possible to combine SEC with on-line multiangle laser light 
scattering and refractrometry (MALS/UV/RI). The molecular mass measured this way is more 
accurate since the measure is independent of the position of elution. AbiV and SaV were subjected 
to mass and size analysis separately and together. The MALS/UV/RI analysis gave a measured 
mass of 47,550 Da and 36,000 Da for AbiV and SaV, respectively, which indicate that both proteins 
form homodimers (Fig 1C and Fig. 2B). When both proteins are injected together, the 
chromatogram shows a single peak. The measured mass (71,410 Da) corresponds to a complex 
consisting of AbiV2SaV2 (75,756 Da, Fig. 2B). The hydrodynamic rayon (Rh) of AbiV and SaV is 
3.0 nm and 3.2 nm, respectively, while the Rh of the complex is 4.0.  
The dynamic of the AbiV-SaV interaction was investigated using fluorescence quenching. 
Since AbiV has no intrinsic fluorescence it was possible to measure the dynamic of the complex 
association by adding aliquots of AbiV to a sample of SaV. Addition of AbiV to SaV leads to the 
reduction of emission of Trp fluorescence when excited at 295 nm. A good fit between the 
experimental data and the theoretical curve could be obtained when two binding sites were taken 
into account (Fig. 2A). The Kd value was 26.5 ± 2.7 nM.  
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Fig. 2. Fluorescence quenching assay fitting curve using a nonlinear regression with a double binding site equation (A). 
The insertion represents the plot of the fluorescence emission in function of the wavelength (nm) of acquisition. SEC-
MALS/UV/RI analysis (B). The abscissa indicates the volume scale of the HPLC injection. The ordinate indicates the 
molar mass in g mol-1 (Da). AbiV data is represented in red, SaV data is in blue and the complex AbiV/SaV is in green. 
The resolution of Fig. 2B is low. Data for obtaining higher resolution was not available at the time of submission of this 
thesis.   
Fig 3: Total synthesis of RNA (squares) and protein (diamonds) in AbiV+ cells (closed symbols) and AbiV- cells (open 
symbols) during lytic cycle of phage p2. RNA and protein synthesis were determined as total incorporation of [14C]-
uridine and [35S]-methionine, respectively 
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The AbiV-SaV interaction affects total synthesis of RNA and protein during phage infection. 
We previously demonstrated that DNA of phage p2 (936 species) is replicated during infection of 
cells containing AbiV but that the infection is aborted prior to packaging of the phage DNA 28. To 
get a more detailed picture of the effects of AbiV on synthesis of macromolecules during phage 
infection, we conducted an experiment in which we measured total synthesis of RNA and protein in 
both AbiV+ and AbiV- cells during infection with phage p2. Exponentially growing cultures of JH-
20 (AbiV+) and JH-54 (AbiV-) were infected with phage p2 (MOI = 5) at OD600 = 0.5 while a non-
infected JH-20 culture served as control. Aliquots of all cultures were immediately added to 
solutions containing 14C-uridine (RNA synthesis) or 35S-methionine (protein synthesis) and samples 
were taken at 5 minute intervals for determination of total RNA or protein synthesis. Lysis of the 
sensitive AbiV- culture was observed 28 minutes after infection. 
Compared to the non-infected control, addition of phages (in both Abi+ and AbiV- cells) 
caused an almost immediate and drastic decline in RNA and protein synthesis indicating that 
production of host factors are shut down by the phage quickly after infection (data not shown). 
RNA and protein synthesis in the infected AbiV- cells (Fig. 3) increased until T28 and T26, 
respectively when synthesis stopped. This coincided with complete lysis of the culture 28 min after 
infection. In the AbiV+ cells RNA was produced though at a reduced rate compared to the AbiV- 
culture (Fig. 3), and synthesis continued throughout the experiment though it levelled off just before 
termination of the experiment. The continued synthesis of RNA in this culture was possibly due to 
the absence of cell lysis and this indicates that despite the slight inhibition of RNA synthesis, the 
primary interference of AbiV with the lytic cycle is not at the level of transcription. On the contrary, 
protein synthesis was severely inhibited in the AbiV+ culture, which compared to the AbiV- culture 
showed significantly slower protein synthesis the first 15 min of the infection, at which time protein 
synthesis stopped completely (Fig. 3). The above data shows that despite a significant production of 
RNA, no protein synthesis was observed which indicates that the mechanism of AbiV involves 
inhibition of translation.  
 
AbiV affects transcription of middle and late phage genes. Knowing that the AbiV mechanism 
probably inhibits phage protein synthesis we wanted to address more specifically which part of the 
phage lytic cycle is targeted by AbiV. In another phage infection experiment, JH-20 (AbiV+) and 
JH-54 (AbiV-) were grown exponentially to OD600 = 0.5 when the cells were concentrated ×10 by 
spinning and resuspending in fresh medium. After infection with phage p2 (MOI = 5) samples for 
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isolation of RNA and protein were taken at 5 min intervals by quick-spin and freezing of the pellet 
in -80ºC liquid ethanol. Lysis of the sensitive AbiV- culture occurred 29 minutes after infection and 
the lysis was accompanied by a rise in phage titer corresponding to a burst size of ca. 50 pfu. 
To quantify the transcription level at different time-points during the lytic cycle of the phage, 
several radioactively labelled oligonucleotide probes covering the early, middle and late regions of 
p2 were used to probe the RNA in a dot blot assay. In the early region, three genes (orf27, orf26 
(sav), and orf25) were analyzed. In the AbiV- cells they all reached the same level of transcription 
which peaked between 6 and 12 minutes after which they gradually decreased throughout the rest of 
the experiment (Fig. 4A). The similar transcription levels of orf27 and sav is due to their position in 
the same operon. In the AbiV+ cells, transcription levels were also equal among the three genes. 
The highest level was observed after 6 minutes after which transcription gradually decreased as for 
the AbiV- cells. In these cells transcription level of the early genes at T6 was 76 % of the level in 
the AbiV- cells. At T12 and throughout the experiment, the level was ca 60 % of the AbiV- cells.  
Two genes (orf48 and orf2) had almost identical transcription patterns (Fig. 4B). Orf48 is part 
of the p2 putative middle operon whereas orf2 is part of the putative late operon. In the AbiV- cells 
both transcripts increased until T23 whereas in the AbiV+ cells they levelled off at T17 reaching ca 
50 % of the level in the AbiV- cells.  
The late transcripts (orf11 and orf16) started to increase in the AbiV- cells between T6 and 
T13 (Fig. 4C). Orf16 was slightly delayed compared to orf11 because of its location ca. 5.5 kb 
downstream of orf11. For both genes, transcription in the AbiV+ cells reached only ca 10 % of the 
level in the AbiV- cells.  
The above transcription data shows that mRNA is produced in the presence of AbiV thus 
supporting the data demonstrating synthesis of total RNA in the presence of AbiV. However, the 
transcription data also shows that there is a differentiation of the synthesized mRNA which is linked 
to the timing of transcription. Thus early transcripts are only little affected (75 % to 60 % of wild 
type level), whereas middle transcripts are slightly more affected (50 % of wild type level) and late 
transcripts are almost completely inhibited (10 % of wild type level). 
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Fig 4: Transcription of early (A), middle (B) and late (C) genes during infection of AbiV+ cells (closed symbols) and 
AbiV- cells (open symbols) with phage p2 
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AbiV inhibits translation of phage proteins. Total protein was isolated from samples taken 
simultaneously with the RNA samples. Using western blotting and antibodies specific for SaV, 
ORF11 and ORF16 we were able to follow the level of translation during the p2 lytic cycle. SaV is 
a non-structural protein located in the early expressed region of the phage while ORF11 is the major 
capsid protein (MCP) and ORF16 probably is associated with the tail. Both are late structural 
proteins.  
In the AbiV- cells SaV translation increased from T12 and continued to rise throughout the 
experiment (Fig. 5). No translated SaV could be detected in the AbiV+ cells at any time during the 
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Fig 5. Translation of phage proteins SaV, ORF11 and ORF16 during infection with phage p2. Western blot (A) shows 
bands in AbiV- cells (control) and AbiV+ cells (AbiV) at different timepoints (-1 to 35 minutes). NI is non-infected, SaV 
is purified SaV and p2 is isolated structural proteins from phage p2. The levels of expression are shown in (B) where open 
and closed symbols represent AbiV- and AbiV+ cells, respectively 
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experiment. The same pattern was observed for the late proteins ORF11 an ORF16 which both 
increased from T17 in the AbiV- cells. Contrary to the SaV samples a basic level of protein was 
observed in the ORF11 and ORF16 samples from AbiV+ cells, which was due to the initial amount 
of phages added in the experiment (MOI = 5). Since ORF11 and ORF16 are structural proteins 
these proteins were detected at a basic and stable level in the AbiV+ cells (Fig. 5A). The observed 
timing of expression of the three proteins was expected due to their position on the phage genome. 
Thus SaV was expressed before ORF11 which was expressed before ORF16 (Fig. 5B). Expression 
of SaV is expected to start immediately after transcription so the observed delay (expression 
increasing from T12) was probably due to lack of sensitivity of the western blotting.  
The western blots showed that translation of both early and late phage proteins were severely 
inhibited. For ORF11 and ORF16 this can be explained by the low level of transcribed mRNA but 
in the case of SaV, the gene is transcribed almost at wild type level (Fig. 4A). The results therefore 
indicate that AbiV in combination with SaV inhibit translation of phage p2 proteins early in the 
lytic cycle and possibly by a direct protein interaction between the two proteins.  
 
Inhibition of DNA replication in phage c2. We previously demonstrated that DNA of the 936-
phage p2 was replicated in AbiV+ cells during a phage infection experiment but that the replicated 
DNA only existed in the concatemeric form 28. We observed the same pattern with the 936 phage 
sk1 (data not shown). An identical experiment was conducted in which phage sk1 was substituted 
with phage c2 to infect the same host (L. lactis MG1363) with and without AbiV. In the AbiV- cells, 
replicated c2 DNA was observed at T55 and starting to decrease at T80 coinciding with lysis of the 
culture (Fig. 6B). The low MOI (ca. 1) used in this experiment probably caused the late lysis of the 
sensitive host. In the AbiV+ cells the pattern of EcoRV digested c2 DNA could not be observed at 
any time during the experiment (Fig. 6A). The bands observed on the gel therefore represent the 
EcoRV digested bacterial chromosome. The data indicates that c2 DNA is not replicated in the 
presence of AbiV thereby demonstrating different phenotypic effects of AbiV on the lytic cycle of 
936- and c2-phages. 
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C 
Fig. 6. Phage DNA replication in AbiV+ cells (A) and AbiV- cells (B) during lytic cycle of phage c2. Total DNA was 
isolated at different timepoints (-10 to 120 minutes) after infection and digested with EcoRV. Restriction maps of c2 
digested with EcoRV is presented (C) where numbers indicate sizes of the restriction fragments. Numbers refer to the 
size of c2 DNA fragments after digestion and heat treatment. L is GeneRuler 100-10,000 DNA ladder (Fermentas) 
 
A B 
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DISCUSSION 
 
In recent studies we have isolated the lactococcal abortive infection mechanism AbiV 28 and 
also characterized the early transcribed phage protein SaV which is necessary for the abortive 
infection phenotype of the system 29. In the present study we demonstrated a direct protein-protein 
interaction between AbiV and the translated phage gene product SaV using cross-linking, SEC-
MALS/UV/RI and fluorescence quenching assays (Fig. 1+2). AbiV and SaV form a complex 
composed of 2 units of each protein. The strength of interaction was measured by fluorescence 
quenching assay and the analysis gave a Kd value of 26.5 ± 2.7 nM. The interaction is significant 
and is, to our knowledge, the first demonstration of a direct interaction between an Abi-protein and 
an interacting phage protein. This data confirmed our previous observations that both AbiV 28 and 
SaV 29 form native dimers. We previously argued that the SaV polypeptide is involved in sensitivity 
to AbiV 29 and it is thus probable that the direct AbiV-SaV protein interaction is responsible for the 
Abi phenotype.  
In order to elucidate the molecular effects of the AbiV-SaV interaction on the lytic cycle of 
936 phages we used phage p2 as a model. Phage p2 is a very close relative to phage sk1 (GenBank 
acc.nr: NC_001835).  
The transcription level of genes located in the early, middle and late region of phage p2 was 
analyzed with and without AbiV at different time points during a lytic cycle (Fig. 4). We observed 
an increasing effect of AbiV on transcription from early to middle and late genes which was most 
pronounced for transcripts in the late region. In the early region we observed a 25-40 % decrease of 
transcription in AbiV+ cells compared to AbiV- cells. In the middle and late regions the decrease 
was 50 % and 90 % respectively. Previous transcription analyses of sk1 have revealed that early 
transcripts appear 2-5 minutes after infection whereas middle transcripts are observed after 7-10 
minutes and late transcripts after 15 minutes 9. In the AbiV- cells, early transcripts are decaying 
from T12 maybe due to a switch-off mechanism as observed in other phages 9,20,52 coinciding with 
the appearance of late transcripts 15 minutes after infection. In the AbiV+ cells these transcripts are 
decaying earlier thus ending at a level which is 60 % of the AbiV- cells. These early transcripts are 
expected to be important primarily in the beginning of the lytic cycle where the effect of AbiV on 
transcription was small (25 % reduction at T6). Previously, half-life of mRNA in L. lactis has been 
determined to ca. 2 minutes 62. Given this rate of mRNA decay, the transcription data suggests that 
there is a continuous mRNA production both in AbiV+ and AbiV- cells. This was supported by 
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results from the total RNA synthesis experiment, in which, data was not influenced by mRNA 
stability (Fig. 3).  
Contrary to RNA synthesis, a profound effect of AbiV was observed on protein synthesis in 
AbiV+ cells compared to AbiV- cells. Total protein synthesis was severely inhibited from the 
beginning and ceased completely after 15 minutes of the lytic cycle. According to the sk1 
transcription data 9 this prevented translation of most middle transcripts (7-10 min after infection) 
and all late transcripts (15 min after infection). Western blotting and antibody identification of 
middle proteins was not performed but as expected, translation of the two late proteins ORF11 and 
ORF16 was completely inhibited by the AbiV mechanism (Fig. 5). Interestingly, translation of SaV 
could not be detected in the AbiV+ cells though the sav transcript was observed in these cells (Fig. 
4A). The Abi phenotype is supposed to involve a translated SaV protein 29 but since this could not 
be detected using western blotting, we suggest that very small amounts of SaV are needed to induce 
the Abi phenotype and that the western blotting method is not sensitive enough to detect this 
amount of SaV. SaV translation is thus almost completely inhibited by the AbiV mechanism while 
transcription of genes in the early region (including sav) is only minimally inhibited by AbiV. 
These observations strongly indicate that the target of the AbiV mechanism is to be found in the 
translation apparatus of the cell.  
To account for the above observations we constructed the following hypothesis on the mode of 
action (MOA) of the AbiV mechanism: Upon translation, the SaV polypeptide interacts with AbiV 
to induce the Abi phenotype inhibiting the translational machinery of the cell. If only small amounts 
of SaV is needed for induction of the Abi mechanism, translation will be arrested early in the lytic 
cycle thereby also preventing further SaV translation, which is therefore only produced in sub-
detectable amounts. Middle genes in sk1 are transcribed from the PM promoter which needs 
activation most probably by an early translated phage protein 3,10,39. Since translation is arrested 
early in the lytic cycle this activator is probably not fully expressed thereby causing the observed 
partial inhibition of middle transcripts. The transcription profile of orf48 is remarkably similar to 
the profile of orf2 (Fig. 4B). In the analysis of the phage sk1 genome the homologue of orf48 was 
assigned to the middle region whereas orf2 was assigned to the late region 10. In the same study a 
putative terminator structure was suggested to exist at nucleotide position 27,890 to 27,908 on the 
sk1 genome (GenBank acc.nr: NC_001835). However this stem-loop structure is not succeeded by 
the oligo(T) sequence (T-stretch) which is crucial for intrinsic transcription termination 27. It is 
therefore likely that the terminator is inefficient thereby causing read-through from the PM promoter 
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which was observed in both sk1 9,27 and p2 (this study). The late transcripts in sk1 were observed 15 
minutes after infection whereas middle transcripts were observed after 7-10 minutes 9, indicating 
that one of the four genes in the middle operon is an activator of late transcription 9. In the present 
study such an activator would be translated at very low levels in the AbiV+ cells due to the 
combined effect of inhibited transcription of the middle region and the translation inhibition by the 
Abi mechanism. The almost complete inhibition of the two late transcripts (orf11 and orf16, Fig. 
4C) could thus be explained by absence of activation. 
Our data does not support a more detailed description of the AbiV-SaV mode of action. 
However, using the software RNAbindR and BindN, we identified a putative RNA binding site at 
codon 81-96 63 or 81-113 of AbiV 57,58. It could be speculated that this RNA binding site is not 
exposed in the native non-toxic form of AbiV 28, but that activation by SaV causes a conformational 
change in which the RNA binding site is exposed. RNA binding by an active AbiV-SaV complex 
could therefore be part of the AbiV mode of action. However, further studies are needed to test this 
hypothesis.  
DNA replication of phage p2 from the 936 species was previously demonstrated to occur in 
AbiV+ cells 28. While the same pattern was observed using the closely related 936 phage sk1 in the 
present study, we showed that DNA replication did not occur when the same host was infected with 
the prolate headed phage c2 (Fig. 6). Since the same host was used in the experiments, differences 
between the two phage types must account for the two observed phenotypes 25. For some Abi 
mechanisms different modes of action have been observed against phages from the 936, c2, and 
P335 species 11,16,56: AbiK allowed DNA replication of phage p2 (936-species) but not ul36 (P335-
species) 7 and AbiG allowed DNA replication of c2 and 936 phages 51 but not of P335 phages 56. 
We previously demonstrated that while the copy-number of AbiV apparently was not important for 
the Abi phenotype against the 936 phages p2 and sk1, protection against c2 infection required high 
expression of AbiV 28. Such stronger Abi effects on 936 phages compared to c2 phages has been 
demonstrated for AbiA 16, AbiG 51, and AbiK 22 suggesting that c2 phages are generally better 
suited to bypass the Abi phenotype compared to 936-phages 56. We previously demonstrated that 
like AbiA 16 and AbiK 6, the phage genes involved in sensitivity to AbiV share only limited amino 
acid similarity between 936 and c2 phages 29. However, a region of SaV which is conserved among 
the 936 and c2 species is probably involved in sensitivity to AbiV which could suggest a common 
mode of action of AbiV against the two phage species. If translation inhibition of phage proteins is 
the MOA of AbiV against both 936 and c2 phages it implies that the mechanism must act before 
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translation of the DNA polymerase (orfs e5, e6, and e7) in c2 8,43. The DNA polymerase subunits 
are transcribed early in the lytic cycle from consensus Lactococcus promoters in both the 936 
phages sk1 and p2 and phage c2. However, the sav homologue (e11) of c2 is transcribed from a 
promoter which is much stronger than the promoter from which the DNA polymerase is transcribed 
42. This strong promoter was previously compared to the strong promoters from phage T5 26,42. It 
has perfect consensus and strong conservation downstream of the start nucleotide and it was 
suggested to be among the strongest lactococcal promoters identified 26,42. Transcription of the sav 
homologue of c2 from such a strong promoter could activate AbiV and thus the Abi phenotype 
before transcription and translation of the DNA polymerase which is being transcribed from a much 
weaker promoter 42. In the analyzed 936 phages such differentiation between the promoters of sav 
and the DNA polymerase was not observed. 
In conclusion, we have analyzed the interaction between the novel Abi mechanism AbiV 28 
and the phage p2 protein SaV which is essential for the function of AbiV 29. The proteins interact 
directly forming an active complex that might involve an exposed RNA binding site in AbiV. 
Ongoing work is aimed at revealing such structural information. The Abi mechanism was 
demonstrated to inhibit protein synthesis in phage p2 at an early stage of the lytic cycle while RNA 
synthesis was primarily inhibited for late mRNA transcripts probably due to absence of activation 
of a late promoter. We propose a hypothesis for the mode of action of AbiV against 936 phages 
which could also explain the different phenotypic effect of AbiV on the lytic cycle of phage c2. 
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ABSTRACT 
 
The lactococcal abortive infection mechanism AbiV is silent on the chromosome of Lactococcus 
lactis subsp. cremoris MG1363. Spontaneous phage resistant mutants were analyzed by reverse 
transcriptase PCR (RT-PCR) and demonstrated to express AbiV. The expression might be related to 
point mutations upstream of abiV. Conjugal transfer of abiV was demonstrated between two 
lactococcal strains by chromosomal transfer, thereby demonstrating, to our knowledge, the first 
conjugal transfer of a chromosomally encoded phage resistance mechanism. 
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 INTRODUCTION 
 
Industrial milk fermentation is a world wide industry which is dependent on well characterized 
metabolic features of industrial starter strains 7. Phage attacks, primarily by the three species 936, c2, 
and P335 33, leading to fermentation failure is a persistent problem for the dairy industry 10 despite 
decades of focused research on lactococcal phages 7,33. A number of natural defense systems exist in 
Lactococcus lactis including adsorption inhibition 15,26 injection inhibition 31, R/M systems 1,15, and 
abortive infection (Abi) mechanisms 5. These mechanisms have been used intensively in a relatively 
small number of industrial starter strains 9, which has favored the emergence of phage mutants that 
are insensitive to the applied anti-phage barriers 10,15,33. This forces the dairy industry to constantly 
finding new ways to protect their starter cultures against phage attacks. Engineered phage resistance 
has been suggested as a supplement to the natural phage resistance mechanisms 7,11,12,23,32,27,31,8. 
However, these mechanisms have only limited efficiency against a narrow range of sensitive phages 
26 and furthermore, industries using genetically modified organisms are facing obstacles as legal 
limitations in many countries 15,33 as well as consumer skepticism 9,15,47. To protect their strains, the 
dairy industry is therefore dependent on isolation of novel natural phage resistance barriers that can 
be transferred to industrial starter strains without the use of genetic manipulation. Most natural R/M 
and Abi systems are plasmid encoded 2,3,5,13,14,16,24,36,46. Many of these plasmids are conjugative and 
the concomitant mobility of the phage resistance mechanisms has been utilized by the dairy industry 
to create phage resistant starter cultures 1,7,22,33,35,39,42. However, some phage resistance mechanisms 
are chromosomally encoded and the industrial application of these anti-phage barriers is dependent 
on the ability to transfer the gene(s) encoding the phage resistance mechanism to the desired 
industrial production strains. Contrary to conjugal transfer of plasmid encoded phage resistance 
mechanisms which has been widely exploited by the dairy industry, the conjugal transfer of 
chromosomally encoded phage resistance mechanisms has to our knowledge not been demonstrated.  
Recently, we isolated and characterized AbiV, a novel Abi mechanism which is silent on the 
chromosome of L. lactis subsp. cremoris MG1363 20.  
Here, we report phage resistant mutants of a L. lactis MG1363 derivative that spontaneously 
has mutated to express AbiV. Furthermore, we demonstrate that abiV can be transferred between 
lactococcal strains by conjugational chromosomal transfer and subsequent recombination events. 
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 RESULTS AND DISCUSSION 
 
Isolation of mutants of L. lactis MB112 spontaneously expressing AbiV. The lactococcal phage 
abortive infection mechanism AbiV is located on the chromosome of L. lactis MG1363 among 
remnants of mobile genetic elements in a region referred to as an “integration hot spot” 48. AbiV 
protects the cell against 936-like and c2-like phages when expressed in an expression vector while 
the level of expression in wild type L. lactis MG1363 is not sufficient to confer phage resistance 20. 
To investigate if L. lactis MG1363 could mutate spontaneously to express AbiV, we isolated 
mutants that could grow in the presence of the lytic phage sk1 (all bacterial strains and phages used 
in the present study are listed in Table 1). Ten independent cultures of exponentially growing L. 
lactis MB112 (30ºC in M17 45 supplemented with 0.5 % glucose) were mixed with the lytic phage 
sk1 (MOI > 1) in presence of 10 mM CaCl2 and incubated 10 min at room temperature before 
plating and incubation at 36ºC overnight. Mutants that spontaneously had gained resistance to sk1 
were observed with a frequency of ca 10-8. Fifty-six single colonies picked randomly among the ten 
independent cultures were purified and cross-streaked 40 against phages sk1, p2, 712 and the AbiV 
insensitive mutant p2.1 21. A mutant expressing AbiV is expected to be resistant to sk1 and p2 but 
sensitive to 712 and p2.1 due to the absence of the early transcribed gene sav in the two latter 
species (Table 1) 21.  
 
TABLE 1. List of bacteria and phages used in the study. 
Bacterial strain 
or phage 
Characteristics 
 
Source 
 
L. lactis   
MB112 L. lactis subsp. cremoris MG1363, Δupp, host for phages p2, sk1, 712, and p2.1; FUR  30 
MG1614 L. lactis MG1363 derivative, host for phages p2, sk1, 712, p2.1; RifR, StrR 18 
JH-20 MB112 (pJH2); CamR, AbiV+ 20 
JH-32 MB112 (pGhost9::ISS1 insert upstream of abiV on chromosome); ErmR, FUR, AbiV+ 20 
JH-54 MB112 (pLC5), CamR, AbiV- 20 
JH-80 MB112, spontaneous resistant to sk1 and p2, AbiV+ This study 
JH-83 MG1614 (R), JH-32 (D) transconjugant, FUS, ErmR, StrR, RifR, p2R, p2.1S, sk1R, 712S This study 
Phages   
p2 Small isometric headed, 936 species, sav+ 34 
sk1 Small isometric headed, 936 species, sav+ 4 
712 Small isometric headed, 936 species, sav- 29 
p2.1 Small isometric headed, 936 species, mutations and deletion in sav, sav- 21 
CamR, chloramphenicol resistance  (5 µg ml-1); ErmR, Erythromycin resistance  (3 µg ml-1); FUR, Fluorouracil resistance 
(0.3 µg ml-1); RifR, Rifampicin resistance  (100 µg ml-1); StrR, Streptomycin resistance (200 µg ml-1); AbiV+, AbiV 
phage resistance phenotype; AbiV-, AbiV phage sensitive phenotype; p2R, resistant to phage p2; p2.1S, sensitive to 
phage p2.1; sk1R, resistant to phage sk1; 712S, sensitive to phage 712; , sav+, functional  sav gene;  sav-, absent or 
unfunctional sav gene. 
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 Of the fifty-six initial mutants, EOP values were obtained for eight possible candidates using 
the phages p2, 712, and p2.1. Phage p2 has an efficiency of plaquing 41 (EOP) of ca 10-4 on cells 
harboring AbiV, and one mutant (JH-80) revealed the expected pattern with EOP values of 2×10-5, 
0.75 and 0.8 obtained with the phages p2, 712, and p2.1, respectively 20. The expected EOP value 
and the phage sensitivity pattern indicated that JH-80 was spontaneously expressing AbiV.  
To verify that the Abi phenotype was indeed caused by expression of AbiV, we investigated 
the transcription of abiV in JH-80 using reverse transcriptase PCR (RT-PCR) as described 
previously 20. The RT-PCR was performed on RNA isolated from JH-80, JH-20, JH-54, and JH-32 
(Fig. 1). While levels of abiV transcription in JH-20 and JH-32 were highest, JH-80 indeed showed 
a higher transcription level compared to the wild type level in JH-54. A negative control was 
included by running an identical experiment just omitting the reverse transcriptase enzyme in the 
process, which demonstrated that the RNA was free of contaminating DNA (Fig. 1B). A positive 
control was performed using primers for the glycolytic genes gapB and pfk excluding artifacts due 
to RNA loss in the sample (data not shown). The above data demonstrates that L. lactis mutants can 
be isolated, which spontaneously express AbiV thereby conferring phage resistance to the cell. 
These findings are of potential value for the dairy industry since expression of AbiV was obtained 
without using genetic modification 7,33,47. It was previously observed that the AbiV activity was not 
gene-dosage dependent against 936 phages when expressed from an expression vector or from a 
chromosomal insert 20. However, the weak expression observed in the present study (Fig. 1A, lane 
3) was not sufficient to confer resistance to 936 phages. 
In an attempt to elucidate the mutation(s) in JH-80 leading to increased abiV transcription, we 
PCR-amplified a ca. 1300 bp region (nucleotides 1828 to 3140 on Genbank acc.nr: AF324839) of 
the chromosome upstream of abiV. The size of the DNA fragment was the same as a fragment 
amplified from wild type L. lactis MG1363, which indicates that no DNA deletions or 
rearrangements had occurred immediately upstream of abiV (results not shown). The PCR-
amplified DNA fragment was sequenced and revealed three point mutations ca 400 bp upstream of 
abiV and further three point mutations about 1 kbp upstream of abiV. All mutations were located in 
an upstream gene trans encoding a putative transposase. This gene was previously demonstrated to 
be silent in L. lactis MG1363 20 and it is therefore not probable that the increased level of abiV 
transcription was caused by an altered protein structure of a trans gene product. We did not identify 
any terminator structures between the point mutations and abiV. On the other hand, the point 
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 mutations did not reveal an obvious lactococcal consensus promoter sequence and we were thus 
unable to reveal the genetic determinant leading to increased transcription of abiV (data not shown). 
Transfer of abiV by chromosomal conjugation. Most known Abi mechanisms are plasmid 
encoded though it has been argued that this overrepresentation could be due to the technical 
advantages of isolating the plasmid encoded Abi systems 5. AbiV, like a few other Abi mechanisms 
6,37,38, is located on the chromosome of its host (L. lactis MG1363) and is thus not readily 
transferable. Conjugation of chromosomal genetic material has been observed in L. lactis 17,19, and a 
chromosomally encoded sex-factor was demonstrated to exist in L. lactis MG1363 43,44 thereby 
permitting lactococcal strains to exchange genetic material by chromosomal transfer and subsequent 
recombination. In the present study we took advantage of this ability, to transfer abiV from JH-32 
(Abi+, ErmR, FUR) 20 to MG1614 (RifR, StrpR) 18. In short, donor and recipient were grown 
separately on plates and subsequently recovered with 0.9 % NaCl before they were mixed at ratios 
of 1:1, 1:3, and 1:9, plated (0.1 ml plate-1) on several plates, and then incubated anaerobically 
overnight at 36ºC (growth at 36ºC prevents excision of a pGhost9::ISS1 insert in JH-32) 20,28. The 
cells were then recovered in 0.9 % NaCl and incubated anaerobically (48 h, 30ºC) on selective 
plates (erythromycin and rifampicin).  
In the recently constructed strain JH-32, the insertional mutagenesis vector pGhost9::ISS1 28 
was inserted immediately upstream of abiV on the bacterial chromosome and it was suggested that 
Fig 1. Reverse transcriptase PCR (25 PCR cycles) carried out on isolated RNA. (A) Experiment done with reverse 
transcriptase enzyme, (B) Control without reverse transriptase. Lanes 1-4 represents: JH-80 (spontaneous mutant), 
JH-20 (high expression of AbiV), JH-54 (wt), JH-32 (insertional mutant), respectively. L is Generuler 100-10,000 
DNA ladder (Fermentas) 
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 the observed transcription of abiV was due to a read-through from the erythromycin resistance gene 
in the inserted plasmid 20. In a chromosomal transfer it is therefore likely that both the ErmR gene 
and abiV will be transferred together due to their close location. This allowed us to select for 
erythromycin resistance (ErmR) instead of using phage resistance as a selection marker for the 
donor phenotype. Rifampicin resistance (RifR) was used to select for the recipient cell phenotype 
and transconjugants were thus isolated using selection for ErmR and RifR. Additional unique 
resistance markers in donor (fluorouracil, FUR) and recipient (streptomycin, StrR) allowed us to test 
the transconjugants for phenotypes against which they were not selected. Using this approach, we 
minimized the risk of isolating false positives due to spontaneous mutations causing the resistance 
phenotype. Thus, isolated transconjugants (ErmR, RifR) could be tested for resistance to fluorouracil 
(FUR, donor) and streptomycin (StrR, recipient). Transconjugants with the phenotype FUS, ErmR, 
phageR, RifR, StrR are expected to originate from MG1614 (RifR, StrR) which have acquired ErmR 
and phageR from JH-32 by chromosomal transfer (Table 2). Seven ErmR, RifR colonies were 
isolated after two days of anaerobic incubation (36ºC). Five of these mutants were identified as 
donors with spontaneous RifR mutations and one was identified as a recipient with a spontaneous 
ErmR mutation. However, one mutant (JH-83) had the recipient phenotype (FUS (grown on SA 
plates supplemented with 0.5 % glucose 25), RifR and StrR) in addition to being ErmR and resistant 
to phage p2 with the same EOP as JH-20 (EOP of ca 10-4). Spontaneous StrR mutations are very 
rare and since streptomycin was not used in the selection process, the subsequent test for StrR were 
used to determine the recipient origin of the mutant. The results therefore strongly indicate that 
chromosomal transfer of ErmR and abiV was responsible for the observed phenotype.  
 
Theoretically, this phenotype could be explained both by transfer of genetic material from 
MG1614 to JH-32 and by transfer of genetic material from JH-32 to MG1614 followed by different 
subsequent recombination events. However, chromosomal gene transfer in L. lactis MG1363 occurs 
in the anti-clockwise direction 17 and the location of the resistance markers on the L. lactis MG1363 
chromosome with, the ErmR/phageR markers being closest to the sexfactor, therefore makes the JH-
TABLE 2. Resistance phenotypes in conjugation experiments 
 Phage Erythromycin Rifampicin Streptomycin Fluorouracil 
JH-32 (D) yes yes no no yes 
MG1614 (R) no no yes yes no 
JH-83 (T) yes yes yes yes no 
Donor (D), recipient (R) and transconjugant (T). Selection for transconjugants done with erythromycin and rifampicin 
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 32 to MG1614 transfer most likely (Fig. 2). This is due to a gradual decrease in conjugation 
frequencies for anti-clockwise locations progressively more distant from the sex-factor. 
PCR amplification of a chromosomal region upstream of abiV (including parts of the ErmR 
gene in the JH-32 insertion) in JH-83 was performed. The patterns of amplified PCR fragments 
were identical in JH-32 and JH-83 while being different from the MG1614 pattern, which indicates 
that abiV and the ErmR had been successfully transferred from L. lactis JH-32 to L. lactis MG1614 
(data not shown). 
The data indicates that abiV can be transferred between lactococcal strains by the means of 
chromosomal transfer. To our knowledge this is the first demonstration of a conjugal transfer of a 
chromosomally encoded phage resistance mechanism.  
For industrial applications it is of great convenience to use phage resistance mechanisms 
encoded on conjugal plasmids, which is indeed the case for most of the isolated natural Abi and 
R/M mechanisms 5,7. AbiV is flanked by two putative transposases (lin and trans) on the 
chromosome of L. lactis MG1363 (Gen.Bank acc.nr. AF324839) 48 and it is thus possible that abiV 
can be mobilized onto a conjugative plasmid due to the location among these mobile elements. 
However, more experiments are needed to test this hypothesis. 
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Fig. 2. Genomic map of L. lactis subsp. cremoris MG1363 with indicated positions of genetic markers used in 
the conjugation experiments. AbiV is expressed from the erythromycin resistance (Erm) promoter. Resistance to 
streptomycin, fluorouracil, and rifampicin is mediated by mutations in rpsL, upp, and rpoB, respectively. 
Chromosomal transfer is initiated at the sexfactor (including the cluA gene) and progresses in an anticlockwise 
direction (arrow) 
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PHAGE RESISTANCE
Technical field of the invention 
The present invention relates to the field of dairy science. In particular the present 5
invention relates to methods for improving dairy starter culture quality.
Background of the invention 
The lactic acid bacterium Lactococcus lactis is used in milk fermentations world 10
wide in the dairy industry to produce a variety of cultured dairy products. Phage 
infections can ruin the fermentation by inactivating the inoculated cultures. 
Phages are the major cause of fermentation failures during the manufacture of 
these cultured dairy products. There is thus a permanent need in the art for L. 
lactis starter cultures to perform at a high level of consistency and efficiency.15
Phages
Lactococcal phages are characterized by having relatively short latent periods and 
relatively large burst sizes. They are the major cause of fermentation failure 20
leading to production loss in the dairy industry. Lactococcal phages are currently 
divided into eight distinct groups of which three groups namely “936”, “c2” and 
“P335” are responsible for the vast majority of phage attacks in industrial 
fermentations. The genomes of the phages within one single group are highly 
conserved except for the P335 group.25
Industrial fermentations are carried out in large fermentation vats in a non-sterile 
environment. Prior to fermentation, the ingredients are usually pasteurized. 
However, the phages are often resistant to the pasteurization process. Presence of 
phages can lead to variations in flavor and texture of the fermented dairy product 30
or even loss of the entire production with serious economical loss as a 
consequence. The dairy industry is therefore using a variety of methods in limiting 
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phage attacks. Such approaches include e.g. improved disinfection processes, 
rotation of starter cultures and application of phage resistant starter strains. 
Phage defense mechanisms
5
During evolution L. lactis has developed a series of defense mechanisms against 
phage attacks. These naturally occurring phage resistance mechanisms (φrm) has 
been studied extensively and also applied in industrial starter cultures. Most of the 
naturally occurring φrms are found on plasmids and they are classified into four 
groups according to their mode of action: 1) adsorption inhibition, 2) blocking of 10
phage DNA injection, 3) restriction/modification systems (R/M) and 4) abortive 
infection mechanisms (Abi). Among these defense mechanisms, the Abi systems 
are considered to be the most powerful due to their diverse mode of action and 
efficiency against the most common phages.
15
Abi mechanisms
Abi mechanisms function in the phage life cycle subsequent to the injection of 
phage DNA into the bacterial cell - typically after expression of early phage genes. 
As a consequence, the phage lytic cycle is terminated and usually the host dies. 20
Very few viable phage progeny are thus released and the phenotypic outcome is a 
reduction in the number and size of plaques and thus a reduction of the severity 
of the phage infection.
To date, twenty-two lactococcal Abi systems have been isolated. These Abi 25
systems target one, two or all three groups of the common phage species 936, c2, 
P335 with varying efficiency (EOP values from 10-1 to <10-8) (fig 1).
Most of the isolated Abi systems are found on plasmids of which many are 
conjugative. By sharing the φrms within the bacterial population, conjugation thus 30
provides an adaptation strategy to the phage containing dairy environment. Only 
a few abi mechanisms have been isolated from the chromosome of L. lactis. This 
may partly be due to the fact that it is generally easier to isolate genes present on 
plasmids compared to isolation of genes present on chromosomes. The procedure 
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used in the present invention to isolate a φrm from the chromosome of L. lactis
can be used to identify other φrms on the bacterial chromosome. 
By isolating spontaneous phage resistant mutants with a similar phenotype with 
regards to efficiency against a range of phage species it is probably possible to 5
identify strains expressing the abi without having to use genetic modification. 
Using this method, non-GMO phage resistant strains can thus be isolated. Use of 
non-GMO starter cultures may be an advantage in some case, in particular in 
relation to the fact that the legislation in some countries does not allow use of 
GMO. Furthermore, some consumers tend to prefer non-GMO derived products. 10
The point of interference with the phage life cycle has been determined to some 
degree for most of the Abi mechanisms: 
· AbiA, AbiF, AbiK, AbiP, AbiR, and AbiT apparently interfere with phage DNA 
replication.15
· AbiC apparently interfere with capsid production. 
· AbiE, AbiI, and AbiQ apparently interfere with phage packaging. 
· AbiB is apparently an RNase.
· AbiD1 seems to interfere with a phage RuvC-like endonuclease. 
· AbiU apparently delays phage transcription.20
· AbiZ apparently causes premature lysis of the infected cell.
These very diverse modes of action are most likely the reason for the very low 
degree of protein homology that exists between the different Abi mechanisms.  
25
Though the point of action in the phage life cycle has been determined, the phage 
protein interacting with the Abi mechanism has only been identified in AbiA, 
AbiD1, AbiK and AbiP. An increasing number of phage genomes are being 
sequenced providing a bulk of sequence data in which numerous putative proteins 
are found. However, experimental evidence for the function of these proteins are 30
lacking behind. 
Several phage resistant strains of L. lactis have been constructed by introducing 
abi systems in phage sensitive industrial starter cultures. However, extensive use 
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of these bacterial cultures leads to problems with emergence of phage mutants 
capable of overcoming the introduced abi systems. 
The evolutionary “arms race” between phage mutants and bacterial φrms means 
that there is a constant need in the art for identifying novel natural φrms. There is 5
a particular need in the art for finding novel Abi-mechanisms that interact with 
previously unknown targets in the phage. Furthermore there is a need in the art 
for novel Abi-mechanisms in Lactococcus bacteria that do not classify as GMO. 
Finally there is a need in the art for identifying φrms that provide efficient 
protection against phages. 10
Summary of the invention 
The present invention thus relates to a polynucleotide conferring at least one 
phage resistance mechanism to a Lactococcus bacterium, wherein said 15
polynucleotide encodes a polypeptide according to SEQ ID NO 1 and/or SEQ ID 
NO 2, and/or SEQ ID NO7 or a fragment or variant thereof. The present invention 
furthermore relates to the polypeptides, uses thereof, expression vectors and cells 
expressing these polypeptide sequences. The present invention also relates to 
methods for producing fermented dairy products as well as the products resulting 20
from these processes. 
The present invention finally relates to methods for identifying φrms on 
chromosomal DNA. 
25
The novel φrm(-s) according to the present invention provide a number of 
advantages as described in the following. 
Brief description of the figures 
30
Figure 1: Characteristics of the twenty-two (including AbiV from the present 
invention) Abi mechanisms isolated to date.
145
42448PC01
5
Figure 2: The sequence from GenBank (acc.nr AF324839) containing orf1 which 
surprisingly turned out to have the capability to function as a φrm according to 
the present invention. Fig 2A: the strains with the transposon containing vector 
pGhost9::ISS1 inserted on the chromosome. Arrows indicate the position and 
direction of the inserted ISS1 sequences. The presence of a promoter and the 5
φrm+ phenotype is indicated to the right. Fig 2B: the strains with the cloned 
fragment including orf1. The lines represent the cloned DNA fragment, and the x 
in JH-24 represent the position of the frame shift mutation introduced into this 
strain. 
10
Figure 3: Time course experiment of a phage infection. Samples are taken during 
infection of phage resistant Lactococcus lactis strain JH-20 (upper panel) and 
phage sensitive Lactococcus lactis strain JH-16 (lower panel) with p2 phage. The 
experiment was run for 120 min and samples were taken at: -10, 0, 10, 20, 30, 
40, 50, 60, 90 and 120 minutes. Total DNA was isolated from the cells and 15
restricted with EcoRI. The resulting restriction fragments are representing EcoRI
digested p2 DNA. Band 1.3 kb and 4 kb are spanning the cos site which marks the 
extremities of the phage DNA. The cos site is cut during packaging of phage DNA 
in the lytic life cycle of the wt phage, revealing mature phage DNA molecules in 
units of one genome. In the phage resistant Abi mutant, the cos site is not cut20
resulting in non-mature phage DNA that can not be packed into the phage 
capsids. The figure thus shows that production of mature phage DNA is 
significantly decreased in the strains containing the AbiV mechanism.
Figure 4: DNA sequence of the 1.3 kb DNA fragment (bp 1021-2320 in GenBank 25
acc.nr AF324839) cloned in vector pJH2. This fragment comprises orf1 (bp 1276-
1878) encoding the φrm. Ribosome binding site is underlined in nucleotides 
matching the lactococcal consensus sequence (AGAAAGGAGGT). The translated 
amino acids are shown below the DNA sequence.
30
Figure 5: DNA sequence of the 499 bp DNA fragment from phage p2 containing 
orf26 and the upstream region towards orf27. Ribosome binding site is underlined 
in nucleotides matching the lactococcal consensus sequence (AGAAAGGAGGT). 
The translated amino acids are shown below the DNA sequence.
35
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Figure 6: Reverse transcriptase PCR carried out on isolated RNA. (A) Experiment 
done with reverse transcriptase enzyme. (B) Control without reverse 
transrciptase. Lanes 1-4 represents: JH-80 (spontaneous mutant), JH-20 (high 
expression of AbiV), JH-54 (wt), JH-32 (insertional mutant), respectively. L is 
Generuler ladder (Fermentas).The present invention will now be described in more 5
detail in the following.
Detailed description of the invention
Definitions 10
Prior to discussing the present invention in further details, the following terms and 
conventions will first be defined:
Phages: A bacteriophage (from 'bacteria' and Greek phagein, 'to eat') is any one 15
of a number of virus-like agents that infect bacteria. The term is commonly used 
in its shortened form, phage. Typically, bacteriophages consist of an outer protein
shell (called capsid or head) enclosing genetic material. The genetic material can 
be ssRNA, dsRNA, ssDNA, or dsDNA between 5 and 500 kilo base pairs long with 
either circular or linear arrangement. Bacteriophages are much smaller than the 20
bacteria they destroy - usually between 20 and 200 nm in size. Phages according 
to the present invention have the ability to infect bacteria of the genus 
Lactococcus.
Phage resistance mechanism: A functional phage resistance mechanism is herein 25
meant to be a mechanism that directly inhibits the phage lytic life cycle. However, 
phage resistance mechanisms as used herein furthermore denote mechanisms 
that works in synergy with a phage encoded product. As an example hereof, the 
present invention relates to use of SEQ ID NO 1 for conferring phage resistance to 
bacterial cells as well as the use of SEQ ID NO 1 in combination with SEQ ID NO 2 30
for obtaining an even more efficient phage resistance mechanism than was 
possible when only using SEQ ID NO 1. 
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Lactococcus: is a lactic acid bacterial genus of five major species formerly 
included as members of the genus Streptococcus Group N and related species. 
They are gram-positive bacteria, and they are typically spherical or ovoid, 0.5–1.2 
µm by 0.5–1.5 µm, and occur in pairs and short chains. They are non-spore
forming and are not motile. The type species for the genus is L. lactis which in 5
addition have two subspecies lactis and cremoris. Lactococcus is commonly used 
in the dairy industry in the manufacture of fermented dairy products. They can be 
used in single strain starter cultures, or in mixed strain cultures comprising other
strains of Lactococcus or lactic acid bacteria such as e.g. Leuconostoc, 
Lactobacillus and Streptococcus.10
A fragment: A fragment according to the present invention is herein defined as a 
fragment of a polypeptide being at least 100 amino acids, preferably at least 110, 
more preferably at least 120 amino acids. With regards to SEQ ID NO 1, the 
fragment is preferably at least 100 amino acids in length, more preferably at least 15
125 amino acids in length, more preferably at least 150 amino acids in length, 
more preferably at least 175 and most preferably at least 190 amino acids in
length.
Promoter: The term "promoter", "promoter region" or "promoter sequence" refer 20
generally to transcriptional regulatory regions of a gene, which may be found at 
the 5' or 3' side of the coding region, or within the coding region, or within 
introns. As used herein the term promoter shall include any portion of genomic 
DNA (including genomic DNA disclosed herein), which is capable of initiating 
expression of but not limited to operably linked nucleotide sequences at levels 25
detectable above background. In the context with the present invention a “strong 
promoter” shall be understood as a promoter which results in expression of a 
polypeptide according to the invention, wherein the level of expression is 
significantly higher compared to the endogenous homologous promoter in the 
Lactococcus genome. The level of expression can be detected and/or measured by 30
e.g. Northern blot, real-time PCR, reporter gene assays, etc.
Expression vector: A vector is a component or composition for facilitating cell 
transduction or transfection by a selected nucleic acid, or expression of the nucleic 
acid in the cell. Vectors include, e.g., plasmids, cosmids, viruses, BACs, PACs, P1, 35
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YACs, bacteria, poly-lysine, as well as linear nucleotide fragments etc. An 
"expression vector" is a nucleic acid construct or sequence, generated 
recombinantly or synthetically, with a series of specific nucleic acid elements that 
permit transcription of a particular nucleic acid sequence in a host cell. The 
expression vector can be part of a plasmid, virus, or nucleic acid fragment. The 5
expression vector typically includes a nucleic acid to be transcribed operably 
linked to a promoter. The nucleic acid to be transcribed is typically under the 
direction or control of the promoter. The expression vector may replicate 
autonomously in the host cell or may integrate into the host genome after the 
transfection or transduction and replicate as part of the genome. Finally “an 10
expression vector” encoding more than one polypeptide sequences according to 
the present invention comprises the situation wherein one expression vector 
comprises polynucleotide sequences encoding more than one polypeptide product 
as well as the situation wherein the polynucleotide sequences are cloned into two 
different expression vectors. 15
pGhost9::ISS1: The term “pGhost9::ISS1” covers a vector with an antibiotic 
resistance marker, a Lactococcus replicon, and preferably also an E. coli replicon. 
The replicon is thermosensitive allowing for selection for integration into the host 
chromosome. Also the vector contains an insertion sequence that enables random 20
integration of the vector into the host chromosome. It follows that vectors with 
similar functions may be used in connection with the present invention. 
Identity: The term ”identity” or “sequence identity” is a measure of the degree of 
identity between polynucleotide sequences on a nucleotide-by-nucleotide basis or 25
amino acid-by-amino acid basis, respectively over a window of comparison. 
Sequences according to the present invention have an identity of at least 70% to 
SEQ ID NO 1, or a fragment thereof. 
Food products: Food products according to the present invention include milk 30
based products that have been subject to fermentation processes. Examples 
thereof include: sour cream, crème fraîche, buttermilk, butter, cheese, cottage 
cheese, quark, cream cheese, fromage frais, yoghurt, etc. However, other types 
of food products may also be produced using fermentation or fermentative 
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microorgansims according to the present invention such as e.g fruit juices, 
fermented vegetables/fruits, processed meat products, etc.
It should be noted that embodiments and features described in the context of one 
of the aspects of the present invention also apply to the other aspects of the 5
invention.
In a first aspect the present invention thus relates to an isolated polynucleotide 
sequence that encodes a polypeptide with at least 70% identity, preferably at 
least 75% identity, more preferably at least 80% identity, more preferably at 10
least 85% identity, more preferably at least 70% identity, preferably at least 75% 
identity, more preferably at least 80% identity, more preferably at least 85% 
identity, more preferably at least 90% identity, and most preferably at least 95% 
identity with SEQ ID NO 1 (AbiV from Lactococcus lactis), or a fragment thereof, 
and wherein expression of said polynucleotide confers at least one phage 15
resistance mechanism to a Lactococcus bacterium. This polynucleotide sequence 
is found naturally in the Lactococcus bacterium, but it is normally not 
transcriptionally active. It has surprisingly been found that expression of this 
polypeptide confers a previously unknown phage resistance mechanism to the 
bacterium. 20
A second aspect of the present invention relates to an isolated polynucleotide 
derived from a Lactococcus lactis phage that encodes a polypeptide with at least 
70% identity, preferably at least 75% identity, more preferably at least 80% 
identity, more preferably at least 85% identity, more preferably at least 95% 25
identity, preferably at least 97% identity, and most preferably at least 99% 
identity with SEQ ID NO 2, or a fragment thereof and/or an isolated 
polynucleotide that encodes a polypeptide with at least 70% identity, preferably at 
least 75% identity, more preferably at least 80% identity, more preferably at 
least 85% identity, more preferably at least 95% identity, preferably at least 97% 30
identity, and most preferably at least 99% identity with SEQ ID NO 7. Optionally, 
the polynucleotide sequence may encode at least one of SEQ ID NO 1, SEQ ID NO 
2, and SEQ ID NO 7 or any variant thereof in the form of one or more 
polynucleotide sequences. 
35
150
42448PC01
10
SEQ ID NO 2 and SEQ ID NO 7 are phage proteins. The inventors have found out 
that these proteins most likely need to be mutated in order for the phage to 
escape the phage resistance mechanism conferred by expression of SEQ ID NO 1 
or variants thereof. Phage proteins according to the present invention therefore 
have at least 70% identity with SEQ ID NO 2 and/or SEQ ID NO 7 in order to 5
provide functional phage protein that may suppress the effects of emergence of 
mutated phage protein that could potentially suppress the effects of the translated 
SEQ ID NO 1 protein or variants thereof. In a preferred embodiment according to 
the present invention, polynucleotide sequences encoding both SEQ ID NO 1 or 
variants thereof as well as SEQ ID NO 2 and/or SEQ ID NO 7 or variants thereof, 10
are thus provided thus conferring highly efficient phage protection mechanisms to 
a host cell. It furthermore follows that the invention relates to expression vectors 
as well as Lactococcus bacteria and/or starter cultures comprising polynucleotide 
sequences encoding such polypeptide sequences.
15
In a third aspect, the present invention relates to an isolated polypeptide 
conferring at least one phage resistance mechanism to a Lactococcus bacterium, 
wherein said polypeptide is selected from one or more of the group consisting of: 
a polypeptide with at least 70% identity with SEQ ID NO 1, or a fragment thereof, 
a polypeptide with at least 70% identity with SEQ ID NO 2, or a fragment thereof, 20
and a polypeptide with at least 70% identity with SEQ ID NO 7, or a fragment 
thereof. 
A fourth aspect relates to the use of one or more polynucleotides according to the 
present invention and/or one or more polypeptides according to the present 25
invention for improving phage resistance in a Lactococcus bacterium.
A fifth aspect relates to a method for fermenting food product, said method 
comprising the step of adding one or more of the components according to the 
present invention. The invention furthermore relates to products that can be 30
obtained and/or are obtained using this method.
A sixth aspect relates to a method for obtaining phage resistant bacterial cells, 
said method comprising use of pGhost9::ISS1 (or similar systems) for random 
insertion into a bacterial cell and subsequently screening and selecting for phage 35
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resistant cells. The invention furthermore relates to cells that can be obtained 
and/or are obtained by such methods. In a preferred embodiment, the cell is a 
Lactocuccus bacterium wherein a polynucleotide encoding SEQ ID NO 1 (or a 
variant thereof) is transcriptionally active.
5
A final aspect relates to a Lactococcus bacterium that expresses at least one 
polypeptide selected from the group consisting of: a polypeptide with at least 70% 
identity with SEQ ID NO 1, or a fragment thereof, a polypeptide with at least 70% 
identity with SEQ ID NO 2, or a fragment thereof, and a polypeptide with at least 
70% identity with SEQ ID NO 7, or a fragment thereof. 10
All patent and non-patent references cited in the present application, are hereby 
incorporated by reference in their entirety.
The invention will now be described in further details in the following non-limiting 15
examples.
EXAMPLES
Example 120
Bacterial strains, plasmids, and media
Strains and plasmids used in this invention are listed in table 1. Escherichia coli
was grown at 37ºC in LB medium. Lactococcus lactis was grown in M17 with the 
supplement of 0.5% glucose (GM17). Lactococci were grown at 30ºC except 25
strains containing the thermo sensitive vector pGhost9::ISS1. These strains were 
grown at 28ºC for replication of the vector or 36ºC to avoid replication. When 
appropriate, antibiotics were added as follows: E. coli, 100 µg/ml of ampicillin, 10 
µg/ml of chloramphenicol, 150 µg/ml of erythromycin; for L. lactis, 5 µg/ml of 
chloramphenicol, 3 µg/ml of erythromycin.30
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Example 2
Bacteriophage propagation and assays.
Bacteriophages used in this invention are listed in table 1. Bacteriophages sk1 and 
jj50 were kindly provided by F.K.Vogensen (University of Copenhagen). Prior to 5
use all phages were purified two times by picking a single plaque with a sterile 
Pasteur pipette and plating it on a sensitive host. Propagation of phages to obtain 
high titer lysates was performed in two steps: 
In the first propagation a single plaque was transferred into a fresh ON culture of 10
a sensitive host inoculated (1%) in GM17 supplemented with 10 mM CaCl2 and 
incubated at 30ºC (or 36ºC in the case of pGhost9::ISS1 containing host strains) 
until lysis. The lysate was filtered through a 0.45 µm syringe filter. 
The second propagation was performed by inoculating an exponentially growing 15
host culture at OD600 = 0.2 with phages from the first propagation (10
4 pfu/ml) in 
GM17 + 10 mM CaCl2. 
The culture was then incubated with agitation (200rpm) until lysis at the same 
temperature as for the first propagation. The lysate was filtered (0.45 µm filter). 20
The titer of phage lysates was determined using conventional methods. 
Efficiency of plaquing (EOP) was calculated by dividing the titer on the tested 
strain with the titer on the sensitive wt strain. Adsorption assays were conducted 
as described by Sanders and Klaenhammer(17) except a 5 min incubation period 25
was used instead of 15 min. Cell survival was assayed by the method of Behnke 
and Malke (2) using a multiplicity of infection (MOI) of 5. One-step growth assay 
(and determination of burst size) and center of infection (COI) assay was 
performed as described previously (14) by using MOIs of 0.2 and 0.5, 
respectively. ECOI (efficiency of COI) was determined by dividing the number of 30
COI from the resistant strain by the number of COI from the sensitive strain. 
Replication of phage DNA was followed in a time course experiment using the 
method of Hill et al. (8). Visualization of phage DNA by labeling with the 
fluorescent dye SYBR-Gold was performed as described by Noble and Fuhrman 
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(15) with the following modifications: The original SYBR-Gold solution was diluted 
(×1000). Phage lysate to be stained was treated with 1 mg/ml DNAse and RNAse 
and incubated for 30 min at 37oC. The lysate was stained with the diluted SYBR-
Gold to give 2.5% final concentration (vol/vol) diluted SYBR-Gold and left ON at 4
ºC in the dark. One µl of the labeled phage stock was mixed with 1 µl 5
exponentially growing cell culture and visualized under a Zeiss axioplan 
epifluorescence microscope.
Example 3
Mutagenesis with pGhost9::ISS110
Random integration of the vector pGhost9::ISS1 into the chromosome of MB112 
and subsequent cloning of flanking chromosomal DNA was performed essentially 
using the method of Maguin et al. (10). The method of Maguin, however, is 
normally used to identify inactivation of genes by randomly inserting the construct 15
in chromosomal genes, thereby inactivating them. Subsequent selection for a 
desired phenotype enables screening for strains containing a loss of function 
mutation. The fact that all inspected mutants in the present invention had 
insertions in non coding regions or genes upstream of orf1 together with the 
observation that presence of the complete vector pGhost9::ISS1 was needed for 20
the Abi+ phenotype led to the hypothesis that the abiV gene (orf1) was 
transcribed from the promoter encoding the erythromycin resistance gene in
pGhost9::ISS1 (fig 2). Previous studies have reported promoter activity in the 
ISS1 sequence (5). No effect on phage resistance phenotype of such promoter 
activity was observed in the present invention. It has not previously been shown 25
that random insertion of the vector and subsequent transcription from the 
promoter of the erythromycin resistance gene can be used to activate existing 
biological mechanisms, such as e.g. Abi-mechanisms. 
To ensure that the mutations in the isolated strains had arisen from independent 30
events, the integration step (growth at 37ºC) was performed on 12 separate 
cultures. After the integration step, the cultures were diluted ×10.000 in GM17 + 
3 µg/ml Erythromycin and left for phenotypic expression ON at 37ºC. These 
cultures were inoculated (1%) and when growing exponentially aliquots were 
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removed. 10 mM CaCl2 (final concentration) was added to these aliquots before 
inoculating with phage sk1 (MOI > 1). After 10 min incubation at 37ºC the 
cultures were spread on selective GM17+Erm plates. A number of phage resistant 
colonies were isolated and purified from each of the 12 independent cultures. Four 
strains were chosen from independent cultures to identify the location of the 5
inserted pGhost9::ISS1. This was performed by rescuing of the inserted vector 
and cloning of flanking chromosomal DNA. The cloned chromosomal DNA 
fragments were subsequently sequenced
Example 410
DNA isolation and manipulation
Plasmid DNA was isolated from E. coli and L. lactis using the QIAprep Spin 
Miniprep Kit (Qiagen); for L. lactis however, lysozyme (15 mg/ml) was added to 
buffer p1 and the solution with the resuspended cells was incubated at 37ºC for 15
30 min before proceeding with the manufacturers protocol. Phage DNA was 
prepared using the Qiagen Lambda Maxi Kit (Qiagen) with the addition of 
proteinase K (20mg/ml) to buffer L3 and subsequent incubation at 65ºC for 30 
min before adding buffer L4. Total intracellular DNA was isolated using the 
method of Hill et al. (8). Restriction enzymes, T4 DNA ligase and Klenow fragment 20
(Fermentas) were used according to the manufacturer’s instructions. 
Electroporation of E. coli and L. lactis was performed as described previously (13). 
The DNA fragment corresponding to bp 1021 to 2320 (fig. 4) in the GenBank 
sequence AF324839 was subcloned in the TOPO TA cloning kit prior to cloning in 
pCI372 and pLC5. 25
Example 5
DNA sequencing and sequence analysis of DNA and protein
Oligonucleotide sequences used for plasmid constructions and sequencing: 30
For sequencing the flanking chromosomal DNA of the rescued pGhost9::ISS1
inserts a primer located in the ISS1 was used (5’-GAAGAAATGGAACGCTC-3’). 
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Phage genome sequencing was performed with an ABI prism 3700 apparatus from 
the genomic platform at the research center of the Centre Hospitalier de
l’Université Laval using a set of oligonucleotides previously used for sequencing of 
936 phage genomes (11). 
5
Sequence data was assembled using the Staden Pregap4 version 1.5. Sequence 
homology searches in databases were done using BLAST (1). Molecular weight 
and pI of the investigated proteins were estimated using the Protein Calculator at 
the website: http://www.scripps.edu/~cdputnam/protcalc.html
10
Example 6
A phage resistance mechanism (φrm) is found on the chromosome of Lactococcus 
lactis subsp.cremoris MG1363
L. lactis subsp. cremoris MG1363 is sensitive to infection of phages from the 936 15
and c2 species. In this invention a transposon mutagenesis system (described in 
details in (10)) was used to identify a novel φrm on the chromosome of MG1363.
The system (pGhost::ISS1) comprises the vector pGhost9 containing an 
erythromycin resistance gene (Emr) and the ISS1 insertion sequence which allows 
for random integration of the construct into the host chromosome. Due to a20
thermosensitive origin of replication (plasmid is not replicating at 37ºC) it is 
possible to select for mutants with the construct inserted in the chromosome by 
growing at 37ºC in the presence of erythromycin, allowing for phenotypic 
expression by growing at selective conditions ON. 
25
This selection was done for a number of independently grown cultures resulting in 
isolation of independent integration events. These cultures were screened for 
resistance to phage sk1 by selecting colonies growing on erythromycin plates in 
the presence of phages (MOI>1). The frequency of mutations conferring phage 
resistance was 100 times higher in cultures with mutants containing the 30
pGhost::ISS1 inserts compared to the control cultures in which the phage 
resistance was caused by spontaneous mutations. This clearly indicates that the 
mutations in the phage resistant mutants containing pGhost9::ISS1 in most cases 
were caused by the insertion of this construct. 
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A number of Emr/ φrm+ colonies were isolated. From four of these independently 
mutagenized cultures, the inserted construct was obtained along with a piece of 
flanking chromosomal DNA. Sequence analysis revealed insertions on the 
chromosome corresponding to bp 1962 (strains JH-32 and JH-46), bp 2240 (JH-
48) and bp 2296 (JH-47) on the sequence available in GenBank under the 5
accession number AF324839 (hereafter designated Lin). Bp 1021 to bp2320 
therein corresponds to SEQ ID NO 6. All strains had insertions in the intergenic 
region between two genes (designated orf1 and trans) or in the 3’ end of the 
trans gene (fig 2A). There are no genes in the same orientation immediately 
downstream of orf1 and since the mutagenizing constructs were all inserted in the 10
same orientation pointing towards orf1 it was hypothesized that orf1 is encoding a 
φrm which is transcribed from the Emr gene promoter when pGhost::ISS1 is 
inserted upstream of orf1. Curing the strains for the vector (leaving a single copy 
of ISS1 at the insertion site) resulted in φrm- phenotype supporting the 
hypothesis that a promoter in pGhost::ISS1 is needed for transcription of orf1 and 15
the resulting φrm+ phenotype. This implies that orf1 is silent in wt MG1363 which 
is supported by the phage sensitive phenotype of this strain.
Example 7
Identification of orf1 as a φrm20
To test if orf1 is a φrm, a fragment corresponding to bp 1021 to 2320 on the Lin 
sequence was cloned in the shuttle vector pCI372 (pJH6) and in the expression 
vector pLC5 (pJH2). These constructs were transformed in MB112 and the 
resulting strains (JH-53 and JH-20, respectively) were tested by cross streaking 25
assay for resistance to phage p2. JH-53 containing pJH6 with no promoter 
upstream of orf1 showed no phage resistance phenotype. In comparison, JH-20 
containing pJH2 with orf1 cloned downstream of a strong promoter revealed 
phage resistance phenotype. 
30
To verify orf1 as being the φrm, a frameshift mutation was introduced in orf1 by 
filling a unique ClaI site with Klenow fragment followed by ligation and 
transformation of this vector (pJH3) in wt MB112. The mutated orf1 was 
sequenced verifying the frameshift mutation. The resulting strain JH-24 had a 
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phage sensitive phenotype and it was therefore concluded that orf1 is encoding a 
φrm.
Example 8
The isolated φrm is effective against phages of the 936 and c2 species5
The three phage species 936, c2 and P335, known to be responsible for the 
majority of phage caused fermentation failures were tested for their sensitivity to 
the φrm. Four strains of the 936 species were tested against JH-20. Efficiency of 
plaquing (EOP) values around 10-4 were obtained for phages p2, sk1 and jj50 10
while phage 712 was insensitive to the φrm (Table 2). pJH2 was inserted into the 
host JH-22 (L. lactis subsp. lactis IL1403) which is sensitive to the 936 phages 
P008 and bIL170. When tested against these phages the φrm revealed EOP values 
around 10-4. Similar values were obtained when testing JH-20 against four phages 
of the c2 species (Table 2). Similar EOP values were obtained for MB112 and JH-15
54 when tested against the 936 and c2 phage species (data not shown), thus 
ruling out the possibility for the vector pLC5 being responsible for the φrm+
phenotype. 
Table 220
Phage Host strain EOP
936 speciesa sk1 JH-20 2.7 ± 1.4 × 10-4
p2 JH-20 4.8 ± 1.8 × 10-4
jj50 JH-20 8.3 ± 0.5 × 10-5
712 JH-20 1.1 ± 0.2
P008 JH-22 3.8 ± 1.5 × 10-4
bIL170 JH-22 3.1 ± 1.2 × 10-4
c2 speciesa c2 JH-20 5.2 ± 0.4 × 10-5
bIL67 JH-20 2.0 ± 1.2 × 10-4
ml3 JH-20 3.4 ± 0.3 × 10-4
eb1 JH-20 2.2 ± 0.7 × 10-4
P335 speciesb ul36 JH-23 1.0
KITI JH-23 1.6
Ø31 JH-23 1.0
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Ø50 JH-23 1.0
Q33 JH-23 0.7
Q30 JH-23 0.8
P335 JH-23 0.4
aEOP of 936 and c2 species is 1.0 on both L. lactis subsp. cremoris MG1363 
(MB112) and MB112 + pLC5 (JH-54). EOP of phages P008 and bIL170 is 1.0 on L. 
lactis subsp. lactis IL1403
bEOP of P335 species is 1.0 on L. lactis subsp. cremoris (SMQ-86).5
To test the φrm for efficiency against P335 phages, the φrm was inserted in a 
suitable host (SMQ-86) resulting in the strain JH-23. When tested against seven 
species of P335 phages EOP values around 1 were obtained. To rule out the 
possibility that modifications had taken place rendering the φrm inefficient, pJH2 10
was prepared from JH-23 and re-inserted into MB112 to give strain JH-26. Tests 
against phage p2 showed an intact φrm phenotype.
Those results showed that the φrm found on the chromosome of L. lactis subsp. 
cremoris MG1363 and expressed from pJH2 is effective against phages from most 15
of the tested 936 species and all tested c2 species while no effect was seen on 
P335 species. 
The results also showed that the φrm encoded by orf1 is efficient in both the 
subspecies (cremoris and lactis) of L. lactis.20
Furthermore the results showed that EOP values did not vary whether the φrm
was expressed from a promoter located in single copy on the chromosome of the 
host or from a strong promoter on the vector pJH2. This indicates that the 
efficiency of the system is not dependent on the copy number of the gene.25
Example 9
Temperature sensitivity
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The efficiency of the φrm was tested against phage sk1 at 30ºC and 37ºC. EOP 
values were in both cases around 10-4 (data not shown) indicating that the φrm is 
stable within this temperature range.
Example 105
Type of phage resistance mechanism
A series of microbiological experiments were conducted to determine the type of 
φrm encoded by orf1. 
10
An adsorption assay showed that the level of adsorption of phage p2 to cells with 
the expressed φrm was 95.9 ± 10.6 % compared to wt MG1363 (data not 
shown). 
An assay was conducted where the φrm+ strains JH-32, JH-46, JH-47, JH-48 and 15
control MB112 was infected with sk1 that had been fluorescently labeled with the 
DNA binding dye SYBR-Gold. Following infection the fluorescently labeled phage 
DNA could be visualized under an epifluorescence microscope. Immediately 
following phage infection (MOI = 10) of wt strain MB112 a fluorescent halo of 
adsorbed phages was seen surrounding the host cells. Less than 10 min after 20
infection the fluorescent signal on the cell surface was decayed and instead a very 
bright fluorescent signal was observed in the center of the cell, thus indicating 
that the phage DNA had been injected into the host cell (data not shown). 
The same result was obtained with the strains having the φrm+ phenotype. This 25
supports the data from the adsorption assay and also shows that the phage DNA 
is being injected in the φrm containing cells. These results indicate that the φrm 
is not an adsorption or injection blocking mechanism.
A cell survival assay showed no increased survival on cells harboring the φrm 30
(Table 3) indicating that the host dies upon infection. The plaque size of phage p2 
was smaller when assayed on φrm+ cells compared to φrm- cells (Table 3). 
Finally, total DNA extraction from φrm+ cells during a time course experiment of 
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infection with phage p2 showed phage DNA replication which persisted in the cell 
throughout the experiment (Fig. 3).
Table 3
5
10
an=3
bMOI = 0.5, n=315
cMOI = 0.2, n=3
dMOI = 5, n=3
eMOI = 2, n=1
All the above results confirm that the mechanism is a φrm that functions as an 20
abortive infection mechanism. This was named AbiV.
Example 11
Sequence analysis of the 1.3 kb DNA fragment containing the φrm
25
The DNA fragment cloned in pJH2 was sequenced (SEQ ID NO 3 and 5). The 
fragment consists of 1300 nucleotides. Nucleotides 1 to 1300 correspond to 
nucleotides 1021 to 2320 in the Lin sequence (GenBank acc.nr: AF324839). One 
significant open reading frame (orf) was found  encoding the polypeptide 
sequence shown in SEQ ID NO 1. This gene encoding the φrm was named abiV30
(SEQ ID NO 3) and the translated protein was named AbiV (SEQ ID NO 1). The 
G+C content of the gene was found to be 31.7%. This value is typical for abi 
mechanisms which are known to have lower G+C contents compared to the 
normal 37% in L. lactis. Searches for promoter sequences upstream of abiV (bp 1 
Assay MB112 (wt) JH-20 (abiV)
EOPa 1.0 4.8 ± 1.8 × 10-4
ECOI (%)b 1.0 0.5 ± 0.2
Burst size (pfu/cell)c 38.8 ± 5.7 11.1 ± 5.2
fraction surviving cellsd 6.1 ± 1.3 × 10-5 3.1 ± 0.3 × 10-6
phage DNA replicatione + + (concatemeric)
plaque size (mm) 1.5 - 1.7 pinpoint - 0.7
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to 430) were performed but no suitable promoter could be found in this region. 
This corresponds well with the hypothesis of the φrm being silent in the wt strain 
MB112. The translation start codon was preceded (8 bp upstream) by a ribosome 
binding site (5’-TGAACGGAGAG-3’, underlined sequence matches consensus 
sequence). 5
Example 12
Analysis of the AbiV protein encoded by abiV in pJH2
Since the abiV gene is the only orf in the cloned sequence of pJH2 and a frame 10
shift mutation in this orf causes the phage sensitive phenotype, it is concluded 
that the protein encoded by this gene is responsible for the φrm+ phenotype. AbiV 
consists of 201 amino acids and has a molecular weight of 22692 Da. The pI was 
estimated to be 5.37.
15
The protein does not contain any putative transmembrane or signalpeptide motifs 
and it is therefore likely that the protein is cytosolic. Homology searches in 
databases did not reveal any homology (at amino acid or nucleotide level) to 
other lactococcal proteins or any proteins with known function. Likewise, no 
conserved domains were found in the protein.20
The deduced function of AbiV is therefore new and the φrm is a novel abi 
mechanism.
Example 1325
Effect of AbiV on phage life cycle
The effects of the AbiV system was tested on the phage p2 life cycle using the 
phage sensitive strain MB112 and the corresponding AbiV containing strain JH-20. 
The following results are summarized in table 3.30
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The propagation of p2 on JH-20 was inhibited as seen by the EOP of ca 10-4 and 
the plaque size was reduced from about 1.5 mm to <1 mm. Very few of the 
infected cells harboring the φrm survived infection.
The ECOI on JH-20 was 0.5 ± 0.2 % indicating that only 5 out of 1000 infected 5
cells managed to release at least one viable phage. In these successful infections 
the burst size was reduced by 72 % (from 38.8 ± 5.7 in MB112 to 11.1 ± 5.2 in 
JH-20).
The combined negative effects of AbiV on cell survival, ECOI and burst size were 10
the cause of the reduced plaque size and EOP of p2 on JH-20.
The replication of phage DNA was followed in a 2h phage infection experiment of 
p2 on phage resistant JH-20 and phage sensitive MB112 (Fig. 3). Phage DNA was 
visualized by digesting the total DNA prepared from an infected cell culture with 15
EcoRV and comparing the resulting fragments run on an agarose gel with the 
EcoRV restriction map of phage p2. 
Ten minutes after infection replication of phage DNA was observed in both strains. 
In MB112 the concentration of phage DNA decreases around 40 min after infection 20
coinciding with lysis of the sensitive host culture. On the contrary, in JH-20 the 
phage DNA persists throughout the experiment which was terminated after 2h. 
Inspecting the EcoRV digested phage DNA fragments, two bands of 1.3 and 4 kb 
respectively and a 5.3 kb fragment are seen in the phage sensitive culture. The 
5.3 kb fragment is spanning the cos site on the phage DNA which is the site where 25
the replicated phage DNA is cut into identical units of complete phage genomes 
before packaging of the DNA into the capsids. Therefore the 1.3 and 4 kb 
fragments represent DNA that has been cut at the cos site. The presence of both 
non-resolved and resolved DNA in the phage sensitive strain is due to the 
continuous DNA replication throughout the phage life cycle and the simultaneous 30
packaging of already resolved DNA into the phage capsids. In JH-20 (AbiV+) only 
the 5.3 kb fragment is observed which indicates that the phage DNA is not cut at 
the cos site in this strain.  
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The above results show that AbiV works after phage DNA replication and is thus 
categorized as a late abi mechanism. The presence of concatemeric DNA 
fragments (cos site not cut) further suggests that the φrm might work at a late 
stage for example during packaging of phage DNA into the capsids. 
5
Example 14
Phage genes involved in sensitivity to AbiV
A number of phage mutants capable of overcoming AbiV were isolated. On JH-20 
AbiV-insensitive mutants of p2, sk1, jj50 and c2 were isolated and named p2.1, 10
sk1.1, jj50.1 and c2.1, respectively. On JH-22, mutants of P008 and bIL170 were 
isolated and named P008.1 and bIL170.1, respectively. 
The full genome of mutant p2.1 was sequenced revealing only mutations in the 
region around the early gene orf26 (SEQ ID NO 4). SEQ ID NO 4 encodes a 15
polypeptide sequence denoted SEQ ID NO 2. The following polynucleotide 
mutations were found in phage p2.1 that escaped the AbiV-mechanism: 
· Two point mutations in orf26 leading to amino acid changes. 
· One point mutation in the intergenic region between orf26 and the 
upstream gene orf2720
· A 55 bp deletion including the startcodon and 6 downstream base pairs of 
orf26. 
The homologues of p2 orf26 in the other phage mutants were sequenced. 
Nonsense mutations were observed in: orf26 (sk1.1), orf25 (jj50.1), orf3325
(P008.1), e24 (bIL170.1) and a point mutation leading to an amino acid change 
(T to P) was seen in e11 (c2.1). 
These data show that AbiV-resistant phage mutants apparently fail to produce 
functional protein encoded by an early gene homologous to phage p2 orf26. In at 30
least one phage mutant (p2.1), orf26 is the only gene which is mutated. Finally, 
phage 712 (936 species) is the only phage among the tested phages from the 936 
and c2 species that does not contain an orf26 homologue. Among the wt phages 
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of the 936 and c2 species, this phage is also the only one which is not sensitive to 
AbiV.
Based on the above results, it is concluded that a functional copy of phage p2 
orf26 (and homologues in other phage species) is mandatory for successful φrm+5
phenotype of AbiV. The gene is named sav (sensitivity to abiV) and the translated 
putative protein was named Sav. It is thus possible to strengthen the AbiV-
mechanism by supplying the AbiV host cell with a polynucleotide sequence 
encoding wt Sav. 
10
A nucleotide blastn analysis orf phage p2 orf26 revealed a high degree of 
sequence homology to other lactococcal phage genes: jj50 orf25 (99.7%), sk1 
orf26 (99.0%), P008 orf33 (91.4%), bIL170 e24 (90.6%). Furthermore the 
translated p2 orf26 showed a more distant relationship (29%) with phage c2 gene 
e11. Despite the low degree of homology the e11 gene of phage c2 is involved in 15
sensitivity to AbiV since a mutation in this gene helps the phage c2.1 escape AbiV. 
Therefore, sequences of either phage 936-like orf26 homologues (SEQ ID NO 2) 
or c2-like e11 homologues (SEQ ID NO 7; DNA sequence: SEQ ID NO 8, derived 
from accession number NC001706 disclosing the complete genome of Lactococcus 
lactis phage c2), or variants or fragments thereof are a part of the present 20
invention. 
Example 15
Analysis of the phage p2 gene orf26 (sav) and the putative protein (Sav) encoded 
by this gene25
The DNA fragment containing phage p2 gene orf26 and the upstream intergenic 
region to orf27 was sequenced on both strands. The sequenced fragment contains 
499 nucleotides (SEQ ID NO 5). The sav gene consists of 384 bp (SEQ ID NO 4). 
Upstream of sav in a suitable (8 bp) distance is found a RBS sequence 30
(GGATTGGGGGT, underlined sequence matches consensus sequence). No 
promoter sequence is found in the region between orf27 and sav. This 
corresponds well with the genetic structure of this region in p2 and in the closely 
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related phage sk1. In both phages orf26 is the last gene in a putative operon 
consisting of orf30 to orf26 where the promoter is upstream of orf30 (4). 
The sav gene is located at the end of the early transcribed region of phage p2.
The putative protein Sav (SEQ ID NO 2) encoded by the gene sav consists of 128 5
amino acids. It has a theoretical molecular weight of 15.3 kDa and an estimated 
pI of 4.62. Homology searches revealed homology to a number of putative 
proteins in related phages of the 936 and c2 species. However, no homology was 
found to proteins with known function. Nor was found any conserved domains in 
the protein. The protein is thus new and it has not previously been associated with 10
sensitivity to phage resistance mechanisms. SEQ ID NO 7 is present in the
database under accession number NC001706 and it has not previously been 
associated with sensitivity to phage resistance mechanisms. 
The interaction of Sav with AbiV is not known but the insensitivity to AbiV of 15
phages with a deleted sav gene clearly indicates that sav is involved in sensitivity 
of the phage to the φrm.
Co-expression of abiV and sav in host cells will most likely enhance the efficiency 
of AbiV since the escaping mutant phages will have to mutate in other genes than 20
sav. Co-expression might also broaden the range of phages against which AbiV is 
effective. These are so far only hypotheses but they are in the process of being 
tested experimentally.
Since sav has not previously been associated with any φrm, the AbiV φrm in the 25
present invention is a new abi mechanism interacting in a so far unknown way 
with the sensitive phage. AbiV is therefore likely to be an efficient φrm capable of 
supplementing already isolated and used phage resistance mechanisms thus 
improving the field of phage resistance mechanisms.
30
The discovery of a phage gene involved in sensitivity to the Abi-resistance 
mechanism may be used for obtaining a phage resistance mechanism that is more 
efficient than use of the AbiV-mechanism alone. It is thus likely that the use of the 
wild type orf26-sequence encoding the polypeptide according to SEQ ID NO 2 
and/or SEQ ID NO 7 will fully or partly prevent that the phage can escape the Abi-35
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mechanism according to the present invention by supplying AbiV-sensitive protein 
(SaV) together with AbiV-protein. 
The present invention thus relates to the use of polynucleotide sequences 
encoding both SEQ ID NO 1 and SEQ ID NO 2 and/or SEQ ID NO 7 (or a variant 5
thereof) within a Lactococcus cell in order to exploit the synergy that exists in this 
combination. Compared to other known Abi-systems, the combination of SEQ ID 
NO 1 and SEQ ID NO 2 and/or SEQ ID NO 7 (or a variant thereof) in the same cell 
provides for a phage resistance mechanism that is extraordinarily efficient in 
preventing phage infections and thus preventing the emergence of AbiV-resistant 10
phages. 
Example 16
Use of bacteria according to the invention
15
The φrm according to the present invention can be used in connection with dairy 
starter cultures in existing dairy production plants to produce any fermented dairy 
food product. 
Example 17 20
Construction of expression vector pLC5
The pGKV259 vector (18) was used as the starting molecule from which pLC5 was 
derived. pGKV259 was digested with PstI (located downstream from the P59 
promoter) followed by gel purification. Two complementary oligonucleotides (5’-25
TGGATCCAAAGGAGGTCCTGCA-3’ and 5’- GGACCTCCTTTGGATCCATGCA-3’) were 
annealed together using standard procedures (16) to create a double stranded 
linker with PstI-compatible sticky ends. This linker also contained a unique BamHI 
site and a ribosome binding site (RBS: 5’-AGGAGG-3’). The linker was inserted 
into the PstI site of pGKV259 and the ligation mixture was transformed into E. coli 30
MC1061. Transformants were selected on LB plates containing 20µg/ml 
chloramphenicol.  Positive clones with the linker inserted in the right direction 
were identified by colony PCR. Correct clones were later confirmed by sequencing. 
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Upon introduction of the linker into pGKV259, the PstI site on the 5’-side of the 
linker was disrupted whereas the one on the 3’-side was conserved. Thus, a 
unique PstI site was created 8-bp downstream from the RBS. Cloning of an insert 
harboring its own ATG start codon into the PstI site of pLC5 enables efficient 
transcription from the P59 promoter, and translation from the introduced RBS. For 5
this invention, however, the native RBS of AbiV and not the RBS in the vector was 
used for translation of the protein.
Example 18
10
RNA isolation, purification and RT-PCR analysis of transcription
Overnight cultures were diluted 100-fold and grown to OD600 = 0.5 at 37ºC. 
Aliquots (2 ml) were harvested by quick centrifugation (20,000 g, 30 sec) and the 
pellet was resuspended in a solution of 0.5 M sucrose with 60 mg/ml lysozyme. 15
Following incubation (37ºC, 15 min), the cells were pelleted and resuspended in 1 
ml TRIzol Reagent (Invitrogen). Total RNA was isolated according to the 
manufacturer’s instructions. Prior to reverse transcription (RT)-PCR, the RNA 
samples were treated with the DNase based TURBO DNA-free kit (Applied 
Biosystems).20
RT-PCR was carried out using the RevertAid First Strand cDNA Synthesis kit 
(Fermentas) as recommended by the manufacturer. As a control, the RT-PCR 
procedure was carried out without reverse transcriptase to ensure that the RNA 
samples were free of contaminating DNA. 25
Example 19
Mutants of L. lactis subsp. cremoris MB112 spontaneously expressing AbiV30
Cultures of L. lactis MB112 in exponential growth were mixed with the lytic phage 
sk1 (MOI > 1) in presence of 10 mM CaCl2 and incubated 10 min at room 
temperature before plating and incubation at 36 ºC overnight. Spontaneous 
mutants were observed with a frequency of ca. 10-8. Forty single colonies were 35
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purified and cross-streaked against phages sk1, p2, 712 and p2.1. A bacterial 
mutant expressing AbiV is expected to be resistant to sk1 and p2 but sensitive to 
712 and p2.1 (Table 1 and Table 2). Possible candidates were tested with EOP for 
resistance to phages p2, 712, p2.1. One mutant (JH-80) revealed the expected 
pattern of a mutant expressing AbiV with EOP values of 2×10-5, 0.75 and 0.8, 5
respectively. 
This mutant was investigated for transcription of the abiV gene using reverse 
transcriptase PCR (RT-PCR) (Fig 6), as described in example 18.
10
These results demonstrate that it is possible to obtain mutants of L. lactis strains 
carrying abiV on the chromosome which spontaneously express AbiV. This 
experiment demonstrates that it is possible to obtain phage resistant bacteria 
expressing AbiV without using genetic modification. This is particular interesting
for the dairy industry that prefers to avoid the use of genetically modified 15
organisms (GMO).
Example 20
Conjugal transfer of abiV20
In order to improve the non-GMO alternative of the φrm invention a conjugation 
experiment was conducted in which the φrm was transferred from the 
chromosome of JH-32 (donor) to MG1614 (recipient) (Table 4). Briefly, donor and 
recipient were recovered from plates and mixed at high cell densities (OD600 = 25
40). After 2 min incubation the cell mixture was plated on non-selective plates 
and incubated overnight in anaerobic conditions. The cells were then recovered 
from the plates and plated with selection for donor (erythromycin resistance), 
recipient (rifampicin resistance) and transconjugants (erythromycin and rifampicin 
resistance), respectively. 30
Since the erythromycin resistance gene is inserted just upstream of abiV in JH-32 
the erythromycin resistance phenotype was used to select for transfer of this gene 
to MG1614 hoping that abiV would be transferred along with it. Rifampicin 
resistance was used to select for MG1614. 35
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A number of transconjugant candidates were isolated and purified. The additional 
phenotypes (resistance to phage, streptomycin and fluorouracil) were used to test 
the isolated candidates for verification of the phage+erythromycin resistance from 
JH-32 to MG1614. In JH-81 the expected pattern was observed (Table 4). An EOP 5
value of 10-4 which is similar to other EOP values obtained with AbiV (Table 2) 
makes it plausible that abiV was transferred and expressed in MG1614.
This experiment demonstrated that it is possible to transfer AbiV by conjugation 
from one bacterium to another. Conjugation is not considered as genetic 10
modification and the method is thus suitable for the industry for transferring AbiV 
between bacterial strains in a non-GMO manner.
Table 4
15
Phenotype of donor (D), recipient (R) and transconjugant (T). Selection for 
transconjugants was done using erythromycin and rifampicin.
Resistance Phage Erythromycin Rifampicin Streptomycin Fluorouracil
JH-32 (D) yes yes no no yes
MG1614 (R) no no yes yes no
JH-81 (T) yes yes yes yes no
20
174
42448EP01
34
References in Table 1 
1. Bolotin, A., P. Wincker, S. Mauger, O. Jaillon, K. Malarme, J. Weissenbach, S. 
D. Ehrlich, and A. Sorokin. 2001. The complete genome sequence of the 
lactic acid bacterium Lactococcus lactis ssp lactis IL1403. Genome Research 5
11:731-753.
2. Emond, E., B. J. Holler, I. Boucher, P. A. Vandenbergh, E. R. Vedamuthu, J. 
K. Kondo, and S. Moineau. 1997. Phenotypic and genetic characterization of 
the bacteriophage abortive infection mechanism AbiK from Lactococcus 
lactis. Appl. Environ. Microbiol. 63:1274-1283.10
3. Hayes, F., C. Daly, and G. F. Fitzgerald. 1990. Identification of the Minimal 
Replicon of Lactococcus lactis subsp. lactis UC317 Plasmid pCI305. Appl. 
Environ. Microbiol. 56:202-209.
4. Leenhouts, K., G. Buist, A. Bolhuis, B. A. ten, J. Kiel, I. Mierau, M. 
Dabrowska, G. Venema, and J. Kok. 1996. A general system for generating 15
unlabelled gene replacements in bacterial chromosomes. Mol. Gen. Genet. 
253:217-224.
5. Gasson, M. J. 1983. Plasmid complements of Streptococcus lactis NCDO 712 
and other lactic streptococci after protoplast-induced curing. J. Bacteriol. 
154:1-9.20
6. Maguin, E., H. Prevost, S. D. Ehrlich, and A. Gruss. 1996. Efficient insertional 
mutagenesis in lactococci and other gram-positive bacteria. J. Bacteriol. 
178:931-935.
7. Martinussen, J. and K. Hammer. 1994. Cloning and characterization of upp, a 
gene encoding uracil phosphoribosyltransferase from Lactococcus lactis. J. 25
Bacteriol. 176:6457-6463.
175
42448EP01
35
Reference list
1. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, 
and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Res. 25:3389-3402.
2. Behnke, D. and H. Malke. 1978. Bacteriophage interference in Streptococcus 5
pyogenes. I. Characterization of prophage--host systems interfering with the 
virulent phage A25. Virology 85:118-128.
3. Bolotin, A., P. Wincker, S. Mauger, O. Jaillon, K. Malarme, J. Weissenbach, S. 
D. Ehrlich, and A. Sorokin. 2001. The complete genome sequence of the 
lactic acid bacterium Lactococcus lactis ssp lactis IL1403. Genome Research 10
11:731-753.
4. Chandry, P. S., B. E. Davidson, and A. J. Hillier. 1994. Temporal transcription 
map of the Lactococcus lactis bacteriophage sk1. Microbiology 140 ( Pt 
9):2251-2261.
5. Dupont, K., T. Janzen, F. K. Vogensen, J. Josephsen, and B. Stuer-Lauridsen. 15
2004. Identification of Lactococcus lactis genes required for bacteriophage 
adsorption. Appl. Environ. Microbiol. 70:5825-5832.
6. Emond, E., B. J. Holler, I. Boucher, P. A. Vandenbergh, E. R. Vedamuthu, J. 
K. Kondo, and S. Moineau. 1997. Phenotypic and genetic characterization of 
the bacteriophage abortive infection mechanism AbiK from Lactococcus 20
lactis. Appl. Environ. Microbiol. 63:1274-1283.
7. Hayes, F., C. Daly, and G. F. Fitzgerald. 1990. Identification of the Minimal 
Replicon of Lactococcus lactis subsp. lactis UC317 Plasmid pCI305. Appl. 
Environ. Microbiol. 56:202-209.
8. Hill, C., I. J. Massey, and T. R. Klaenhammer. 1991. Rapid Method To 25
Characterize Lactococcal Bacteriophage Genomes. Appl. Environ. Microbiol. 
57:283-288.
176
42448EP01
36
9. Leenhouts, K., G. Buist, A. Bolhuis, B. A. ten, J. Kiel, I. Mierau, M. 
Dabrowska, G. Venema, and J. Kok. 1996. A general system for generating 
unlabelled gene replacements in bacterial chromosomes. Mol. Gen. Genet. 
253:217-224.
10. Maguin, E., H. Prevost, S. D. Ehrlich, and A. Gruss. 1996. Efficient insertional 5
mutagenesis in lactococci and other gram-positive bacteria. J. Bacteriol. 
178:931-935.
11. Mahony, J., H. Deveau, G. S. Mc, M. Ventura, C. Canchaya, S. Moineau, G. F. 
Fitzgerald, and S. D. van. 2006. Sequence and comparative genomic analysis 
of lactococcal bacteriophages jj50, 712 and P008: evolutionary insights into 10
the 936 phage species. FEMS Microbiol. Lett. 261:253-261.
12. Martinussen, J. and K. Hammer. 1994. Cloning and characterization of upp, a 
gene encoding uracil phosphoribosyltransferase from Lactococcus lactis. J. 
Bacteriol. 176:6457-6463.
13. Moineau, S., S. Pandian, and T. Klaenhammer. 1994. Evolution of a lytic 15
bacteriophage via DNA acquisition from the Lactococcus lactis chromosome. 
Applied and Environmental Microbiology 60:1832-1841.
14. Moineau, S., E. Durmaz, S. Pandian, and T. R. Klaenhammer. 1993. 
Differentiation of Two Abortive Mechanisms by Using Monoclonal Antibodies 
Directed toward Lactococcal Bacteriophage Capsid Proteins. Appl. Environ. 20
Microbiol. 59:208-212.
15. Noble, R. T. and J. A. Fuhrman. 2000. Rapid virus production and removal as 
measured with fluorescently labeled viruses as tracers. Appl. Environ. 
Microbiol. 66:3790-3797.
16. Sambrook, J. and D. W. Russell. 2001. Molecular cloning, a laboratory 25
manual. Cold Spring Habour Laboratory Press, Cold Spring Habour, N.Y.
17. Sanders, M. E. and T. R. Klaenhammer. 1980. Restriction and Modification in 
Group N Streptococci: Effect of Heat on Development of Modified Lytic 
Bacteriophage. Appl. Environ. Microbiol. 40:500-506.
177
42448EP01
37
18. van der Vossen, J. M., D. van der Lelie, and G. Venema. 1987. Isolation and 
characterization of Streptococcus cremoris Wg2-specific promoters. Appl. 
Environ. Microbiol. 53:2452-2457.
178
42448EP01
38
Claims 
1. An isolated polynucleotide sequence that encodes a polypeptide with at least 
70% identity with SEQ ID NO 1, or a fragment thereof, and wherein expression of 
said polynucleotide confers at least one phage resistance mechanism to a 5
Lactococcus bacterium.
2. An isolated polynucleotide that encodes a polypeptide with at least 70% 
identity with a sequence selected from the group consisting of SEQ ID NO 2, or a 
fragment thereof, and SEQ ID NO 7 or a fragment thereof and wherein said 10
polynucleotide optionally furthermore encodes a polynucleotide according to claim 
1, and wherein expression of said polynucleotide confers at least one phage 
resistance mechanism to a Lactococcus bacterium. 
3. An expression vector encoding at least one of the polypeptides according to 15
claims 1 and 2.
4. A Lactococcus bacterium comprising an expression vector according to claim 3.
5. A starter culture composition comprising the bacterium according to claim 4.20
6. An isolated polypeptide conferring at least one phage resistance mechanism to 
a Lactococcus bacterium, wherein said polypeptide is selected from one or more of 
the group consisting of: a polypeptide with at least 70% identity with SEQ ID NO 
1, or a fragment thereof, a polypeptide with at least 70% identity with SEQ ID NO 25
2, or a fragment thereof, and a polypeptide with at least 70% identity with SEQ 
ID NO 7 or a fragment thereof.
7. Use of one or more polynucleotides according to any one of claims 1 or 2 or 
one or more polypeptides according to claim 6 for improving phage resistance in a 30
Lactococcus bacterium.
8. A method for fermenting a food product, said method comprising the step of 
adding one or more of the components selected from the list consisting of: an 
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expression vector according to claim 3, a bacterium according to claim 4, a starter 
culture according to claim 5, and a polypeptide according to claim 6 prior to 
fermentation of said food product.
9. A food product obtainable by a method according to claim 8.  5
10. A method for obtaining phage resistant bacterial cells, said method comprising 
use of pGhost9::ISS1 for random insertion into a bacterial cell and subsequently 
screening and selecting for phage resistant cells.
10
11. A phage resistant cell with improved phage resistance obtained by the method 
according to claim 10.
12. A cell according to claim 11, wherein a polynucleotide sequence encoding SEQ 
ID NO 1 is transcriptionally active and wherein the cell is a Lactocuccus bacterium.15
13. A Lactococcus bacterium that expresses at least one polypeptide selected from 
the group consisting of: a polypeptide with at least 70% identity with SEQ ID NO 
1, or a fragment thereof, a polypeptide with at least 70% identity with SEQ ID NO 
2, or a fragment thereof, and a polypeptide with at least 70% identity with SEQ 20
ID NO7, or a fragment thereof. 
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Abstract
The present invention relates to the field of dairy science. In particular, the 
present invention relates to methods for improving dairy starter culture quality as 
well as food products that can be obtained using such methods. 
5
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SEQUENCE LISTING
<110>  DTU
Haaber, Jakob Brandt Borup
<120>  Phage resistance
<130>  P42448EP01
<160>  18    
<170>  PatentIn version 3.3
<210>  1
<211>  202
<212>  PRT
<213>  Lactococcus lactis
<220>
<221>  VARIANT
<222>  (202)..(202)
<223>  Xaa can be any naturally occurring amino acid
<400>  1
Met Phe Asp Lys Asp Asn Tyr Ala Leu Gly Lys Met Lys Asn Thr Leu 
1               5                   10                  15      
Asn Thr Lys Glu Ser Lys Phe Ser Leu Lys Ser Thr Asp Asp Leu Asn 
20                  25                  30          
Lys Cys Ile Asp His Ile Ser Val Leu Ile Lys Asp Ala Tyr Leu Leu 
35                  40                  45              
Tyr Thr Asn Glu Ser Phe Ala Thr Ser Thr Phe Ile Ser Ile Thr Ile 
50                  55                  60                  
Ile Glu Glu Val Gly Lys Thr His Ile Gly Met Phe Ile Ser Glu Asn 
65                  70                  75                  80  
Lys Asp Ile Lys Arg Gly Lys Asp Pro Leu Arg Asn His Lys Ser Lys 
85                  90                  95      
His Ala Phe Gly Ser Leu Pro Thr Ile Lys Met Gly Gly Arg Leu Asn 
100                 105                 110         
Lys Ala Ile Gly Asp Glu Met Ile Asp Lys Ile Val Glu Asp Ala Glu 
115                 120                 125             
Thr Gly Glu Leu Ile Ser Ile Arg Glu Ser Ser Leu Tyr Ala Asp Ile 
130                 135                 140                 
Ile Asp Asp Ile Leu Glu Val Pro Ser Glu Lys Ile Ser Lys Glu Gln 
145                 150                 155                 160 
Ser Arg Ala Leu Leu Leu Tyr Ala Ile Glu Cys Phe Asp Asp Ser Leu 
165                 170                 175     
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Val Gly Tyr Thr His His Ser Phe Glu Val Ser Glu Thr Thr Asp Glu 
180                 185                 190         
Leu Phe Glu Lys Leu Ala Asn Asn Lys Xaa 
195                 200         
<210>  2
<211>  128
<212>  PRT
<213>  Lactococcus 1 bacteriophage
<400>  2
Met Asn Tyr Gly Thr Asn Asn His Tyr Ala Asn Glu Tyr Gly Met Glu 
1               5                   10                  15      
Leu Asn Glu Tyr Phe Lys His His Phe Asn Tyr Glu Glu Leu Ala Gly 
20                  25                  30          
Trp Tyr Thr Met Gln Val Leu Lys Tyr Leu Val Arg Ala Gly Lys Lys 
35                  40                  45              
Glu Gly Glu Ser Tyr Asp Lys Asp Arg Asn Lys Ala Leu Asp Tyr Ala 
50                  55                  60                  
Gly Glu Leu Ala Asn Leu Ser Asn Glu Asn Glu Leu Thr Glu Tyr Thr 
65                  70                  75                  80  
Thr Asp Asp Ile Met Gly Phe Ala Gln Asp Ile Ala Asp Asp Phe Lys 
85                  90                  95      
Gln Trp Lys Asp Glu Arg Asn Asn Phe Lys Ser Glu Phe Thr Lys Glu 
100                 105                 110         
Glu Ile Lys Ala Ile Asp Glu Arg Tyr Leu Glu Phe Ile Glu Glu Val 
115                 120                 125             
<210>  3
<211>  603
<212>  DNA
<213>  Lactococcus lactis
<400>  3
atgtttgata aagacaacta tgcattagga aaaatgaaga atacccttaa taccaaagaa     60
agtaagtttt ctctaaagtc aactgatgat cttaataaat gcatcgatca tatttcagtc    120
ttaataaaag atgcatatct gctttatacg aatgaatcat ttgccacttc tacattcatt    180
tcaataacaa ttattgaaga agttggtaaa actcatatag gtatgtttat cagtgagaat    240
aaagatataa agcgtgggaa agaccctttg agaaatcata aatccaaaca cgcttttgga    300
tctcttccaa ctataaaaat gggaggacga cttaataagg ctattggaga tgaaatgatt    360
gataaaatcg tcgaagatgc cgaaactggt gaacttattt caatacggga gtcatctttg    420
tatgcagata ttattgatga tattcttgaa gtacctagtg aaaaaattag taaagaacaa    480
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agtagagcat tgctccttta tgcgatagaa tgttttgatg acagtttagt tggctataca    540
catcattcat ttgaagtatc agagacaact gatgagttgt ttgaaaagtt agcaaacaat    600
aaa                                                                  603
<210>  4
<211>  384
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  4
atgaattatg gtacaaataa gcactatgcc aatgaatacg gtatggaact taacgaatac     60
tttaaacatc attttagcta tgaagagctt gcaggctggt atacaatgca ggtattaaag    120
tatctagtga gagctggcaa gaaagagggt gaaagctacg acaaagaccg taacaaggct    180
ttagactatg caggagaact tgctaactta agtaacgaga atgagcttac agaatacact    240
actgacgaca ttatgggctt tgcacaagat atagctgatg atttcaaaca atggaaaggc    300
gaaagaaata actttaaatc agagttcacg aaagaagaga taaaagcgat tgatgaaaga    360
tacttggaat ttattgaaga ggtc                                           384
<210>  5
<211>  565
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  5
aagatacagt aaaaacttta atgatagctg taggtatagg ctttacactt atcgctatca     60
cttggatagg tataattgca acgttgctta ttacatggat tgggggtaac atctaatgaa    120
ttatggtaca aataagcact atgccaatga atacggtatg gaacttaacg aatactttaa    180
acatcatttt agctatgaag agcttgcagg ctggtataca atgcaggtat taaagtatct    240
agtgagagct ggcaagaaag agggtgaaag ctacgacaaa gaccgtaaca aggctttaga    300
ctatgcagga gaacttgcta acttaagtaa cgagaatgag cttacagaat acactactga    360
cgacattatg ggctttgcac aagatatagc tgatgatttc aaacaatgga aaggcgaaag    420
aaataacttt aaatcagagt tcacgaaaga agagataaaa gcgattgatg aaagatactt    480
ggaatttatt gaagaggtct aaagttaatt cttgacaaat ataaagtaat ttgataatat    540
tgttttatag aaaggggatt aaaca                                          565
<210>  6
<211>  1300
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  6
aaaaagagag tgggtgtatc aatttaaata taagaacttt gaagaagcct atcagagtat     60
tttctggtac atcgaagcct tttataattc aaaacgaatc catcaaagtt tagggtatct    120
tacacctaat caatttgaaa aggtaagtgc ttaaaataaa tagattaaaa ttctacgttt    180
gttactctaa aaacttgact taacgtcact tcttgagtta acttcgcata ataaagaaaa    240
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caaagacttt ttggatgaaa tagacaaaac ttactctaaa attgatactg tcaatactaa    300
agttagacaa actgaagtag ctgcaactac taatcaactt gcgctaacta aagcaaatgt    360
acaaattcat acccttttag taattgctag taattattat caatcagtat ggatccagat    420
taaagaatga acggagagtt ttatgtttga taaagacaac tatgcattag gaaaaatgaa    480
gaataccctt aataccaaag aaagtaagtt ttctctaaag tcaactgatg atcttaataa    540
atgcatcgat catatttcag tcttaataaa agatgcatat ctgctttata cgaatgaatc    600
atttgccact tctacattca tttcaataac aattattgaa gaagttggta aaactcatat    660
aggtatgttt atcagtgaga ataaagatat aaagcgtggg aaagaccctt tgagaaatca    720
taaatccaaa cacgcttttg gatctcttcc aactataaaa atgggaggac gacttaataa    780
ggctattgga gatgaaatga ttgataaaat cgtcgaagat gccgaaactg gtgaacttat    840
ttcaatacgg gagtcatctt tgtatgcaga tattattgat gatattcttg aagtacctag    900
tgaaaaaatt agtaaagaac aaagtagagc attgctcctt tatgcgatag aatgttttga    960
tgacagttta gttggctata cacatcattc atttgaagta tcagagacaa ctgatgagtt   1020
gtttgaaaag ttagcaaaca ataaatagtt aaatcttgag tttgattttg ctgaatattc   1080
tgcatttatc gggcggaatg atgcccttag actttgcaac agaacctcga ttttaattcg   1140
ttcagaatag gttatactag acaaaagatc ggctcctaaa aatgggtttg tgataaacac   1200
cattttaaag gaagctggtc ttttttgtcc aaacactggt cagacaattt tggggcctat   1260
gatatttggt gttgatagat aaaattcatc aacactattc                         1300
<210>  7
<211>  123
<212>  PRT
<213>  Lactococcus bacteriophage c2
<220>
<221>  VARIANT
<222>  (123)..(123)
<223>  Xaa can be any naturally occurring amino acid
<400>  7
Met Ala Gln Asp Tyr Tyr Ala Asn Lys Tyr Gly Ile Gln Leu Glu Glu 
1               5                   10                  15      
Phe Leu Ile Trp Gly Ser Glu Trp Asp Leu Lys Phe Trp Lys Tyr Asn 
20                  25                  30          
Phe Thr Thr Gly Gln Gly Phe Ala Leu Thr Asn Ala Leu Lys Tyr Thr 
35                  40                  45              
Val Arg Ala Gly Lys Lys Pro Asp Glu Pro Tyr Glu Lys Asp Met Gly 
50                  55                  60                  
Lys Tyr Asn Asp Tyr Ile Asp Met Ala Val Lys Met Gly Phe Glu Arg 
65                  70                  75                  80  
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Ser Glu Ala Glu Asp Trp Val Ala Leu Gln Lys Ser Ile Phe Glu Glu 
85                  90                  95      
Phe Lys Gly Lys Lys Ala Glu Ile Glu Glu Leu Glu Lys Arg Lys Glu 
100                 105                 110         
Met Lys Glu Asn Asp Glu Ile Arg Arg Leu Xaa 
115                 120             
<210>  8
<211>  366
<212>  DNA
<213>  Lactococcus bacteriophage c2
<400>  8
atggctcaag attattatgc aaataagtac ggtattcaat tagaagagtt cctgatttgg     60
ggttctgaat gggacttaaa attttggaag tataacttta caactggtca aggttttgca    120
ctaactaacg ctttaaagta cactgtaagg gcagggaaaa agccagatga accgtatgaa    180
aaagatatgg gcaaatataa cgactacatc gacatggctg ttaaaatggg ctttgaacgg    240
tctgaagcag aagactgggt agcacttcaa aaatcaatat ttgaggagtt taaaggaaaa    300
aaagcagaaa ttgaagaact tgaaaaaaga aaggaaatga aagaaaatga tgaaattcgt    360
cgcctt                                                               366
<210>  9
<211>  11
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  9
agaaaggagg t                                                          11
<210>  10
<211>  11
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  10
agaaaggagg t                                                          11
<210>  11
<211>  17
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  11
gaagaaatgg aacgctc                                                    17
<210>  12
<211>  11
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  12
tgaacggaga g                                                          11
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<210>  13
<211>  11
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  13
ggattggggg t                                                          11
<210>  14
<211>  22
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  14
tggatccaaa ggaggtcctg ca                                              22
<210>  15
<211>  22
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  15
ggacctcctt tggatccatg ca                                              22
<210>  16
<211>  6
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  16
aggagg                                                                 6
<210>  17
<211>  1300
<212>  DNA
<213>  Lactococcus lactis
<400>  17
aaaaagagag tgggtgtatc aatttaaata taagaacttt gaagaagcct atcagagtat     60
tttctggtac atcgaagcct tttataattc aaaacgaatc catcaaagtt tagggtatct    120
tacacctaat caatttgaaa aggtaagtgc ttaaaataaa tagattaaaa ttctacgttt    180
gttactctaa aaacttgact taacgtcact tcttgagtta acttcgcata ataaagaaaa    240
caaagacttt ttggatgaaa tagacaaaac ttactctaaa attgatactg tcaatactaa    300
agttagacaa actgaagtag ctgcaactac taatcaactt gcgctaacta aagcaaatgt    360
acaaattcat acccttttag taattgctag taattattat caatcagtat ggatccagat    420
taaagaatga acggagagtt ttatgtttga taaagacaac tatgcattag gaaaaatgaa    480
gaataccctt aataccaaag aaagtaagtt ttctctaaag tcaactgatg atcttaataa    540
atgcatcgat catatttcag tcttaataaa agatgcatat ctgctttata cgaatgaatc    600
atttgccact tctacattca tttcaataac aattattgaa gaagttggta aaactcatat    660
aggtatgttt atcagtgaga ataaagatat aaagcgtggg aaagaccctt tgagaaatca    720
taaatccaaa cacgcttttg gatctcttcc aactataaaa atgggaggac gacttaataa    780
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ggctattgga gatgaaatga ttgataaaat cgtcgaagat gccgaaactg gtgaacttat    840
ttcaatacgg gagtcatctt tgtatgcaga tattattgat gatattcttg aagtacctag    900
tgaaaaaatt agtaaagaac aaagtagagc attgctcctt tatgcgatag aatgttttga    960
tgacagttta gttggctata cacatcattc atttgaagta tcagagacaa ctgatgagtt   1020
gtttgaaaag ttagcaaaca ataaatagtt aaatcttgag tttgattttg ctgaatattc   1080
tgcatttatc gggcggaatg atgcccttag actttgcaac agaacctcga ttttaattcg   1140
ttcagaatag gttatactag acaaaagatc ggctcctaaa aatgggtttg tgataaacac   1200
cattttaaag gaagctggtc ttttttgtcc aaacactggt cagacaattt tggggcctat   1260
gatatttggt gttgatagat aaaattcatc aacactattc                         1300
<210>  18
<211>  499
<212>  DNA
<213>  Lactococcus bacteriophage
<400>  18
aagatacagt aaaaacttta atgatagctg taggtatagg ctttacactt atcgctatca     60
cttggatagg tataattgca acgttgctta ttacatggat tgggggtaac atctaatgaa    120
ttatggtaca aataagcact atgccaatga atacggtatg gaacttaacg aatactttaa    180
acatcatttt agctatgaag agcttgcagg ctggtataca atgcaggtat taaagtatct    240
agtgagagct ggcaagaaag agggtgaaag ctacgacaaa gaccgtaaca aggctttaga    300
ctatgcagga gaacttgcta acttaagtaa cgagaatgag cttacagaat acactactga    360
cgacattatg ggctttgcac aagatatagc tgatgatttc aaacaatgga aaggcgaaag    420
aaataacttt aaatcagagt tcacgaaaga agagataaaa gcgattgatg aaagatactt    480
ggaatttatt gaagaggtc                                                 499
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Discussion and outlook 
 
The results of my PhD project have revealed a novel Abi mechanism and provided data to 
describe the mode of action (MOA) and industrial applicability of this system. The results have 
been discussed in the accompanying manuscripts and this discussion is thus meant as a summary 
and a supplementary discussion. Finally, perspectives of the findings and suggestions for further 
work are presented.  
 
DESCRIPTION OF THE ABIV PHAGE RESISTANCE SYSTEM 
The novel lactococcal abortive infection mechanism AbiV consists of the bacterial protein AbiV 
and the phage protein SaV. Both proteins were isolated and characterized during my 3-year PhD 
study. The proteins interact after phage infection at an early stage of the lytic cycle to inhibit phage 
protein synthesis in the host cell whereby further phage proliferation is halted. Below, a description 
of the individual components of the system as well as more detailed discussion of their interaction is 
presented along with suggestions for the industrial applications of the system.  
 
Characteristics of the bacterial protein AbiV 
AbiV is a newly discovered and characterized lactococcal protein that confers resistance against 
936-like and c2-like phages when expressed in L. lactis (Manuscript I). The phenotypic effects on 
cells expressing AbiV during a phage infection are normal adsorption and transfer of phage DNA 
into the host cell along with death of the cell with very limited release of infective phages. These 
are all well known characteristics of an Abi mechanism and AbiV was concluded to be a novel Abi 
protein. A frameshift mutation in the abiV gene abolished the phage resistance phenotype, 
indicating that a translated AbiV is responsible for the phage resistance phenotype. The protein 
consists of 201 amino acids and it was shown in several independent experiments to form a dimer in 
the native form that most probably exists in the cytosol of the cell (Manuscript I and III). With only 
few common characteristics of Abi proteins 26, such basic structural information might be of value. 
However, to date AbiV is the only Abi protein for which the multimeric state has been revealed. 
AbiV contains a putative RNA binding site 145 which might be involved in the systems mode of 
action as discussed below. AbiV, like most Abi proteins showed no amino acid similarity to known 
proteins or contained any conserved domains when database searches were performed, which 
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prevented us from doing predictions on the MOA of the system 26. The majority of the isolated Abi 
systems are encoded by a single plasmid borne gene though a few Abi systems are encoded by two 
11,32,35,59,117 or more 150 genes. AbiV is encoded by a single gene with the characteristic low G+C 
content and it is located in the “integration hot spot” region of L. lactis MG1363 chromosome 154. 
This region is characterized by a high concentration of remnants of mobile DNA, which makes it 
tempting to speculate that a plasmid borne abiV previously integrated in this region. Contrary to the 
other chromosomally encoded Abi systems, abiV is not expressed from the chromosome of wild 
type L. lactis MG1363 (Manuscript I). Though both abiH, abiN, and abiB are expressed from the 
host chromosome 124,126,28, the over-representation of plasmid encoded Abi systems, indicates that 
expression of chromosomal Abi genes is not a common strategy in L. lactis. However, Chopin et al. 
argued that the under-representation of isolated chromosome-encoded Abi systems could be due to 
the methodological advantages in isolating phage resistance mechanisms from plasmids 26.  
AbiV was discovered and isolated using the insertional mutagenesis system pGhost9::ISS1 99,100, 
which is normally used in experiments where selection is made for loss-of-function effects 
47,95,127,147.  However, Luccini et al. isolated phage resistant mutants of S. thermophilus where the 
insertion conferred upregulation of a downstream gene encoding a R/M phage resistance 
mechanism 95. A similar property of the pGhost9::ISS1 system caused upregulation of abiV and led 
to the discovery and isolation of the abiV gene. 
Though the ISS1 insertion sequence is reported to integrate randomly on the chromosome of L. 
lactis 100, we observed that in several independently obtained mutants, ISS1 had integrated within a 
350 bp region of the 2.5 Mbp chromosome of L. lactis MG1363. In Manuscript I, we suggest that 
insertion sequences of the ISS1 type may integrate into the 59-kb “integration hot spot” on the L. 
lactis MG1363 chromosome with a high frequency compared to other parts of the chromosome 
based on the high concentration of insertion sequences in this region (almost 20% of the 71 
insertion sequences found in the MG1363 genome). Thus ISS1 integration in MG1363 appears to be 
not completely random with a preference for insertion in the integration hot spot region which could 
explain the observed high frequent integration events upstream of abiV. 
 
Possible function of the early phage gene sav 
To analyze the genetic component(s) of the phage that interact with AbiV to cause the phage 
resistance phenotype, we took advantage of the ability of different lactococcal phages to form AbiV 
insensitive mutants (Manuscript II). The complete genome of one of these phage mutants (p2.1) was 
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sequenced and compared to the wild revealing several mutations in a small part of the early 
transcribed region of the phage. Sequencing of this region in other AbiV-insensitive phage mutants 
revealed that a gene which is transcribed early in the wild type phage was involved in sensitivity to 
AbiV. The gene was named sav for sensitivity to AbiV. In total, the sav gene homologue was 
investigated in four phage mutants of the 936 species (p2.1, sk1.1, bIL170.1, and P008.1) and two 
mutants of the c2 species (c2.1 and bIL67.1). 
Most of the observed mutations in the sav homologues of the six investigated phage mutants 
effectively prevented translation of the SaV protein (nonsense mutations, deletion of start-codons) 
apparently without causing significant fitness loss for the phage (Manuscript II). SaV thus seemed 
to be redundant in the p2 lytic cycle. Phages are normally considered to be restricted in the size of 
their DNA due to limited space in the capsid 77 and this has been used to explain the existence of 
overlapping genes (out of phase, in phase, and antiparallel) 132 often observed in phages 88. 
Therefore it seems like a paradox that the phage would carry a gene (sav) which is not used. On the 
other hand, such “gene redundancy” has been observed in other phages as for example the large 
(170 kbp) genome of the coliphage T4 82. Among many other T4 genes, several early expressed 
proteins used to re-direct the host RNA polymerase (RNAP) from host to phage gene transcription 
were demonstrated to be non-essential for phage proliferation 113. However, this gene redundancy is 
only valid for the conditions under which the redundancy of the gene was tested (normally under 
optimal laboratory conditions) 87 and redundant pathways has been suggested to be an important 
factor in the great success of phages as molecular parasites since it allows the phage to adapt to 
several physiological and environmental conditions 87,113.  
The middle region of the SaV protein is highly conserved among very distantly related phages 
(infecting gram positive hosts, gram negative hosts and cyanobacteria). This region also contained 
the majority of the mutations in the phage mutants, which led to either radical amino acid changes 
or prevented translation, thereby indicating the involvement of a translated SaV protein in the Abi 
phenotype. A phylogenetic analysis of this conserved region clustered phages belonging to the same 
group together suggesting that this region of SaV has evolved from a common ancestor (Manuscript 
II).  
Induction of SaV demonstrated a fast working and severe toxic effect in both L. lactis and E. coli 
(Manuscript II). Interestingly, a mutated version of SaV with amino acid changes in the conserved 
region had lost the toxic property indicating that this region contains the active site for both toxicity 
and interaction with AbiV (Manuscript II + III). It is often observed that early transcribed phage 
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proteins can have antimicrobial properties when overexpressed in bacterial cells. In many cases this 
is caused by redirection or inactivation of critical processes in the bacterial cell machinery that 
facilitates production of phage components 92. These effects include re-direction of transcription in 
E. coli by interaction with the host RNAP 115 or σ70 transcription factor 121 or re-direction of DnaB 
helicase to favour phage DNA replication 101,120.  
In the present study it was demonstrated that during infection with wild type p2, total RNA and 
protein synthesis is inhibited (Manuscript III), suggesting that such early re-direction mechanisms 
also exist in lactococcal phages. Intuitively, this makes sense since the lactococcal phages do not 
carry their own RNA polymerase and thus are dependent on host factors for both transcription and 
translation of phage genes. In these situations where the phage has to compete for RNAP and 
ribosomes with the host, it is often observed that early phage encoded proteins shut-down host RNA 
and protein synthesis 82,87. Since the function of these early regulatory proteins is to ease 
competition for host factors, they are usually not essential under normal laboratory conditions 113. It 
can be speculated that SaV due to its early expression and quick toxic effect directed against 
conserved components in L. lactis and E. coli, its evolutionary relationship with a wide range of 
phage proteins, and redundancy in the lytic cycle might be such an early regulatory protein. 
 
Interaction of AbiV and SaV 
We demonstrated a direct interaction between the two proteins AbiV and SaV using several 
different methods. Using gel-filtration, the native form of both proteins was shown to be a dimer 
(Manuscript I and II), which was confirmed by the SEC-MALS/UV/RI, fluorescence quenching, 
and cross-linking experiments (Manuscript III). The cross-linking assay suggested that in addition 
to the interaction between the two homodimers a distinct interaction also existed between 
monomers of the proteins that reacted to form an AbiV-SaV heterodimer (Manuscript III). This 
observation certainly demonstrates that AbiV interacts with SaV but the observation of 
heterodimers might be an artefact caused by the denaturation step in the assay that may have broken 
the homodimer interactions in AbiV and SaV. The strength of data obtained in the SEC-
MALS/UV/RI and fluorescence quenching assays is that the observations are made on native 
proteins. It is therefore most likely that the AbiV and SaV interaction occurs between two 
homodimers. 
We previously argued that translated AbiV and SaV polypeptides are involved in the Abi phenotype 
(Manuscript I and II). It is thus possible that the direct AbiV-SaV interaction is mediating the Abi 
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phenotype for example by activation of the non-toxic AbiV by SaV. Phage induced activation of 
Abi mechanisms are common in Lactococci 8,26,28,51 and also in the well described phage exclusion 
systems in E. coli 137. Activation by phage induced transcription of the Abi gene upon infection 
26,3,52 is the mechanism when the Abi gene itself is toxic as demonstrated for AbiD1, AbiK, AbiN 
and AbiO 26. We showed in Manuscript I that high expression of AbiV has no effects on cellular 
growth rate and thus that the cellular death caused by the AbiV system must be due to a subsequent 
reaction with a phage component. This observation supports the hypothesis that the AbiV 
phenotype is caused by the AbiV-SaV protein interaction.  
The interaction sites in the two proteins are not known. However, the mutations in the conserved 
region of the sav gene suggested that this region is involved in the interaction with AbiV 
(Manuscript II). Furthermore, the mutations also caused the protein to loose the antimicrobial 
properties (Manuscript II), suggesting a dual function of this region of SaV.   
 
Effects on the phage life cycle 
Transcription of phage genes was negatively affected during infection of cells harboring AbiV 
(AbiV+ cells). In the early region we observed a 25-40 % decrease of transcription in AbiV+ cells 
compared to AbiV- cells, whereas the middle and late regions showed a decrease of 50 % and 90 % 
respectively (Manuscript III). The transcription data suggested continuous mRNA production both 
in AbiV+ and AbiV- cells throughout the lytic cycle which was supported by an experiment 
measuring cumulated RNA synthesis through 14C-uridine incorporation into RNA. 
Contrary to RNA synthesis, phage protein synthesis was severely inhibited by AbiV. From the 
beginning of the phage infection, total protein synthesis rate was diminished and synthesis ceased 
completely after 15 minutes. According to transcription data from phage sk1 this prevented 
translation of most middle transcripts (7-10 min after infection) and all late transcripts (15 min after 
infection) 21. As observed in Manuscript III, translated SaV was not detectable in the AbiV+ cells 
while transcription of genes in the early region (including sav) was only minimally inhibited by 
AbiV. This strongly indicates that the AbiV system targets a component in the cell translation 
apparatus quickly after infection and that the effects on transcription probably are secondary. Since 
our data indicates that the AbiV system consists of an AbiV-SaV complex but no SaV translation 
was observed in the AbiV+ cells, we suggest that very small amounts of SaV were produced, which 
reacted with AbiV to cause the AbiV phenotype. However, the western blot method might not have 
been sensitive enough to detect low levels of SaV expression. 
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It was not possible to compare our transcription and translation data to other studies since such a 
time-course experiment with investigation of phage transcription and translation during a phage 
infection has not been performed with other lactococcal Abi systems. 
One way to characterize Abi mechanisms is if they work before or after phage DNA replication 54. 
When DNA replication is observed, it is usually in the concatemeric (non-mature) form 3,11,14,51, 
which can be caused by arrest of the lytic cycle prior to DNA packaging 20,78 or cell death before the 
end of the lytic cycle 26,50. We observed replicated but concatemeric phage DNA when AbiV+ cells 
were infected with 936-like phages while no DNA replication was observed when the same host 
was infected with c2 phages (Manuscript III). Since the same host was used, differences between 
the two phage types must account for the observed different phenotypes 62. Similarly, different 
DNA replication patterns have been observed for other Abi systems when tested against the three 
phage species 936, c2, and P335 26,40,143. For example, AbiK allowed DNA replication of phage p2 
(936-species) but not ul36 (P335-species) 14 and DNA replication of c2 and 936 phages 117 but not 
of P335 phages was observed in AbiG+ cells 143. Interestingly, the level of AbiV expression was not 
important for the Abi phenotype against 936-like phages, while protection against c2 infection 
required high expression of AbiV (Manuscript I) as observed previously 40,117,52,143. If the Abi 
phenotype involves the conserved region in SaV (which is common among 936 and c2 phages) it 
may be speculated that the same mode of action (translation inhibition) is imposed on both phage 
species. This would imply that the AbiV system must act before translation of the DNA polymerase 
in c2 17,94. The DNA polymerase subunits are transcribed early in the lytic cycle from consensus 
Lactococcus promoters in both the 936 phages sk1 and p2 and the c2 phage. However, in c2, the sav 
homologue is transcribed from a very strong promoter compared to the promoter in front of the 
DNA polymerase 93. This strong early promoter was suggested to be among the strongest 
lactococcal promoters identified 93 and it is thus possible that transcription of the sav homologue in 
c2 from such a strong promoter could activate AbiV and thus the Abi phenotype before translation 
of the DNA polymerase. This promoter type was not observed in the analyzed 936 phages. 
 
A model for the molecular mode of action (MOA) of the AbiV system 
Based on the data in Manuscripts I-III, the following hypothesis on the MOA of the AbiV system 
against 936-like phages was constructed (Fig. 6). It should be noted that several parts of the 
hypothesis are still speculations and further studies are needed to clarify the exact molecular MOA 
of the AbiV system. 
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Shortly after infection, genes in the early region of the phage are transcribed from several 
lactococcal consensus promoters as described for phage sk1 22 and translation of these transcripts 
starts. Among the early transcripts is the phage DNA polymerase 17 and presumably also phage 
proteins that induce the observed arrest of host RNA and protein synthesis (Manuscript III) 92. SaV 
is translated quickly after infection, which triggers interaction with AbiV and subsequent shut-down 
of the translational machinery of the cell (Fig. 6). Presumably, SaV is only needed in small amounts 
to induce the Abi phenotype. This causes early arrest of translation, including the translation of SaV, 
which is therefore only produced in sub-detectable amounts (Manuscript III).  
The early inhibition of translation probably also prevents expression of a putative phage encoded 
activator, which like in phage sk1 is needed for transcription of the middle genes 8,22,86 thereby 
causing the 50 % decrease in middle transcripts (Manuscript III).  
As in phage TP901-1 18, the middle operon of phage sk1 21 and p2 probably contains an activator of 
late gene transcription that induces transcription just downstream of the activator gene. In AbiV+ 
cells such an activator would be translated at very low levels due to the combined effect of inhibited 
transcription of the middle region and the translation inhibition by the Abi mechanism. Altogether 
Fig. 6. Model of the MOA of the AbiV system against 936 phages.  Black boxes symbolize phage genes where 
act.A and act.B are putative phage encoded activators encoding proteins A and B, respectively. PE, PM, and PL are 
early, middle, and late promoters respectively. In wild type cells translation occurs normally, ActivatorA induces 
middle transcription where ActivatorB is expressed, which in turn activates the late promoter for transcription of 
structural genes. 
In AbiV+ cells, SaV activates AbiV and translation is shut down. ActivatorA is therefore only produced in small 
amounts, ActivatorB is not produced and the lytic cycle is arrested. Transcription and translation levels are 
presented as percentage in AbiV+ cells compared to wild type. 
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this could explain the very limited transcription of late genes (Manuscript III and Fig. 6). 
Interestingly, a putative RNA binding site was observed in AbiV using different predictor software 
144,145. Since the native AbiV homodimer is not harmful to the cell (Manuscript I), it could be 
speculated that this RNA binding site is only exposed due to a conformational change upon 
interaction with the SaV protein. RNA binding by the activated AbiV-SaV complex could thus be 
part of the MOA of the system, though it is unlikely that the RNA binding leads to RNase activity 
(as observed with AbiB 122). It is interesting to note the similarities between the MOA of AbiV and 
the two well characterized E. coli phage exclusion systems Lit and PrrC 137. For all three systems it 
was observed that the abortive infection enzyme is constitutively expressed in an inactive form 
which is activated by a small phage encoded peptide upon infection. The activated protein 
subsequently functions by cleaving conserved and essential components of the cell translation 
apparatus thereby killing the cell and preventing phage proliferation.  
 
Industrial applications of the AbiV system 
The dairy industry has worked more than 70 years to protect their production strains against phages 
and though significant progress has been made, phages remain a significant problem for the dairy 
industry. Thus it has been estimated that between 0.1 % and 10 % of all milk fermentations are 
negatively affected by phage attacks thereby causing substantial economical losses to the industry 
109. Phages are ubiquitous in the environment and many phages are still viable after pasteurization 
of the raw milk used in fermentation 25. Phage control is therefore focused on several phases of the 
fermentation process. Measures such as proper hygiene, disinfection and efficient air-filtration are 
important in combination with rotation of the mixed starter cultures to control phage infections 29,109. 
Also natural phage resistance mechanisms, which are often encoded on conjugative plasmids have 
been used extensively and systematically since the discovery of plasmids harboring different phage 
resistance mechanisms 135.  
The extensive use in a relatively small number of industrial starter strains 33 has favored the 
emergence of phage mutants that are insensitive to the applied anti-phage barriers 34,54,107 thereby 
driving the need in the dairy industry for constantly seeking new anti-phage strategies. Different 
types of engineered phage resistance mechanisms have been developed 42,43,104,72,97,103,31, but limited 
efficiency 81 and more importantly legislative obstacles 54,107 as well as consumer skepticism 33,54,153 
of genetically modified organisms (GMO) make this approach less attractive. Therefore, isolation 
and conjugal transfer of novel anti-phage barriers remain an important strategy for the dairy 
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industry for protection against phages 109. The efficiency of protection against phage attack is 
measured as efficiency of plaquing (EOP) and varies from 10-1 to <10-8 for the different isolated 
Abi mechanisms 32,51 (Introduction, Table 2). The EOP of AbiV is ca. 10-4 and the system is thus 
characterized as a medium strength Abi system 107. AbiV is a novel abi mechanism, i.e. similarity to 
other amino acid sequences or MOA with an interacting phage component of other Abi mechanisms 
was not found. Furthermore, since AbiV was demonstrated to work in both subspecies of L. lactis 
(lactis and cremoris) it is suitable to work either as a single anti-phage barrier or in combination 
with other phage resistance mechanisms. 
We demonstrated in Manuscript IV that L. lactis can mutate to spontaneously express AbiV and 
thus confer phage resistance to the host. This can be of great industrial value as the AbiV phenotype 
can be applied to strains without the use of genetic modification. However, most R/M and Abi 
systems are encoded on plasmids 11,14,26,50,51,60,73,117,150, many of which are conjugative and for the 
chromosomally encoded phage resistance mechanisms as AbiV, the industrial application is 
dependent on the ability to transfer the resistance gene(s) to industrial production strains 
2,29,66,107,116,130,140. We demonstrated that abiV can be transferred between lactococcal strains via 
chromosomal conjugation (Manuscript IV). Furthermore it can be speculated that abiV due to its 
location in the L. lactis MG1363 “integration hot spot” region where it is flanked by two putative 
transposases (lin and trans) can be mobilized onto a conjugative plasmid. 
 
PERSPECTIVES AND OUTLOOK 
The results presented in this thesis have provided a detailed description of a novel lactococcal phage 
abortive infection system and its mode of action. This includes isolation and characterization of 
both the bacterial protein AbiV and the phage protein SaV that interact directly to cause the Abi 
phenotype. Moreover, the mode of action was revealed to inhibit protein synthesis early in the lytic 
cycle of 936-phages. A model explaining the possible molecular interactions of the AbiV system 
was proposed and the results altogether provide one of the most comprehensive descriptions of a 
lactococcal Abi system. 
Due to their economical value, lactococcal Abi systems are among the best investigated bacterial 
Abi mechanisms 81. Still, for most of the isolated lactococcal Abi systems, the mode of action is 
unknown and they are often only characterized according to their action early (before phage DNA 
replication) or late (after phage DNA replication) in the lytic cycle 62,81. In the few cases where the 
mode of action has been revealed, the interaction of lactococcal Abi mechanisms with the lytic 
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cycle of phages has proven to be complex 13,14,26,40,52,55. This is supported by reports of a single Abi 
mechanism using different modes of action against the three main lactococcal phage species.  
The characterization of lytic lactococcal phages including the function of most of their early 
transcribed proteins and the molecular processes during the lytic cycle is virtually unknown. For 
some E. coli phages (e.g. T4), the lytic cycle is described in much greater detail and has revealed an 
efficient molecular parasite that adapts to environmental changes through a complex network of 
interactions 82,87,113. Though the genomes of lactococcal phages are much smaller (13% and 17% of 
the T4 genome for the phages c2 and sk1, respectively) it is likely that early proteins of lactococcal 
phages are involved in interaction networks with both phage and host factors and that Abi 
mechanisms through a variety of phage targets exhibit complex mode of actions that differ 
according to the infecting phage.  
Thorough investigation of the different Abi mechanisms and the interaction with genes and gene 
products in phages from all three main species (936, c2, and P335) is thus necessary to obtain the 
knowledge that can help designing future starter cultures with improved phage resistance properties. 
 
Obtaining the three-dimensional structure of the Abi protein, the interacting phage protein as well 
as the complex of the two (when protein-protein interaction occurs) will provide a powerful tool in 
determining the protein functions, their active sites and relationship (functional and or evolutionary) 
to other proteins 128,138,139,149. Ongoing work in collaborating groups is focused on determining the 
structure of AbiV, SaV and the AbiV-SaV complex in an attempt to elucidate the exact molecular 
function of the AbiV system. It would be of great interest to reveal the specific mechanism of which 
the complex inhibits protein synthesis by combining the structure data (if obtained) with RNA 
binding and in vitro translation assays to test if the complex binds RNA and maybe prevents 
translation by steric hindering of the ribosome access to the mRNA. 
 
If 3D structure information of SaV is obtained, it might also prove to be valuable for determination 
of the host target of SaV that causes the strong antimicrobial effect when the protein is expressed in 
E. coli or L. lactis. The identification of the SaV host target might also be determined using affinity 
chromatography as described by Liu et al. 92 or by sequence analysis of SaV resistant bacterial 
mutants. The possibility of SaV being a novel antimicrobial molecule makes it very interesting to 
pursue the investigation of this protein. 
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Finally, from an industrial point of view, it would be interesting to mobilize abiV from the 
chromosome of L. lactis MG1363 onto a conjugal plasmid for use in industrial production strains.
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